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Acute Myeloid Leukaemia (AML) arises from a dysregulation in haematopoietic stem and 
progenitor cells (HSPCs), leading to the production of highly proliferative blast cells. Current 
chemotherapies can eliminate these cells but fail to eradicate the leukaemic stem 
cell (LSC) source. There has been increasing interest in the microenvironment in which LSCs, 
as well as their haematopoietic stem cell (HSC) counterparts reside, with particular focus on 
the hypoxic nature of the niche. As such, this led us to investigate Hypoxia Inducible Factors 
(HIFs) in leukaemia development where our previously published data shows that HIFs 
are tumour suppressors in AML.  
 
This thesis builds on this work, investigating the therapeutic potential of Prolyl Hydroxylases 
Domain (PHD) inhibition, which stabilises HIFs. Results show that deletion of the Phd isoforms 
Phd1 and Phd2 reduces leukaemic transformation and development in vitro. Additionally, 
when leukaemic cells deficient in Phd1 and Phd2 were transplanted into syngeneic lethally 
irradiated recipient mice, there was a reduction in leukaemic engraftment, resulting in an 
increase in disease latency when compared to the control cells. In addition, I further validated 
this result by using a doxycycline-inducible shRNA model to knockdown levels of Phd2 in 
leukaemic cells. Mirroring the results of the gene deletion study, Phd2 knockdown led to a 
regression of leukaemia both in vitro and in vivo. 
 
To further validate PHDs as therapeutic targets in AML, I investigated the impact of deletion 
of Phd1 and Phd2 specifically in the hematopoietic system using Vav-iCre. Steady state 
analysis of the HSPC and differentiated cell compartments found there were no significant 
differences when compared to control mice. Moreover, further utilising the inducible shRNA 
model, I acutely deleted Phd2 in vivo, discovering a decrease in the frequency and functionality 
of the HSC compartment, with no other discernible phenotypes. Given there were no 
significant detrimental effects on normal haematopoiesis, this study provides a strong rationale 
for studying the inhibition of Phds in combination with current chemotherapeutic regimes, 
aiming to provide targeted therapies for AML. 
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Lay Summary  
Acute Myeloid Leukaemia (AML) is an aggressive blood cancer, with poor long-term survival 
outcomes due to high rates of fatal disease relapse. Importantly these problematic disease 
relapses are caused by leukaemic stem cells (LSCs), which are highly mutated forms of 
normal haematopoietic stem and progenitor cells (HSPCs) that sustain blood production 
throughout life. Both HSPCs and their LSC counterparts reside in bone marrow 
microenvironment, which is very low in oxygen, known as hypoxia. Cells adapt to this low 
oxygen condition through the HIF (Hypoxia Inducible Factor) pathway. Deleting HIF, the 
orchestrator of this pathway, increased the potency of LSCs, making the disease more 
aggressive. This thesis found that stabilising HIF levels, through deletion of the HIF-inhibitor 
PHD, decreased LSC potency, reducing the disease burden in mice. Using a PHD inhibitor in 
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Chapter 1 Introduction 
1.1 Haematopoiesis  
Haematopoiesis describes the commitment and differentiation processes that lead to the 
production of all blood components required to sustain life. All blood cells are derived from a 
rare population of multipotent haematopoietic stem cells (HSCs), which reside at the top of the 
haematopoietic hierarchy, and undergo several discrete steps to produce mature, functional 
blood cells (Ema et al., 2014). 
 
The discovery and biology of HSCs began in the 1950s, with two groups performing bone 
marrow (BM) transplantations on lethally irradiated mice and guinea pigs. After receiving the 
donor BM cells, the animals were rescued from lethality, and were seen to have developed 
functional myeloid and lymphoid differentiated cells, indicating the BM contained HSCs 
capable of repopulating the entire blood system (Jacobson et al., 1951; Lorenz et al., 1951). 
Further seminal research conducted by Till and McCulloch in 1961 utilised the in vivo colony-
forming spleen (CFU-S) assay, to confirm the existence of clonogenic BM cells, and their 
ability to produce multilineage haematopoietic colonies in the spleens of lethally irradiated 
recipient mice. Moreover, it was discovered that a small fraction of these cells were able to 
reconstitute the entire haematopoietic system of secondary recipient mice, proving that HSCs 
can yield multilineage haematopoiesis, but also retain their stem-cell properties.  
 
More recent studies have developed upon this notion, and have confirmed that HSCs reside 
at the top of a complex haematopoietic hierarchy, giving rise to progenitors which are 
progressively more restricted in their lineage, until unilineage terminal differentiation occurs, 
producing mature blood cells such as red blood cells (RBCs), megakaryocytes, myeloid and 
lymphoid cells. HSCs, as stem cells, are also capable of self-renewal, producing additional 




HSCs are functionally defined by their unique capacity to reconstitute the entire 
haematopoietic system of an organism, and as such have been used extensively in the clinic 



























1.1.1 Early haematopoiesis  
Since the process of hematopoiesis is conserved throughout all vertebrate species, animal 
models, such as mice, have been used to supplement and develop the study of human 
hematopoiesis (Orkin and Zon, 2008). 
 
Early murine studies found that haematopoiesis occurs in multiple stages in specific 
anatomical sites (Johnson and Moore, 1975; Medvinsky and Dzierzak, 1996; Moore et al., 
1972; Palis et al., 1999). As described in Figure 1-1, in mice, haematopoiesis originates in the 
yolk sac blood islands at embryonic day (E) 7.5, functioning to produce RBCs to oxygenate 
various tissues in the embryo as it develops. Megakaryocytes and macrophages are also 
produced in an aid to dispose of apoptotic cells and debris generated during the embryonic 
development process (Serrano et al., 2012). This initial wave of haematopoietic cell production 
is termed the "primitive wave", which is rapidly replaced by the "definitive wave" of 
haematopoiesis. The next stage in the development of the haematopoietic system occurs in 
the aorta-gonad mesonephros (AGM) region, in which definitive HSCs emerge at E 10.5 
(Medvinsky and Dzierzak, 1996). Notably, at day E 10.5, there is limited HSC activity, whereas 
at E 11, the HSCs are functional, and thus capable of reconstituting lethally irradiated 
recipients. Notably, at this point in embryonic development, there are also HSCs present in 
the placenta (Alvarez-Silva et al., 2003). However, it is still debated if these cells arise from do 
novo generation, or blood circulation. Additionally, their contribution to the adult HSC 
population still remains largely contested (Gekas et al., 2005; Ottersbach and Dzierzak, 2005). 
 
The definitive wave of haematopoiesis continues with the colonisation of the foetal liver (FL) 
at E 12.5, where active haematopoiesis occurs at E 14.5. As such, the FL is the main site of 
embryonic haematopoiesis, where HSCs will expand and differentiate, producing the 
hierarchical haematopoietic system (Kumaravelu et al., 2002; Morrison et al., 1995). Shortly 
before birth, the thymus, spleen and BM are colonised between E 16 and E 17, ready to 














Figure 1-1 - Sites of HSC emergence during murine embryonic development. The mesoderm forms 
during gastrulation at embryonic (E) day 6.5, followed by the development of the yolk sac blood islands 
at E 7.5. The definitive wave of haematopoiesis begins with the emergence of HSCs in the aorta-gonad 
mesonephros (AGM) region at E 10.5. Active haematopoiesis occurs in the foetal liver (FL) at E 14.5 and 

















"Primitive" wave "Definitive" wave 
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1.1.2 Properties of HSCs 
HSCs are a relatively rare stem cell population at the apex of the haematopoietic differentiation 
hierarchy. These cells sustain adult haematopoiesis through their ability to self-renewal, 
maintaining the HSC pool, as well as differentiating into all mature blood lineages (Na Nakorn 
et al., 2002; Till and Mc, 1961). 
 
HSCs, like other tissue stem cells, rely heavily on their microenvironment to regulate their 
biology (Ferraro et al., 2010). As such, changes in the stem cell microenvironment during 
embryogenesis impacts the intrinsic properties of HSCs. For example, due to the demanding 
requirements of the developing embryo, foetal liver HSCs are shown to actively cycle. 
Contrastingly, BM HSCs are largely quiescent, which protects them from genotoxic stress, 
while ensuring their long-term functionality in case of stress or injury (Arai and Suda, 2007; 
Essers et al., 2009; Orford et al., 2008). Notably, HSC quiescence can also have a detrimental 
effect, with nonhomologous end joining (NHEJ)-mediated DNA repair found to promote genetic 
mutation in these resting HSCs (Milyavsky et al., 2010; Mohrin et al., 2010) 
 
When directed to exit quiescence, HSCs enter the cell cycle, typically dividing asymmetrically 
to produce one daughter cell resembling the parent, a process known as self-renewal, while 
the other will differentiate into a mature blood cell (Clevers, 2005; Doe and Bowerman, 2001) 
However, under conditions of stress, such as injury or transplantation, HSCs can also divide 
symmetrically, where daughter cells will share the same fate (Zhang et al.). HSCs can undergo 
other cellular fates such as apoptosis, which regulates the fitness and numbers of HSCs 
(Domen et al., 2000). Notably, dysregulation in these division processes can lead to serious 


















Figure 1-2 - HSC fates The tight regulation of adult HSCs protects the stem cell pool, whilst maintaining 
mature blood cell differentiation under steady state and stress conditions. Adult HSCs are primarily in a 
quiescent state, but upon entering the cell cycle, can self-renew, or differentiate, ultimately yielding 
mature functional haematopoietic cells. HSCs can also undergo apoptosis in an aid to regulate the fitness 
























1.1.3 The haematopoietic hierarchy  
Following seminal HSC transplantation experiments in the 1950s and 1960s (Jacobson et al., 
1951; Lorenz et al., 1951; Till and Mc, 1961), haematologists in the 1970s and 1980s sought 
out to define the haematopoietic hierarchical process, ultimately proposing a tree-like 
roadmap, hypothesising haematopoiesis as a step-wise differentiation process, from multi-
potent HSCs, to oligo- and unipotent progenitors (Abramson et al., 1977). Initial experiments 
using invasive stable clonal labelling, which were later replaced by the identification and use 
of cell-surface markers, allowed researchers to define the differentiation process in blood 
lineages (Lemischka et al., 1986). Following the successful and efficient isolation of pure HSCs 
using various combinations of cell-surface markers, the study of HSCs and their progeny 
evolved into a complex, and often controversial field (Adolfsson et al., 2001; Goodell et al., 
1996; Oguro et al., 2013)  
 
The original haematopoietic hierarchy, referred to as a the "classical" haematopoietic 
hierarchy roadmap, describes a distinct differentiation process from HSCs to their progeny. As 
shown in Figure 1-3A, this hierarchy divides HSCs, at the peak of hematopoiesis, into two 
distinct populations; long-term (LT)-HSCs, followed by short-term (ST) HSCs, placed further 
down the hierarchy (Ikuta and Weissman, 1992; Morrison et al., 1994; Spangrude et al., 1988). 
Notably, utilising in vivo limiting dilution assay (LDA) transplantation experiments, Morrison 
and Weissman in 1994 found that LT-HSCs were indeed able to provide successful long-term 
hematopoietic repopulation of irradiated recipient organisms, whereas ST-HSCs had a limited 
self-renewing capacity, able to sustain haematopoiesis in recipient organisms for 8 to 12 
weeks. In 1997, Morrison and colleagues identified multipotent progenitor (MPP) cells, which 
were able to give rise to both myeloid and lymphoid lineages, but had no detectable self-
renewal potential compared to HSCs. 
 
Experiments by Konodo et al in 1997, and Na Nakorn et al in 2002, identified common 
lymphoid progenitors (CLPs), a progenitor cell population restricted to the lymphoid lineage, 
and common myeloid progenitors (CMPs), which give rise to mature myeloid cells. Both 
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populations are derived from MPPs, and together, in turn, differentiate into all functional blood 
cells.  
 
In 2010, the "classical" haematopoietic hierarchy roadmap was updated to include a transitory 
HSC population referred to as intermediate-term (IT) HSCs, whose self-renewal ability falls 
between LT-HSCs and ST-HSCs (Benveniste et al., 2010; Yamamoto et al., 2013). 
Additionally, the MPP population was sub-divided into 4 distinct populations (MPP1, MPP2, 
MPP3 and MPP4), based on their immunophenotyped, BM abundance, cell-cycle status and 
differentiation ability. As shown in Figure 1-3B, the MPP1 population shares similar properties 
to that of the ST-HSCs, whereas MPP2 has a myeloid differentiation bias, and MPP4, a 
lymphoid differentiation bias (Cabezas-Wallscheid et al., 2014; Oguro et al., 2013; Pietras et 
al., 2015). Furthermore, Adolfsson and colleagues in 2005 discovered a sub-population of 
HSCs, with high expression of Flt3, ultimately defined as lymphoid-primed multipotent 































Figure 1-3 - Classical and revised haematopoietic hierarchy roadmaps (A) The "classical" model of 
the hematopoietic hierarchy describes long terms (LT) HSCs and short term (ST) HSCs, respectively, at 
the apex of the differentiation hierarchy. The HSCs give rise to multi-potent progenitor (MPP) cells, which, 
in turn, commit to either a committed lymphoid progenitor (CLP), which differentiate into lymphocytes, or 
committed myeloid progenitor (CMP). CMPs produce mature myeloid cells through the 
megakaryocyte/erythrocyte progenitor (MEP), or granulocyte/macrophage progenitor (GMP). (B) In the 
revised roadmap, LT-HSCs, IT-HSCs and ST-HSCs are all multipotent progenitors occupying the top of 
the hierarchy. HSCs then differentiate into MPP2, MPP3, and MPP4/LMPP cells. The MPP2 population 
gives rise to CMP cells, whereas MMP4/LMPP cells differentiate to yield cells of the lymphoid lineage. 













"Classical"  "Revised"  
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1.1.3.1 Advances in the haematopoietic hierarchy 
Until recently, dissection of the haematopoietic hierarchy relied upon functional transplantation 
assays, and well as cell-surface markers, identifying distinct, obvious hierarchical boundaries 
(Laurenti and Gottgens, 2018). Innovation in experimental design and techniques, such as 
single-cell RNA sequencing, gave rise to the study of individual HSCs, tracking their journey 
from the most primitive stem-cell status, to their differentiated cell fate (Zhang et al., 2018). 
 
Computational analysis of high-throughput single-cell transcriptome data has been used to 
study the interaction dynamics between haematopoietic cells. Conducted in both zebrafish 
and murine models, these studies have unmasked the true nature of the haematopoietic 
process (Alemany et al., 2018; Briggs et al., 2018; Farrell et al., 2018). Using this strategy, 
multiple groups identified that instead of existing as a distinct, step-wise hierarchy, 
haematopoiesis occurs as a continuous process. In addition, lineage tracing experiments 
conducted by Sawai et al in 2016 verified that HSCs support endogenous steady-state 
haematopoiesis. Thus, the hierarchy is maintained by low-primed undifferentiated 
haematopoietic stem and progenitor (HSPC) cells, which gradually differentiate into mature 
functional blood cells (Plass et al., 2018; Velten et al., 2017). 
 
Seminal work by Mansson and colleagues in 2007 further challenged the "classical" 
haematopoietic hierarchy by discovering that lineage segregation occurs during early 
haematopoiesis and does not rely upon linear hierarchical differentiation processes. In these 
studies, Sanjuan-Pla et al in 2013 found that some HSCs in their primitive state were found to 
have high expression of the von Willebrand factor (Vwf), a megakaryocyte-specific gene. Upon 
transplantation, these vWF+ HSCs had robust short- and long-term reconstitution ability for 
megakaryocytes. In concordance with this, more recent studies have found that the generation 
of megakaryocytes can bypass the stages of MPP, CMPs and MEPs, and can directly 
differentiate from HSCs (Notta et al., 2016). Moreover, it is now evident that within the 
immunophenotypically cell-surface marker defined HSC compartment, there is a population of 
HSCs which are not multipotent, but are instead pre-disposed to a lineage fate (Copley et al., 
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2012; Muller-Sieburg et al., 2012). Tang et al in 2017, and Buenrostro et al in 2018 found that 
heterogenic HSCs retain their HSC-linked gene expression signature, but have altered 
chromatin architecture at lineage-specific gene loci, thus directing their lineage fate. Thus, 
these data present strong evidence of a continuous, unbalanced-lineage differentiation 



























1.1.4 Immunophenotypic characterisation of murine HSPCs 
As previously mentioned, the study of hematopoiesis and its hierarchy was significantly 
propelled   by the research into, and the success of, immunophenotypic characterisation of 
murine HSPCs (Goodell et al., 1996; Heimfeld and Weissman, 1991; Ikuta and Weissman, 
1992; Weissman et al., 2001). Ikuta and Weissman in 1992 found that 5 to 10 % of all BM cells 
expressed the mast/stem cell growth factor receptor, CD117, also referred to as cKit. This 
marker of primitive haematopoiesis was combined with the stem cell antigen-1 (Sca-1+), within 
the lineage negative population (Lin−), to isolate Lin-cKit+Sca-1+ (LSK) HSPC cells. This cell-
surface marker combination successfully characterises LT-HSCs, ST- HSCs and MPPs, and 
still remains relevant in the haematopoietic field (Li and Johnson, 1995; Spangrude et al., 
1988; Weissman et al., 2001). 
 
Adolfsson and colleagues in 2001 and 2005 sought to further dissect the LSK compartment 
using CD34 and Flt3. It was discovered that there was no CD34 or Flt3 expression in the LT-
HSCs at the top of the haematopoietic hierarchy, but cells acquire these markers as they 
become more progenitor-like in nature, with ST-HSCs expressing CD34 (LSKCD34+Flt3−), and 
LMPPs expressing both CD34 and Flt3 (LSKCD34+Flt3+). Notably, as an alternative to CD34 
and Flt3, the HSPC compartment can be sub-categorised using the SLAM family of surface 
markers. These cell surface markers include CD48, CD150 and CD224 and can isolate LT-
HSCs (LSK CD150+CD224−CD48−), MPPs (LSK CD150-CD224+CD48-) and the committed 
progenitors HPC1 (LSK CD150-CD224−CD48+) and HPC-2 (LSK CD150+CD224+CD48+) (Kiel 
et al., 2005; Kim et al., 2006; Oguro et al., 2013).  
 
Currently, experiments requiring the isolation and purification of HSPCs rely on LSK analysis, 
in combination with either CD34 and Flt3, or CD150 and CD48 cell-surface markers (Guitart 
et al., 2017; Guitart et al., 2013; Kranc et al., 2009; Takubo et al., 2010; Vukovic et al., 2016). 
Notably, more committed progenitors such as CMP, CLP, MEP and GMP can also be studied 
using various cell surface markers including CD16/32, CD41, CD105, CD244.2, CD229, 














Figure 1-4 - Immunophenotypic characterisation of the murine haematopoietic hierarchy using 
cell-surface markers LT-HSCs (CD34-CD150+CD48-CD41-Flt3-CD49lo) reside at the top of the 
hierarchy giving rise to IT-HSCs (CD34-CD150+CD48-CD41-Flt3-CD49hi), ST-HSCs (CD34-
CD150+CD48-Flt3+) and MPP cells (CD34+CD150+Flt3+). MPPs then further differentiate into LMPPs 
(Sca-1hicKithiFlt3+CD127+) and which, in turn, commit either the CLP (Sca1locKitloFlt3+CD127+) or GMP 
(CD16/32hiCD34hiSca-1-) fate. Concerning the myeloid lineage, the CMP (CD16/32loCD34intSca-1-) can 



















1.1.5 Regulation of HSCs 
The emergence, development and differentiation of HSCs is orchestrated by various intrinsic 
and extrinsic factors such as cytokines, growth factors, transcription factors, and the HSC 
niche. Understanding how these factors implicate the biology of HSCs is vital, as disruption of 
this fine balance of factors can result in pathological disorders such as BM failure or 
haematological malignancies (Krause., 2002).  
 
1.1.5.1 Transcription factors 
Intricate biological processes such as haematopoiesis rely on large transcriptional networks, 
with a high degree of connectivity between transcriptional factors (TFs) and transcriptional 
cofactors. By binding to specific DNA sequence motifs within gene regulatory regions, TF 
proteins are crucial in controlling gene expression, and thus control cellular phenotypes 
(Gottgens, 2015).Despite its complexity, multiple molecular techniques such as DNase1 
mapping, whole genome sequencing and chromatin immunoprecipitation assays, have 
unveiled over 50 transcription factors (TF), which have all been shown to affect the 
functionality of HSCs (Wilson et al., 2008). Notably multiple TFs vital for HSC regulation such 
as Stem Cell Leukaemia (SCL), Runt-related transcription factor 1 (RUNX1), Mixed Lineage 
Leukaemia (MLL) and Lim Only domain 2 (LMO2) are also commonly present in chromosomal 
translocations in haematopoietic malignancies, demonstrating the vital importance in 
dissecting the role of these TFs in normal and malignant haematopoiesis (Chen et al., 2009; 
Okuda et al., 1996; Patterson et al., 2007; Robb et al., 1995). A summary of the main 
transcription factors implicated in haematopoiesis is shown below in Table 1-1. 
 
In addition to roles in primitive haematopoiesis, there are multiple TFs that are essential to the 
lineage specification of HSCs and progenitor cells. Given the complexity of the haematopoietic 
hierarchy, there are various sets of TFs, which physically interact with one another, and play 
antagonising roles in lineage differentiation. For example, Purine-rich sequence 1 (PU.1), 
which activates genes involved in myelopoiesis, impacting the CMP, GMP and CLP 
populations, interacts with GATA-1, which is highly expressed in MEPs (Rhodes et al., 2005).  
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Table 1-1 Transcription factors controlling haematopoiesis 
 
  
Transcription Factor (TF) Role in haematopoiesis  
Stem Cell Leukaemia  
(SCL) 
A basic helix-loop-helix (bHLH) TF and a common translocation partner in 
T-ALL (Begley et al., 1989; Bernard et al., 1990). SCL dictates HSC fate 
towards the erythroid and megakaryocyte lineages (Kunisato et al., 2004; 
Zhang et al., 2005). 
Runt-related transcription 
factor 1 (RUNX1) 
A core binding factor (CBP) required for the emergence of HSCs in the yolk 
sac, and development of HSCs throughout adulthood (North et al., 2004; 
Teitell and Mikkola, 2006).  
Mixed lineage leukaemia 
(MLL) 
MLL has a critical role in HSCs in foetal and adult HSCs, as well as an 
involvement in AML and ALL (McMahon et al., 2007; Slany, 2009). It 
encodes a SET-domain containing a histone methyltransferase region, 
which is shown to be active in chromatin remodelling, activating Hox genes 
(Milne et al., 2002). 
Lim only domain 2 (LMO2) LMO2 belongs to the large zinc finger protein LMO family (Kadrmas and 
Beckerle, 2004), and is required for definitive haematopoiesis, and 
commitment to the erythroid lineage (Yamada et al., 1998). 
Globin transcription factor 
2 
(GATA2) 
GATA2 is essential for erythropoiesis and definitive haematopoiesis, with 
broad expression across all haematopoietic cells (Tsai et al., 1994; Weiss 
and Orkin, 1995). It is involved in the production and expansion of HSCs in 
the AGM, and the proliferation of HSCs in the BM (Ling et al., 2004). 
Purine-rich sequence 1 
(PU.1) 
An ETS-family TF that functions in the early and late stages of both 
lymphoid and myeloid lineage differentiation and commitment (Gupta et al., 
2009; Laslo et al., 2006). 
Homeobox A9  
(HOXA9) 
HOXA9 is member of the class I homeobox genes and is highly expressed 
in both FL and BM primitive haematopoietic compartment (Ramos-Mejia et 
al., 2014; Sauvageau et al., 1994). 
Myeloid ecotropic viral 
integration site 1  
(MEIS1) 
First discovered as a common viral integration site in the BXH-2 model of 
myeloid leukaemia (Moskow et al., 1995), MEIS1 is highly expressed in the 
primitive compartment, and is downregulated in differentiated cells 




1.1.5.2 HSC niche 
In adults, HSCs reside within the BM microenvironment, which helps protect and nourish HSCs 
through the secretion of soluble factors and instigating vital cell-cell interactions (Calvi et al., 
2003; Kiel et al., 2005). First coined by Schofield in 1978, the "niche hypothesis" proposed 
that the BM niche prevented HSCs from entering the cell cycle, and so protected them from 
exhaustion and errors in DNA repair, thus ensuring efficient life-long haematopoiesis. 
Experiments by (Dexter et al., 1977)Dexter and colleagues in 1977 corroborated this 
hypothesis, discovering that BM stromal cells from the HSC niche promoted ex vivo 
proliferation and differentiation of HSPCs in long-term cultures. 
 
Despite a greater understanding of the anatomy of the stem cell niches within the bone 
marrow, there is continued debate over the positioning of HSCs within this niche, and thus 
which cell-cell interactions directly implicate HSC biology. Initial studies aiming to locate the 
HSC niche within the BM microenvironment transplanted labelled HSPCs into recipient mice, 
and found that these primitive cells locate to the highly vascularised endosteal region near the 
bone surface (Nilsson et al., 2001; Xie et al., 2009). Further investigations by Kiel and 
colleagues in 2005, and Nombela-Arrieta and colleagues in 2013, found that the majority of 
HSCs are present in the perivascular region, and are enriched in the endosteal region.  
 
Recent advances in imaging technology, in combination with simplified HSC isolation 
protocols, have greatly progressed the study and understanding of the HSC niche. Central to 
the biology of the BM microenvironment is the highly vascularised setting present in the long 
bones of adult mammals (Figure 1-5). In these bones, central arteries give rise to radial 
arteries, that ultimately branch into arterioles near the endosteum (Nombela-Arrieta et al., 
2013). The vascular network includes venous sinusoids, which extend back toward the central 
cavity of the bone, where they form a large central sinus. Notably, despite the high vascular 
density of the tissue, the bone marrow microenvironment is hypoxic, with the lowest oxygen 


















Figure 1-5 - Anatomy of the BM HSC niche The highly vascularised setting in the long bones of adult 
mammals dictates the biology of the HSC niche. Arterioles near the endosteum are hypothesised to 
support dormant HSCs, where factors such as CXCL12 and SCF secreted by perivascular, endothelial, 
Schwann, and sympathetic neuronal cells promote their maintenance. Venous sinusoids support 
quiescent or activated HSCs in the central BM. The revised model of oxygen tensions in the bone marrow 
revealed that the peri-sinusoidal region is more hypoxic than endosteal region, which is supplied with 
arterioles  (Taken and adapted from Boulais et al., 2015; Spencer et al., 2014). 
 
 
Interestingly, recent studies elucidate that the endosteal region itself can conceptually be split 
into two separate stem cell niches: the sinusoidal-megakaryocyte niche, which contains 
sinusoidal endothelial cells, megakaryocytes, and CAR cells; and the arteriolar-pericyte niche, 
which includes arteriolar endothelial cells, NG2+ arteriolar pericytes, CAR cells, sympathetic 
nerves, and non-myelinating Schwann cells (Figure 1-6). Advocates of the sinusoidal-
megakaryocyte niche argue that approximately 20 % of phenotypic HSCs are localised 
adjacent to megakaryocyte cells, which in turn, are closely associated with BM sinusoidal 
epithelial tissue, showing close physical interaction between the niche and HSCs. 
Megakaryocytes are thought to suppress HSC proliferation, as ablation of megakaryocytes 





In support of the arteriolar-pericyte niche, Kunisaki and colleagues in 2013 demonstrated that 
the arteriolar niche, enclosed by a rare population of NG2+ pericytes, helps maintain the 
quiescence of HSCs. Elements of this niche; the bone marrow endothelial cells and arteriolar 
pericytes, both produce multiple factors that contribute to HSC maintenance, including stem 
cell factor (SCF), CXCL12, and E-selectin (Ding et al., 2012; Greenbaum et al., 2013). 
Additionally, this niche is aided by cells of the nervous system, where sympathetic nerves 
regulate HSC egress from the bone marrow through controlling stromal cell CXCL12 
expression (Katayama et al., 2003; Mendez-Ferrer et al., 2008), and non-myelinating Schwann 










Figure 1-6 - Endosteal stem cell niches (A) The sinusoidal-megakaryocyte niche contains sinusoidal 
endothelial cells, megakaryocytes, and CAR cells. (B) The arteriolar niche includes arteriolar endothelial 
cells, NG2+ arteriolar pericytes, CAR cells, sympathetic nerves, and non-myelinating Schwann cells. 
Notably, a subset of HSCs are known to localise near the endosteum, placing osteoblast lineage cells 
(OB) in these niches (Taken from Calvi et al., 2015). 
 
 
The localisation of HSCs to endosteal sites supports the hypothesis that osteoblast lineage 
cells, also referred to as osteolineage cells, are a fundamental component of haematopoiesis. 
Osteolineage cells produce a number of cytokines implicated in HSC regulation, including 
granulocyte colony-stimulating factor (G-CSF), thrombopoietin, angiopoietin 1, and CXCL12, 
suggesting a supportive role in haematopoiesis (Jung et al., 2006; Qian et al., 2007; Taichman 
and Emerson, 1994; Yoshihara et al., 2007). Indeed, genetic studies using mice deficient in 




the foetal liver and spleen of mutant embryos as a direct result of bone marrow failure (Deguchi 
et al., 1999). Zhang and colleagues in 2003 proposed that osteoblasts support HSC function, 
as they found a direct correlation between the number of spindle-shaped N-cadherin+CD45- 
osteoblastic (SNO) cells and HSCs. In addition, Calvi et al in 2003 found that an increase in 
osteoblastic cells resulted in an expansion of HSCs.  
 
Opposing these data completely, Acar et al in 2015 reported that non-dividing HSCs were 
more abundant in the perisinusoidal region of the central marrow, not in the endosteal regions. 
This study used a novel GFP reporter mouse, under control of the Ctnnal1 gene, which is 
expressed almost exclusively in HSCs, producing a very specific HSC reporter. It is evident, 





















1.1.6 Hypoxia and HSCs 
HSCs reside within the BM microenvironment, which exhibits low pO2 when compared to 
other tissues in the adult organism (Takubo et al., 2010). Seminal studies into the bone 
marrow microenvironment were conducted by Draenert and Draenert in 1980, who utilised a 
scanning electron microscope to generate three-dimensional images of the vascular 
organisation of the BM. These images revealed a unique vascularisation architecture, 
whereby arterioles gave rise to an enlarged canonical arrangement of arterial capillaries in 
the sinusoids, enabling easy movement of HSCs. The nature of this highly vascularised 
structure leaves it vulnerable to the limited perfusion and low pO2. This is especially evident 
in the endosteal region of the BM, where HSCs are thought to reside (Nilsson et al., 2001; 
Wilson et al., 2008; Xie et al., 2009). 
 
Oxygen measurements of BM aspirates of healthy individuals found a relatively high mean 
pO2 value of 55 mmHg ± 0.95, and mean O2 saturation of 87.5 % ± 1.1 % (Harrison et al., 
2002). Simulation studies, however, predicted that close proximity (within 100 μm) to the BM 
vasculature resulted in a 90 % drop in the pO2, consolidating the relationship between BM 
vasculature and low oxygen levels. Notably, due to abundance of haemopoietic cells in the 
BM, there is high O2 consumption, lowering pO2 overall (Chow et al., 2001). 
 
The relationship between HSCs and their hypoxic bone marrow niche was dissected in a 
series of insightful experiments which injected mice with a perfusion dye, pimonidazole (Pimo), 
and the nucleic acid dye, Hoechst 33342 (Parmar et al., 2007; Simsek et al., 2010). Notably, 
Pimo is a 2-nitroimidazole-hypoxia probe, which is reduced in hypoxia, forming hydroxylamine, 
which covalently binds to thiol-containing proteins in hypoxic cells. The protein adducts can be 
detected using immunostaining techniques (Olive et al., 2000). These experiments found that 
cells isolated from areas of the BM with the highest concentration of HSCs and primitive 
progenitors, were at the lowest end of the Hoechst perfusion dye gradient. Furthermore, these 
cells with low Hoechst perfusion, highly retained the Pimo dye, suggesting the hypoxic nature 
of the HSCs (Parmar et al., 2007). 
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In concordance with this, to analyse the relationship between HSPCs and the cells of the BM 
niche, Lo Celso and colleagues in 2009 used a combination of high-resolution confocal 
microscopy and two-photon video imaging to study the calvarium BM of live adult mice. The 
authors found that transplanted HSPCs were found in close proximity (0 - 16 μm) to the 
vasculature, where there are low pO2 levels. Interestingly, localisation of transplanted HSPCs 
closer to the highly vascularised endosteum region improved their engraftment potential, 
suggesting a role between hypoxia and HSC biology. Notably, employing live-imaging 
techniques in the calvarium, Spencer and colleagues in 2014 found that the perisinusoidal 
niche of the BM had lower pO2 values when compared to the endosteal niche. The endosteal 
region (0-20 μm from the bone) was found to have pO2 levels of 21.9 mm Hg (2.9 %) in the 
vessels, and 13.5 mm Hg (1.8 %) outside the vessels. Further from the bone (>40 μm), the 
perisinusoidal region had significantly lower pO2 levels of 17.7 mm Hg (2.4 %)  in the vessels, 
and 9.9 mm Hg (1.3%) outside the vessels. Notably, the authors also hypothesised this 
hypoxic sinusoidal region was the residence of non-diving HSCs. Despite their geographical 
differences, both Lo Celso and colleagues in 2009, and Spencer and colleagues in 2014 
support the notion of a hypoxic HSC niche.  
 
Interestingly, HSCs that are localised in a low-oxygenated niche remain quiescent, expressing 
high levels of Notch1, N-cadherin, and the cell cycle inhibitor p21, compared to cells residing 
near well-oxygenated vasculature (Jang and Sharkis, 2007). In agreement with this, Hermitte 
and colleagues in 2006 found that under extreme hypoxic conditions (0.1 %), human CD34+ 
cells acquired a quiescent state. Moreover, human CD34+CD38- cord blood cells cultured in 
1% O2, re- acquired this hypoxic induction of quiescence, and exhibited improved 
reconstitution potential with enhanced expression of p21 when transplanted into 
immunodeficient mice (Danet et al., 2003; Shima et al., 2009). This suggests hypoxia protects 
the immature, quiescent state of HSCs, and so, in turn, safeguards lifelong haematopoiesis. 
 
Unwin and colleagues in 2006 compared the proteome of primitive LSK cells, with the 
proteome of haematopoietic cells lacking cKit expression (Lin-Sca-1+cKit-). The authors found 
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145 dysregulated proteins, a large percentage of which were involved in metabolic adaption, 
with LSK cells favouring anaerobic glycolysis over mitochondrial oxidative phosphorylation. 
Simsek et al in 2010 corroborated this result, and stated that LT-HSCs switch to glycolysis to 


























1.2 Hypoxia signaling pathways 
Cellular responses to low oxygen levels are predominantly orchestrated by the hypoxia-
inducible factors (HIFs), Hif-1, Hif-2, and Hif-3. These factors regulate gene expression of 
important cellular processes such as cell cycle and cell growth, metabolism, oxygen 
homeostasis, apoptosis and autophagy (Greijer et al., 2005). Experiments utilising genomic 
chromatin immunoprecipitation (ChIP) assay techniques, found that HIF binds to more than 
100 genomic loci, suggesting it is actively involved in the transcription of hundreds of genes 
(Mole et al., 2009; Schodel et al., 2011). 
 
HIFs exist as heterodimeric transcription factors, comprising of a cytoplasmic oxygen-
regulated α subunit (HIF-α) and a stable constitutive nuclear β subunit (HIF-β) (Kaelin and 
Ratcliffe, 2008; Wang et al., 1995). Under normoxic conditions, the HIF-α subunit is 
hydroxylated by the HIF-prolyl hydroxylases (HPHs), also referred to as prolyl hydroxylase 
domain (PHDs) proteins (Masson and Ratcliffe, 2003). PHDs recognise a specific LXXLAP 
motif in the oxygen-dependent degradation domain (ODDD) of the HIF-α subunits, and 
hydroxylate two conserved proline residues, Pro402 and Pro564. Notably, PHDs belong to a 
subfamily of dioxygenases that use 2-oxoglutarate (2-OG) and O2 as co-factors, and are thus 
oxygen-dependent. This process is highly efficient, as HIF is almost undetectable when 
oxygen is available. Following hydroxylation by PHDs, the hydroxylated HIF-α subunits are 
recognised by VHL (von Hippel-Lindau), which fittingly has a 1000-fold increase in affinity for 
hydroxylated HIF, compared to its non-hydroxylated form (Masson et al., 2001). VHL then acts 
as an E3 ubiquitin ligase, and HIF-α is rapidly destroyed via the polyubiquitination/proteasomal 
degradation pathway (Ivan et al., 2001; Jaakkola et al., 2001; Maxwell et al., 1999). In hypoxic, 
or low oxygen conditions, there is a decrease in the activity of PHDs, yielding a significant 
reduction in the hydroxylation of HIF-α subunits, resulting in their accumulation. As such, HIF-
α translocates to the nucleus, where it binds with its HIF-β partner and recruits p300/CBP co-
activator to form a transcriptionally active complex (Wang et al., 1995) (Figure 1-6). 
Downstream, the HIF complex binds to the hypoxia response elements (HREs) of hypoxia-
responsive genes, such as EPO (erythropoietin) and VEGF (vascular endothelial growth 
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factor), promoting their transcription (Elvidge et al., 2006; Ruas et al., 2005; Schodel et al., 
2011). 
 
Notably, in addition the PHD proteins, HIF regulation, and thus the hypoxia response, is 
controlled by another member of the 2OG dependent oxygenase family, FIH-1 (factor inhibiting 
HIF-1). FIH-1 hydroxylates an asparagine residue (Asn 803) in the C terminus of HIF-α, 
preventing its binding to the transcriptional co-activator p300/CBP (Elvidge et al., 2006). While 
PHDs are highly dependent on oxygen and have significant affinity to HIF, FIH on the other 
hand is known to be active under severe hypoxia and has alternative substrates, namely 
members of the ankyrin repeat domain (ARD) family, for which it has a higher affinity to than 













Figure 1-7 - Hypoxia signalling pathway (A) Under normoxic conditions, PHD enzymes hydroxylate 
the Hif-α subunits, targeting them degradation in the proteasome. (B) In low oxygen conditions, the PHD 
enzymes are less active, and so the Hif-α subunits are able to translocate to the nucleus, bind to their 
Hif-β partners, and activate expression of multiple genes vital for the hypoxia response (Taken from 







1.2.1 HIF in haematopoiesis 
Given the intricate relationship between the hypoxic bone marrow niche and haematopoiesis, 
there have been significant research efforts to understand the role of the HIF in normal and 
malignant haematopoiesis. Early experiments in this field found that both Hif-1α and Hif-2α 
are highly expressed in HSCs, and that Hif-1 is upregulated at both a transcriptional and 
protein level in primitive LSK cells (Takubo et al., 2010; Simsek et al., 2010). 
 
Following this, multiple research papers, including those published by the Kranc laboratory, 
have dissected the role of HIF in haematopoiesis using transgenic mouse models (Gezer et 
al., 2014; Guitart et al., 2013; Vukovic et al., 2015; Vukovic et al., 2016). Published in 2013, 
Guitart and colleagues generated a transgenic mouse model which deleted Hif-2α specifically 
within the haematopoietic system (Hif-2αCKO). These conditional knockout mice were used to 
study the effect of Hif-2α deletion on steady-state and stressed haematopoiesis. Analysis of 
these mice found that deletion of Hif-2α had no effect on the number of HSCs, or their self-
renewal capacity under transplantation assay. Additionally, co-deletion of Hif-1α and Hif-2α 
had no effect on the HSC compartment. Further studies by the Kranc laboratory unveiled that, 
analogous to results shown in the Hif-2αCKO mice, Hif-1α deletion proved to be dispensable for 
cell-autonomous HSC survival, even in stress-induced conditions (Vukovic et al., 2016). 
Altogether, these results present significant evidence that both Hif-1α and Hif-2α are not 
essential regulators of HSC function.  
 
Conversely, work published by Takubo et al in 2010 reported that Hif-1α had a vital role in 
HSC regulation, with Hif-1αCKO mice displaying decreased HSC numbers, as well as a 
reduction in HSC fitness upon transplantation. Notably, these experiments were conducted 
using the same Hif-1αCKO (Hif1fl/fl;Mx-Cre+), mice and were carried out with only minor 





After comprehensively investigating the effect of HIF deletion in haematopoiesis, and 
discovering that deletion of  Hif-1α and Hif-2α has no effect of normal hematopoiesis, this 
manuscript focuses on the role of the HIF prolyl hydroxylase domain (PHDs) proteins, the 


























1.3 Prolyl hydroxylase domain proteins (PHDs) 
Prolyl hydroxylase domain proteins (PHDs) belong to a superfamily of iron- and 2-
oxoglutarate-dependent dioxygenases, referred to as 2-oxoglutarate (2-OG) dioxygenases. In 
mammals there are 4 PHD isoforms; PHD1, PHD2, PHD3, and the recently discovered PDH-
TM (Koivunen et al., 2007). Overall the PHDs show a 42 – 59% sequence similarity, with PHD2 
most closely related to the ancestral HIF-PHDs found in Drosophila melanogaster and 
Caenorhabditis elegans (Appelhoff et al., 2004). Notably, there is significant literature on 
PHD1, PHD2 and PHD3, but little is known about the function of PHD-4 (also referred to as 
P4H-TM) (Fan et al., 2014). 
 
The full-length structures of PHD1 and PHD2 have over 400 amino acid residues (407 and 
426 in humans, respectively), and share approximately 55 % identity within the well-conserved 
hydroxylase domain at their C-terminus. The N-terminal halves, however, are more variable, 
and have not been extensively characterised (Epstein et al., 2001). Notably, the PHD3 protein 
is significantly shorter than PHD1 or PHD2, composed of only 293 amino-acid residues in 
humans. It contains the shared hydroxylase domain, but only a short stretch of divergent N-
terminal sequence (Jokilehto and Jaakkola, 2010) (Figure 1-7). 
 
 All PHD isoforms hydroxylate proline residues on HIF-α but differ in their substrate specificity. 
Interestingly, it was found that PHD2 has a greater affinity to HIF-1α than HIF-2α, whereas 


















Figure 1-8 – Structure of PHDs PHD1, PHD2 and PHD2 all have a conserved hydroxylase domain 
(P4HC) at the C-terminal ends. Additionally, PHD2 contains a zf-MYND (zinc-finger domain) that may 
interact with regulatory proteins. Both PHD1 and PHD2 contain potential subcellular localization signal 























1.3.1 PHD activity 
Post-translation protein hydroxylation has been well studied and characterised in structural 
biology, however, the hydroxylation of HIF-α by the PHD proteins is the first identified example 
of a hydroxylation reaction being used in cell signalling (Schofield and Ratcliffe, 2005). 
Therefore, the activity of PHDs is of great biochemical and physiological interest.  
 
Hirsila et al in 2005 found that, similarly to protein hydroxylases which orchestrate structural 
modifications, PHDs have a high enzymatic turnover rate, measuring at approximately 50 
mol/mol/min. Despite this high rate of turnover, and the low abundance of the enzymatic 
substrate HIF, the hypoxia response is limited by the hydroxylation activity of PHDs. In all 
situations, except a blockade in VHL activity, accumulation of HIF is in a non-hydroxylated 
form, elucidating that the hydroxylation step is rate limiting. Additionally, genetic or 
pharmacological inactivation of PHDs leads to consistent constitutive activation of the HIF 
pathway, regardless of the oxygen status (Joharapurkar et al., 2018). 
 
Given the evident importance of PHD activity within the hypoxia response, it is vital to 
understand the regulation of PHDs in vivo. For PHDs to function as hydroxylases, they require 
molecular oxygen, the citric acid cycle 2-oxoglutarate (2-OG), iron (Fe2+), and ascorbic acid 
(vitamin C) (Bruick and McKnight, 2001; Epstein et al., 2001; Schofield and Ratcliffe, 2005). 
As such, each of these factors can limit the activity of the PHDs, thus the hypoxia response. 
Moreover, as shown in Figure 1-8, there are also multiple intracellular factors that can impact 
the activity of PHDs. 
 
Following on from their previous research into the enzymatic activity of PHDs, Hirsila and 
colleagues in 2005 found that all PHDs have Km values for oxygen between 230 and 250 μm, 
which is above the concentration of atmospheric O2 at approximately 200 μm. Intracellular 
oxygen concentrations are typically below this, thus high Km values ensure facilitation of 
oxygen-dependent hydroxylase activity, given sufficient levels of all other substrates and 
cofactors. Supporting this, human and murine cell lines cultured under very low oxygen 
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conditions (0.5 - 2 % O2) accumulate HIF-1α. Notably, Pan et al in 2007, and Hagen et al in 
2013 found that this HIF-α accumulation is dependent on functional mitochondria.  
 
Mitochondria have a significant role in the activity of PHDs as they produce 2-OG, an essential 
co-substrate in the hydroxylation reaction due to its role in the Fe2+ coordination in the catalytic 
centre (Epstein et al., 2001). Moreover, mitochondria produce other TCA cycle intermediates 
such as succinate and fumarate, which have an inhibitory role in the enzymatic activity of the 
PHDs, by competing for the 2-OG active site (Selak et al., 2005). Under normal physiological 
circumstances, the cytosolic concentrations of succinate and fumarate are very low, and so 
do not pose a threat to PHD activity. However, mitochondrial defects, or experimental 
overexpression of these factors does lead to a significant accumulation of HIF-1α levels 
(Hewitson et al., 2007). 
 
Reactive oxygen species (ROS), which can also be produced by the mitochondria, are also 
thought to inhibit PHDs by chelating Fe2+ and oxidising PHD bound Fe2+ to Fe3+, essentially 
disrupting the interaction between oxygen and PHDs (Ozer and Bruick, 2005; Pan et al., 2007). 
Notably, other heavy metals including Co2+, Ni2+ and Mn2+ are also chelators of Fe2+, inhibiting 
























Figure 1-9 – Factors regulating the function of PHDs PHDs require 2-OG, O2 and Fe2+ to hydroxylate 
HIF-α. Inhibitory factors of PHD function include the metabolic intermediates succinate and fumarate; 
divalent metal ions such as Co2+ or Ni2+, which compete with Fe2+ binding to PHDs; and reactive oxygen 



















1.3.2 HIF-independent functions of PHDs 
Despite the strong affinity to HIF, and an intimate relationship with molecular oxygen, PHDs 
are also known to function in a HIF-independent manner, where they are able to regulate the 
expression of target proteins, with or without hydroxylation (Hiwatashi et al., 2011). Notably, 
this is an emerging area of research, with further HIF-independent PHD functions likely to 
emerge.  
 
Studies by Koditz et al in 2007 sought to identify novel PHD protein interactions through a 
yeast-2-hybrid experimental system. Results from these experiments revealed an interaction 
between ATF-4 and both PHD1 and PHD3. ATF-4 is a member of the ATF/CREB family of 
transcription factors, which are activated following cellular stress (B'Chir et al., 2013). Koditz 
et al also reported that HeLa cells treated with the PHD inhibitor dimethyloxalylglycine 
(DMOG), had an increase in ATF-4 activity, suggesting that PHD negatively regulates ATF-4. 
In concordance with this, co-immunoprecipitation assays confirmed the direct interaction 
between PHD1 and ATF04, and PHD3 and ATF-4, entirely independent from HIF (Hiwatashi 
et al., 2011). 
 
Additionally, multiple papers have unveiled an association between the PHD family and the 
NF-κβ pathway, which is known to play a role in many biological processes such as apoptosis, 
differentiation, proliferation and immune responses (Liu et al., 2005). Studies by Fu and 
Taubman in 2007 found that cells treated with DMOG had an enhanced activation of the NF-
κβ signalling pathway. Downstream, PHD inhibition also induced expression of NF-κβ target 
genes such as YY1 and Cyclin D1. Notably, PHD1 has also been reported to bind and inhibit 
Iκκβ, which is known to regulate NF-κβ activity (Cummins et al., 2006).  
 
Furthermore, a fascinating study by Duran et al in 2013 found that amino acid starvation results 
in depletion of 2-OG, resulting in a reduction in PHD activity, but not HIF stabilisation. Inhibition 
of PHDs with DMOG and short-hairpin constructs targeting the PHD family, resulted in 
increased autophagy, and prevented mammalian target of rapamycin complex 1 (mTORC1) 
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activation by amino acids. These PHD dependent phenotypes were also found to function in 
a HIF-independent manner. This paper suggests that in addition to their oxygen sensing role, 
PHDs are also involved in the amino-acid sensing process, possibly unveiling a role for PHDs 


























1.3.3 Biological function of PHDs 
The hypoxia dependent, and newly discovered hypoxia-independent roles of the PHD family, 
translate into various biological functions in vivo. First discovered in the model organism 
Caenorhabditis elegans, loss of EGL-9, the prototype of PHDs, was found to significantly 
elevate levels of HIF-α and reduce egg-laying function (Epstein et al., 2001). In Drosophila 
melanogaster its single PHD protein was found to be essential for cell growth in fat bodies and 
wing imaginal discs (Frei and Edgar, 2004; Frei et al., 2005).  
 
In humans, the hypoxia pathway is implicated in multiple biological processes including 
angiogenesis, energy metabolism and erythropoiesis (Pugh and Ratcliffe, 2017). As such, the 
PHD enzymes have a number of important developmental and physiological functions. For 
example, during normal development, PHD3 orchestrates the apoptosis of sympathetic 
neuronal precursor cells. Deletion of PHD3 in this setting results in a failure of apoptosis and 
development of neuroendocrine tumours known as pheochromocytomas (Lee et al., 2005). 
However, PHDs have also been reported to have an anti-apoptotic role, with deletion of PHDs 
in maturing chondrocytes, promoting cell survival rather than apoptosis (Bohensky et al., 
2007). 
 
Takeda and colleagues in 2007 investigated the role of PHDs in vivo using Phd2 conditional 
knockout mice and found that deletion of Phd2 resulted in an increase in angiogenic factors 
such as VEGF-A and erythropoietin (EPO). Increase in circulating levels of VEGF and EPO 
resulted in an increase in vascular growth observed in the density and lumen sizes of 
vasculature tissues. Given that cells deficient in PHD2 have increased erythropoiesis and 
vascular growth, there is now substantial interest in the pharmacological value of PHD 
inhibitors, with multiple compounds showing positive therapeutic results in kidney disease and 






1.3.4 The role of PHDs in cancer 
The vast growth and colonisation of solid tumours results in abnormal vasculature and rapid 
proliferation of cancer cells. As a result, this environment is very low in oxygen, and so relies 
upon the hypoxia signaling pathway response (Harris, 2002). Multiple laboratories have 
worked to dissect the role of PHDs in cancer, with great debate over their tumour suppressor 
or oncogenic status.   
 
The PHD2 isoform is frequently associated with cancer and is often associated with a tumour 
suppressor function. Kato et in in 2006 reported that around 60% of endometrial cancers 
studied had an increased incidence of PHD2 mutations. Introduction of the wild-type PHD2 
gene (EGLN1) into endometrial cancer cell lines that carried a mutant EGLN1 induced 
senescence, reducing their growth. Studies into colorectal tumours found that PHD2 
expression was decreased in carcinogenic tissue compared to the surrounding healthy colon 
tissue, suggesting that PHD2 may regulate tumour development. Transplantation of colorectal 
carcinoma cells with silenced PHD2 levels into severe combined immunodeficient (SCID) 
mice, found that recipient mice had increased tumour growth in absence of PHD2. These 
tumours lacking PHD2 exhibited increased blood vessel formation, suggesting that PHD2 
functions as a tumour suppressor by negatively regulating angiogenesis (Chan et al., 2009).  
 
Contradicting the tumour suppressor function of PHD2, overexpression of all PHD isoforms 
have been recorded in multiple other tumour types and are associated with a negative 
outcome in patients. Overexpression of PHD1, PHD2 and PHD3 have all been recorded in 
non-small cell lung cancer (NSCLC) and are associated with poor survival rates (Andersen et 
al., 2011). In human hepatocellular carcinoma (HCC), high PHD2 expression is associated 
with larger tumour size and limited tumour differentiation, resulting in shorter disease-free 




In addition to solid tumours, PHDs isoforms have been recently implicated in haematological 
malignancies. Recent research by Bur and colleagues in 2018 found that overexpression of 



























1.4 Acute Myeloid Leukaemia 
Acute myeloid leukaemia (AML) is a heterogenous clonal disorder, resulting from the 
expansion of primitive, undifferentiated myeloid progenitors (myeloblasts) within the BM 
microenvironment (Khwaja et al., 2016; Metzeler et al., 2016). Replacement of healthy BM 
cells with these malignant, dysfunctional myeloblasts results in anaemia, haemorrhage and an 
inability to fight infection. These myeloblasts then infiltrate other tissues in the body including 
the liver, spleen, lymph nodes and the central nervous system (Lowenberg et al., 1999).  
 
Strikingly, the standard therapy for AML has not been significantly altered in over 30 years 
(Dohner et al., 2010). AML therapy typically involves induction chemotherapy, followed by 
further cycles of consolidation and maintenance chemotherapy. Patients may also receive an 
HSC transplant, which can result in a high rate of curability (Wunderlich et al., 2013; Zuber et 
al., 2009). The induction phase of treatment is referred to as the “7 + 3” method and commonly 
combines 7 to 10 days of continuous infusion of cytarabine (Ara-C), with 3 days of an 
anthracycline (typically daunorubicin or idarubicin). Due to a higher tolerance, this treatment 
schedule is repeated 3 - 4 times in younger people, whereas older patients (> 70 years) 
typically receive 2 -3 round due to the toxic effects of chemotherapy. As such, AML is 
particularly difficult to eradicate in older patients and, in addition, many older adults are 
ineligible for stem cell transplantation due to the risks associated with high-dose chemotherapy 
(Guinn et al., 2007).  
 
Notably, AML has a very poor long-term survival outcome, even in patients who achieve 
disease remission. This is due to the fact that a large proportion of AML patients will suffer a 
disease relapse, which is often fatal (Sarkozy et al., 2013). Historically, this was thought to be 
a result of mutation-based drug resistance, with mutations arising from toxic chemotherapeutic 
drugs (Goldie and Coldman, 1984). Recent evidence, however, suggests that this disease 
relapse is in fact caused by re-emergence of a rare cancer stem cell population, that is not 




1.4.1 Leukaemic Stem Cells (LSCs) 
Following investigations into the cell of origin in AML, John Dick in 2003 coined the “cancer 
stem cell hypothesis”, which describes a rare population of cancer cells, stem-like in nature, 
which through their self-renewal ability, can initiate and sustain the bulk cancer population 
(Krivtsov et al., 2006). In the context of AML, these cancer stem cells are referred to as 
leukaemic stem cells (LSCs), and mirror the HSC hierarchy, with the LSCs at the apex, and 
















Figure 1-10 – HSC and LSC hierarchies (A) Normal haematopoiesis is a hierarchical process in which 
HSCs sit at the apex, and give rises to progenitor precursor cells, ultimately resulting in mature 
differentiated cells. (B) In AML, the HSC hierarchy is paralleled, will LSCs at the apex. LSCs generate 
leukaemic progenitor cells, which give rise to immature, dysfunctional AML blast cells. (Taken from 








In concordance with the HSC field, LSCs are characterised by their ability to initiate and serially 
propagate AML disease upon transplantation (Schepers et al., 2015). Parallels between the 
phenotypes and functions of HSCs and LSCs, pointed to a stem-cell cell of origin in AML 
(Wang and Dick, 2005). Recent research, however, suggests that in an aggressive leukaemia 
such as AML, LSCs may not be confined to the HSC compartment, but instead can also derive 
from progenitor cells (Eppert et al., 2011; Goardon et al., 2011).  
 
In an aid to dissect the cell of origin in AML, Wang and Dick in 2005 transplanted LSCs into 
secondary and tertiary recipient mice and found significant variations in their repopulation 
ability. This indicated that there may be distinct subsets of LSCs with differing self-renewal 
abilities. Experiments by Krivtsov and colleagues in 2006, transformed granulocyte 
macrophage progenitor (GMP) cells with an MLL-AF9 fusion protein and transplanted them 
into irradiated syngeneic recipient mice. LSCs isolated from these mice were able to give rise 
to leukaemic disease in secondary recipients. These cells were found to retain the gene 
expression profile of GMPs, but also expressed a subset of genes highly expressed in HSCs. 
This suggests that both HSCs and committed progenitors, through the acquisition of an HSC 
gene expression pattern, can give rise to LSCs (Cozzio et al., 2003; Krivtsov et al., 2006; 
Wong et al., 2007).  
 
Given that LSCs have different repopulation capacities, multiple clinical and scientific papers 
were published investigating the link between LSC activity and the clinical outcome of AML 
disease.  In this vein, van Rhenen and colleagues in 2005 found that an increased stem cell 
frequency in patients at diagnosis predicts a high minimal residual disease and poor survival 
outcome. Moreover, Pearce et al in 2005 used in vivo transplantation assays to further dissect 
the relationship between LSC status and patient survival. The authors discovered that patient 
samples which were able to engraft in immunocompromised NOD/SCID recipient mice were 
derived from patients with a significantly shorter overall survival when compared to samples 
which did not engraft. This shows a direct link between functional LSC activity and prognostic 
outcome. Importantly, Krivstov and colleagues in 2013 found that murine LSCs deriving from 
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an HSC source were more resistant to the chemotherapeutic drugs cytarabine and 
doxorubicin, when compared to LSCs derived from a GMP progenitor source.  
 
All together, these experiments suggest that an increase in primitive LSC frequency decreases 
patient survival through both an increase in disease maintenance, as well as chemotherapy 
resistance.  Given the current failures in AML treatment, it is vital to identify therapeutic targets 
that can eliminate LSCs. Using these, in conjunction with current chemotherapies, could lead 























1.5 Hypothesis and Aims 
Given that deletion of Hif1 and Hif2 was found to accelerate the development of AML, this 
thesis aims to investigate the therapeutic potential of targeting LSCs using the HIF-pathway 
through inhibition of the Prolyl Hydroxylases Domain (PHD) enzymes. To further 
validate PHDs as therapeutic targets in AML, this thesis explores the impact of developmental 
and systemic deletion of Phd1 and Phd2 in vivo. As a potential therapeutic target, it is vital to 
ensure that inhibition of PHDs has no detrimental effect on steady-state or stressed 
hematopoiesis.  
 
This thesis hypothesises that inhibition of the Prolyl Hydroxylase Domain enzymes will target 
and eradicate leukaemic stem cells, but will not be detrimental to normal haematopoiesis. As 
such, this thesis is an investigation into the role of Prolyl Hydroxylase Domain enzymes in 
normal and malignant haematopoiesis. Experiments were designed to address the following 
specific aims: 
 
1) To examine the effect of genetic deletion of Phd1, Phd2 or both Phd1 and Phd2 specifically 
within the haematopoietic system (Chapter 3) 
 
2) To investigate the effect of systemic Phd2 deletion on the haematopoietic system (Chapter 
4) 
 
3) To evaluate if genetic deletion or knockdown of Phd1, Phd2 or both Phd1 and Phd2 inhibits 

















Chapter 2 Materials and methods 
2.1 Mouse strains 
Vav-iCre mice were purchased from Jackson Laboratory (Stock no. 008610). Vav1-Cre mice, 
also known as Vav-iCre, were originally developed by de Boer et al in 2003, and are a well-
established transgenic line utilised for tissue-specific deletion within the haematopoietic 
system (Ogilvy et al., 1998; Ogilvy et al., 1999; Shimshek et al., 2002). Although originally 
discovered as proto-oncogene in oesophageal cancers, expression of the normal Vav allele is 
only found in haematopoietic tissues, resulting in the synthesis of a 95 kDa protein (Bonnefoy-
Berard et al., 1996; Katzav et al., 1989). Murine Vav expression begins at embryonic day (E) 
11, and increases at E 14, shortly after the emergence of definitive haematopoiesis (de Boer 
et al., 2003). 
                                                                                                                                                                                                  
Phd1fl/fl, Phd2fl/fl mice were donated by Sir Peter J Ratcliffe (Mazzone et al., 2009). Phd1fl/fl; 
Vav-iCre and Phd2fl/fl; Vav-iCre mice were generated by crossing Phd1fl/fl and Phd2fl/fl males 
to Vav-iCre females. Littermates from these crosses were then bred to generate Phd1fl/fl; 
Phd2fl/fl; Vav-iCre mice.  
 
Double heterozygous, double transgenic CAG-rtTA+/-;TRE-shPhd2+/- (referred to in this 
thesis as rtTA/shPhd2) and CAG-rtTA+/-;TRE-/- (referred to as Control rtTA) mice were 
donated by Chris W Pugh and Sir Peter J Ratcliffe and were bred to generate CAG-rtTA+/-
;TRE-shPhd2+/- and CAG-rtTA+/-; TRE-shPhd2-/- mice used in all experiments. The reverse 
tetracycline trans-activator (rtTA), under the cytomegalovirus early enhancer element and 
chicken β-actin (CAG) promoter allows strong ubiquitous expression. Upon doxycycline (Dox) 
treatment, there is activation of the tetracycline response element (TRE) controlled GFP-
shPhd2 cassette (TRE-shPhd2), which is downstream of the collagen type I gene (Col1a1). 
This results in transcription of both GFP and shPHD2 in the rtTA/shPhd2 mice, and not the 




All mice were on the C57BL/6 genetic background. All transgenic and knockout mice were 
CD45.2+. Congenic recipient mice were CD45.1+ /CD45.2+. Animal experiments were 
authorized by the UK Home Office. All mice were mixed sex, and tissues analysed at 8 - 12 




Figure 2-1 - Inducible shPhd2 knockdown mouse model Schematic of Phd2-targeted shRNA 
transgenic strains: CAG-rtTA+/-;TRE-/- (Control) and CAG-rtTA+/-;TRE-shPhd2+/- (shPhd2/rtTA). (A) 
Both mouse strains express a CAG-promoted tetracycline reverse trans-activator (rtTA). (B) In the 
presence of doxycycline (Dox) there is transcription of an mRNA encoding GFP and a silencing shRNA 
directed against Phd2. 
 
 
2.2 Doxycycline administration 
2.2.1 Doxycycline treatment in vivo 
Control (rtTA) and experimental (rtTA/shPhd2) mice received 2 mg/ml of Dox (Doxycycline 
hyclate, Alfa Aesar) in drinking water, with 3.5 % sucrose to improve palatability. For 
transplantation experiments, CD45.1+/CD45.2+ recipient mice were treated with 2 mg/ml Dox, 
with 3.5 % sucrose in their drinking water 4 weeks post-transplantation. For Meis1/Hoxa9 pre-
LSC transplantation experiments, mice were treated with 2 mg/ml Dox; 3.5 % sucrose in their 
drinking water 60 days post-transplantation. The water bottle containing Dox and sucrose was 
















2.2.2 Doxycycline treatment in vitro 
Initial Dox titration experiments in vitro with Meis1/Hoxa9-transformed pre-LSCs used an 
incremental scale of 0 - 1000 ng/ml of Dox dissolved in dH2O. Based on these experiments, a 
250 ng/ml Dox was added in all future experiments. 
 
2.3 DNA extraction 
Genomic DNA from animal tissue (mouse ear notch, foetal liver (FL) or bone marrow (BM)) or 
cultured cells was extracted and prepared for PCR using Mouse Direct PCR Kit (B40013-BIT, 
Stratech). Tissue or cells were resuspended in 100 µL of Buffer L, with 2 µL of Protease Plus 
added to each sample. Samples were then incubated for 25 - 30 min at 55 °C, followed by 5 
min at 95 °C.  Extracted DNA was stored at -20 °C. 
 
2.4 Genotyping and PCR primers 
The PCR Mix for Vav-iCre, and Phd1, Phd2, Cag (rtTA) and Col1a1 (TRE-shPhd2) was 
prepared using Mouse Direct PCR Kit (B40013-BIT, Stratech). Each reaction used 2 µL of 
genomic DNA. All primers were at a concentration of 100 µM. The sequence of the primers 
and the PCR programs are listed in Table 2-1. 
 
 
2.5 Gel Electrophoresis 
PCR product, along with a DNA ladder and H2O loading control was loaded into an agarose 
gel (1.5 % to 2.5 %) (Thermo Fisher Scientific, 17852) stained with SYBRTM SAFETM DNA Gel 
Stain (Invitrogen S33102). Following electrophoresis, images of the agarose gel where taken 
using UV excitation. A representative image of an agarose gel from Vavi-Cre genotyping is 












Figure 2-2 - Representative gel electrophoresis image Vav-iCre PCR product, DNA ladder and an 
H2O loading control were loaded into a 2.5 % agarose gel, stained with SYBRTM SAFETM DNA stain. 
Following electrophoresis, an image was taken using UV excitation. Positive and negative genotyping 







































2.6 Maxiprep of plasmids 
Maxiprep of all plasmids was conducted using the HiSpeed Plasmid Maxi Kit (12662, 
Qiagen), according to the manufacturer's instructions. Briefly, a starter culture was incubated 
ON at 37 °C in 500 mL of LB media with 100 mg/mL ampicillin. The bacteria were harvested 
by centrifugation at 6,000 x g for 15 min at 4 °C. The bacterial pellet was resuspended in 10 
mL of Buffer P1, followed by 10 m L of Buffer P2, and incubated for 5 min at room temperature.  
Following this, 10 mL of chilled Buffer P3 was added and the cell lysate was filtered through 
an equilibrated HiSpeed Tip. Following this, 60 mL of Buffer QC was added to wash the 
HiSpeed Tip, and the DNA was eluted with 15 mL of Buffer QF Concentration of eluted DNA 
was measured by a nanodrop spectrometer (Nanodrop ND1000 Spectrophotometer; Labtech 
International Ltd, East Sussex, UK), recording absorbance at wavelength 260 nm. The DNA 
purity was assessed through the ratio of absorbance at 260 nm and 280 nm.  
 
2.7 RNA extraction 
RNA was extracted and purified using RNeasy micro Kit (74004, Qiagen) according to the 
manufacturer’s instructions. Briefly, cells were harvested, and 350 µL RLT buffer was added 
to cell pellets, followed by 350 µL 70 % ethanol. The mixture was centrifuged in RNeasy 
MiniElute spin columns for 15 sec at 8,000 x g. Following this, 350 µL RWI buffer was added 
and the columns were centrifuged for 15 sec at 8,000 x g. 80 µL of DNase I incubation mix 
was added and incubated for 15 min at room temperature. 350 µL RWI buffer was added and 
columns were centrifuged for 15 sec at 8,000 x g. 500 µL RPE buffer was then added and 
samples were centrifuged again for 15 sec at 8,000 x g. Subsequently, 500 µL 80 % ethanol 
was added and columns were centrifuged for 2 min at 8,000 x g to wash the spin column 
membrane. The spin column was centrifuged at full speed for 5 min to dry the membrane. 
Finally, 15 µL RNAse free water was added and centrifuged for 1 min at 8,000 x g to elute 






RT-PCR was performed in order to transcribe the RNA into cDNA using the reverse 
transcriptase enzyme. The High-Capacity cDNA Reverse Transcription Kit was used for all 
RT-PCR reactions (Applied BiosystemsTM - 4368813). The mix consisted of 2 µL 10X RT 
buffer, 0.8 µL dNTP mix (100 mm), 2.0 µL 10X RT random primers, 1.0 µL reverse 
transcriptase, 0.5 µL RNase inhibitor, and 3.7 µL distilled water (DNase and RNase free; 
Gibco®, ThermoFisher Scientific - 10977-035). The samples were processed using 
Professional Basic Thermocycler, using the cDNA synthesis program that ran at 25 °C for 10 
min, 37 °C for 120 min, and 85 °C for 5 min. 1 µg of RNA was used in each reaction, diluted 
1x after cDNA synthesis. 
 
2.9 qPCR 
Equal concentrations of RNA were reverse transcribed as indicated in 2.6. mRNA levels were 
quantified for Phd2 in BM samples of Dox-treated shPhd2/rtTA and control mice. Technical 
triplicates of each sample were analysed and reactions were performed in a 5 µL volume. 
Each well was filled with 2.5 µL TaqMan® Universal PCR Master Mix (Applied BiosystemsTM, 
ThermoFisher Scientific, Cat. 4304437), 0.25 µL of the TaqMan ® probe/primer set for each 
gene (see Table 2-2 below), 1.25 µL distilled water, and 1 µL of the cDNA sample. The 
samples were analysed using LightCycler® 480 (Roche), using the following program: 50 °C 
for 2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. 
Finally, 60 °C for 5 min and 40 °C for 5 min. All signals were quantified using the ΔΔCt method 
using β-actin as the housekeeping gene (as optimised in the Kranc laboratory). 
 
Table 2-2 TaqMan probes for Phd2 expression 
 





2.10 Preparation of haematopoietic tissues 
Tibias and femurs of both hind legs were taken from adult mice and crushed using a pestle 
and mortar until a homogenous cell suspension was achieved. Cells were collected in cold 
phosphate-buffered saline, supplemented with 2% heat-inactivated foetal calf serum and 2 
mM ethylenediaminetetraacetic acid (PBS, 2 % FCS, 2 mM Ethylenediaminetetraacetic acid 
(EDTA)), and filtered through a 70 µm nylon strainer (BD Falcon, 352340). Spleen, thymus 
and lymph node tissue were dissected from adult mice and crushed with a syringe plunger to 
produce a single cell suspension in PBS (2 % FBS, 2 mM EDTA). Foetal liver (FL) cells were 
retrieved from 14.5 dpc embryos and mashed through a 70 µm nylon strainer. 
 
2.11 Immunophenotypic characterisation of haematopoietic cells  
 
SLAM staining: 12x106 bone marrow (BM) cells were incubated in CD16/32 (Fc Block) 
antibody in 50 µL of cold PBS (2% FCS, 2 mM EDTA) for 5 min on ice. 50 µL of 2X SLAM 
antibody mix containing a biotin-conjugated lineage cocktail (CD3, CD4, CD5, CD8a, Gr-1, 
CD19, B220, Ter119) and Sca-1, CD117 (cKit), CD48 and CD150 was added and cells were 
incubated at 4 °C (protected from light) for 30 - 45 min. Cells were then washed in cold PBS 
(2% FCS, 2 mM EDTA) and pelleted by centrifugation at 500 x g for 5 min. The pellet was then 
re-suspended in 100 µL of Streptavidin and incubated for 15 min at 4 °C. Cells were then 
washed, pelleted by centrifugation and prepared for flow cytometry analysis. 
 
Lineage staining: 2x105 of BM, spleen or thymus cells were incubated with antibody mix: 
myeloid (CD11b, Gr-1); B-lymphoid (CD19, B220), T-lymphoid (CD4, CD8a), erythroid 
(Ter119, CD71) and incubated for 20 min at 4 °C (protected from light). Cells were then 




Transplantation analysis staining: To evaluate the engraftment of transplantation 
experiments, BM, spleen, thymus, lymph node and foetal liver cells were additionally stained 
by anti-CD45.1 and CD45.2 antibodies. 
 
For all experiments, cells were acquired on FACSFortessaV (BD). Cell sorting was performed 
on a FACSAria Fusion cell sorter (BD). Data were acquired through BD FACSDiva (BD 
Biosciences) and analysed by Flowjo software (Tree Star Inc., USA). The gating strategy for 
subsequent cell sorting and analysis was performed based on single stains, as no isotype 
controls were used. The antibodies used in these experiments are listed in Table 2-3. 
Representative gating strategies for all flow cytometry experiments are shown in Figure 2-3, 






















Table 2-3 Flow cytometry antibodies 
 
 Antibody Concentration Conjugate Cat. No. Clone Manufacturer 
Lineage Cocktail 
CD4 0.3125 μg/mL biotin 553649 H129.19 BD Biosciences 
CD5 0.625 μg/mL biotin 553019 53-7.3 BD Biosciences 
CD8a 0.625 μg/mL biotin 553029 53 -6.7 BD Biosciences 
CD11b 2.5 μg/mL biotin 553009 M1/70 BD Biosciences 
CD45R/B220 2.5 μg/mL biotin 553086 RA3-6B2 BD Biosciences 
Ter119 10 μg/mL biotin 553672 TER-119 BD Biosciences 




CD117/cKit 1 μg/mL APC 105812 2B8 Biolegend 
Sca-1/Ly- 1 μg/mL APC-Cy7 122513 E13-161.7 Biolegend 
Sca-1/Ly- 2.5 μg/mL FITC 122506 E13-161.7 Biolegend 
CD48 0.4 μg/mL PE 103406 HM48-1 Biolegend 
CD150 1 μg/mL PE-Cy7 115914 12F12.2 Biolegend 
Erythroid 
Ter119 0.2 μg/mL APC-Cy7 116223 TER119 Biolegend 
CD71 0.2 μg/mL PE 113807 RI7217 Biolegend 
B Cells 
CD19 0.2 μg/mL APC-Cy7 115530 6D5 Biolegend 
CD45R/B220 0.2 μg/mL PerCP 103236 RA3-6B2 Biolegend 
Myeloid Cells 
CD11b 0.5 μg/mL APC 101224 M170 Biolegend 
Gr-1/Ly-6G/C 0.2 μg/mL PE-Cy7 108416 RB6-8C5 Biolegend 
T Cells 
CD4 0.2 μg/mL PE 130310 H129.19 Biolegend 
CD8a 0.08 μg/mL PE 100708 53-6.7 Biolegend 
CD8a 0.2 μg/mL APC 100712 53-6.7 Biolegend 
Transplantation 
Assays 
CD45.1 0.5 μg/mL FITC 110706 A20 Biolegend 
CD45.1 0.2 μg/mL BV711 110739 A20 Biolegend 
CD45.2 0.5 μg/mL Pacific Blue 109820 104 Biolegend 
Strepavidin 
Strepavidin 0.5 μg/mL Pacific Blue 405225 - Biolegend 
Strepavidin 1 μg/mL PerCp 405213 - Biolegend 





Figure 2-3 - Representative flow cytometry gating strategy for HSPC SLAM analysis Total BM cells 
were first live and size gated using forward scatter area (FSC-A) and side scatter area (SSC-A). Doublets 
were excluded using FSC-A versus FSC height (FSC-H). Lineage positive cells were excluded by gating 
on the lineage negative (Lin-) population which contains the LK (Lin-cKit+) and LSK (Lin-cKit+Sca-1+) cells. 
LSK cells were further sub-gated on haematopoietic stem cells (HSCs: LSK CD48-CD150+), multipotent 
progenitors (MPPs: LSK CD48-CD150-), haematopoietic progenitor cells-1 (HPC-1: LSK CD48+CD150-) 
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Figure 2-4 - Representative flow cytometry gating strategy for lineage staining analysis Total BM 
cells were first live and size gated using forward scatter area (FSC-A) and side scatter area (SSC-A). 
Doublets were excluded using FSC-A versus FSC height (FSC-H). Differentiated haematopoietic 
population were then gated as shown. (A) Gating of monocyte (Mac1+) and granulocyte (Mac1+Gr1+) 
populations. (B) Erythrocyte populations were analysed using Ter119 and CD71 staining (Ter119-
CD71high), (Ter119+CD71high), (Ter119+CD71mid) and (Ter119+CD71-) (Rasmussen et al., 2010). (C)   



































































































Figure 2-5 - Representative flow cytometry gating strategy for transplantation analysis Total 
peripheral blood cells were lysed with NH4Cl and live and size gated using forward scatter area (FSC-A) 
and side scatter area (SSC-A). Doublets were excluded using FSC-A versus FSC height (FSC-H). Anti-
CD45.1 and anti-CD45.2 antibodies were used to evaluate the engraftment of transplanted cells in 
CD45.1+ /CD45.2+ congenic recipient mice. Representative gating strategy of CD45.1+ (support), 
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2.12 Transplantation assays  
Irradiation Details: 8 to 12 weeks old mice were subjected to whole body gamma irradiation 
(Gammacell 40 Executor unit, Serial number 59R (Best Theratronics); source: Caesium 137) 
using a 33% attenuator. Lethal irradiation of CD45.1+ /CD45.2+ recipient mice was achieved 
using a split dose of 11 Gy (two doses of 5.5 Gy administered at least 4 h apart) at an average 
rate of 0.58 Gy/min.  
 
Primary transplantations: For total BM transplantations, 500 000 unfractionated CD45.2+ 
BM cells from transgenic mice were mixed with 500 000 unfractionated WT support cells 
expressing CD45.1+ (or Ly5.1) and injected via the tail vein into healthy lethally irradiated 
CD45.1+ /CD45.2+ syngeneic recipient mice (11Gy). For HSC transplantations, 200 Lin-
cKit+Sca-1+ (LSK) CD48-CD150+ (HSCs) were sorted from donor BM (CD45.2+) and 
transplanted together with 200 000 unfractionated CD45.1+ WT BM wild-type cells. All donor 
mice were 8 to12 weeks old.  
 
Meis1/Hoxa9-driven AML transplantation assays: 100 000 cKit+ Pre-Leukaemic Stem Cells 
(Pre-LSCs) from Colony Forming Assay (CFC) 3 were harvested and mixed with 200 000 
unfractionated CD45.1+ WT BM wild-type cells. These cells were then injected via the tail vein 
into healthy lethally irradiated CD45.1+ /CD45.2+ syngeneic recipient mice (11Gy). For 
secondary transplantation assays 50,000 LSCs (CD45.2+ cKit+) from the BM of primary 
recipients were transplanted into secondary lethally irradiated CD45.1+ /CD45.2+ syngeneic 
recipient mice (11Gy). 
 
2.13 Blood sampling 
To assess transplantation engraftment, peripheral blood (PB) samples were taken from the 
tail vein every 4 weeks. Blood was collected using capillary blood collection tubes coated with 





2.14 Isolation of HSPCs from 14.5 dpc FL cells  
Embryos were aseptically removed and a homogenous cell suspension was achieved as 
previously described (Section 2.10). Red blood cells (RBCs) were lysed by incubation with 
ammonium chloride (NH4Cl) (Stem Cell Technologies - 07850) for 1 min. Cells were washed 
in cold PBS (2% FCS, 2 mM EDTA) to stop the reaction, and pelleted by centrifugation at 500 
x g for 5 min. Cells were re-suspended in 100 µL of PBS (2% FCS, 2 mM EDTA) and incubated 
with immunomagnetic microbeads, conjugated to monoclonal anti-mouse CD117 (cKit) 
antibody (isotype: rat IgG2b) (Miltenyi Biotec – 130091224) for 25 min at 4 °C. Cells were 
added to a MACS LS column (Miltenyi Biotec - 130042401) attached to a QuadroMACS 
(Miltenyi Biotec) magnetic separator, and washed four times with PBS (2% FCS, 2 mM EDTA). 
To collect the cKit enriched cells, PBS (2% FCS, 2 mM EDTA) was added, the column was 
removed from the magnet, and the cKit enriched fraction was flushed out. 
 
2.15  Retroviral production  
Meis1/Hoxa9 retroviral production was conducted using a packaging cell line (Platinum E), 
allowing for retroviral packaging with a single plasmid transfection (Vukovic et al., 2015). The 
Platinum E (Plat-E) cell line, based on the 293T cell line, ensures high and stable expression 
of gag, pol and env (packaging viral proteins) through the EF1α promoter (Cell biolabs, Inc; 
https://www.cellbiolabs.com/platinum-e-plat-e-retroviral-packaging-cell-line). 
 
2.15.1 Transfer vectors and components  
MSCV-Meis1-puro: cDNA encoding murine Meis1 was cloned into the MSCV (murine stem 
cell virus) vector, MSCVPGK. PGK (phosphoglycerate kinase internal promoter) controls the 
expression of the puromycin resistance cassette and the long terminal repeat (LTR) region 
drives the expression of Meis1 gene (Kroon et al., 1998). 
 
MSCV-HoxA9-neo: cDNA encoding murine HoxA9 fragment was inserted at BamHI-XhoI site 
of a pMSCVneoEB (neomycin (G418) resistance) (Kroon et al., 1998). The LTR region controls 
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the expression of HoxA9 gene and PGK promoter drives the expression of the neomycin 
resistance cassette. 
 
PGK: the phosphoglycerate kinase (PGK) promoter drives the expression of antibiotic 
resistance genes, and therefore enables the selection of infected cells on the basis of antibiotic 
resistance.  
 
MSCV: The Murine Stem Cell Virus (MSCV) retroviral vector is optimized for introducing and 
expressing target genes in pluripotent cells, including murine haematopoietic cells.  
 
LTR: the retroviral long terminal repeat (LTR) contains promoters that drive gene expression 
in many infected cell types, including multiple haematopoietic lineages.  
 
Subcomponents of LTR: U3-R-U5- element. U3 and U5 are found at the end of the viral 
genomic RNA and contain sequences necessary for activation of viral genomic RNA 
transcription.  
 
2.15.2 Packaging vectors 
VSV-G: Vesicular stomatitis virus G glycoprotein is the envelope vector that determines the 
tropism of the virus (broad tropism envelope protein). 
 
2.15.3 Preparing the retrovirus 
Plat-E cells were transfected by the Calcium Phosphate method, a method that involves the 
formation of calcium phosphate-DNA precipitates that facilitate the binding of condensed DNA 
to the cell surface, allowing the DNA to enter the cell by endocytosis (Kingston et al., 2003). 
The supernatant (containing viral particles) was collected 24 h after transfection, filtered 
through a 0.45 mm non-protein binding filter (Merck Millipore Corporation, SLHVM33RS) and 




2.16 Retroviral transduction of HSPC cells 
cKit+ FL cells were incubated overnight in Iscove’s Modified Dulbecco’s Medium (IMDM) with 
10 % FCS, 40 ng/mL of mouse recombinant stem cell factor (SCF) (carrier-free) (Biolegend, 
Cat. 579702), 20 ng/mL of recombinant mouse IL-3 (carrier-free) (Biolegend, Cat. 575502) 
and IL-6 (Biolegend, Cat. 575702) to promote cell cycle entry and proliferation of cells. Non-
tissue culture treated 24 well plates (Nunc, 144530) were coated with RetroNectin® (Takara, 
T100A) and left overnight at 4 °C. RetroNectin® is a recombinant human fibronectin fragment 
which was used to enhance retroviral mediated gene transduction. The next day, 
RetroNectin® was removed from each well and 1 mL (500 µL of Meis1, 500 µL Hoxa9) of 
retroviral supernatant was added to the wells. The plate was centrifuged at 2000 x g for 2 h at 
32 °C in order for the viral particles to bind to the plate. After centrifugation, the viral 
supernatant was removed and 250 000 cKit+ cells in IMDM with 10 % FCS, and 40 ng/mL 
SCF, 20 ng/mL IL-3 and 20 ng/mL IL-6, were seeded onto the virus-coated plate and left 
overnight at 37 °C, 5 % CO2. 12 h later, a second RetroNectin®-coated plate was similarly 
prepared with virus. The cKit+ cells were then washed off the first plate and transferred onto 
the new viral plate. This sequence was repeated 12 h later, after which the cKit+ cells were 
transferred onto a non-coated plate to recover and start expressing antibiotic resistance 
genes. 24 h later, cells were seeded in media (IMDM with 10 % FCS, and 40 ng/mL SCF, 20 
ng/mL IL-3 and 20 ng/mL IL-6) containing 1.5 μg/mL puromycin and 1 mg/mL neomycin. 
Antibiotic selection lasted for 3 days.  
 
2.17 Colony-Forming Cell (CFC) assay 
2500 Meis1/Hoxa9 transduced cKit+ cells were plated in MethoCultTM M3231 (Stem Cell 
Technologies, 03231) supplemented with 20 mL IMDM; 20 ng/mL of SCF; 10 ng/mL of IL-3; 
10 ng/mL of IL-6 and 10 ng/mL of GM-CSF (granulocyte-macrophage colony stimulating 
factor; Biolegend - 576302), 100 Units/mL penicillin and 100 mg/mL streptomycin. 1.5 μg/mL 
puromycin and 1 mg/mL neomycin were added for continued antibiotic selection. Empty wells 
were filled with PBS in order to avoid evaporation of the semi-solid medium. After 6 days in 
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culture (CFC1), colonies were counted and re-plated at the same concentration with the same 
culture conditions (CFC2, CFC3). After CFC3, these cells are referred to as pre-LSCs. 
 
2.18 Colony size assessment  
1250 cells/well were seeded into MethoCultTM M3231 (Stem Cell Technologies, 03231) on a 
6-well plate. Images were acquired at 37°C 5% CO2 after 6 days in culture on an Operetta 
high content microscope (Perkin Elmer). Image analysis was performed in Columbus 2.7.1 
(Perkin Elmer) by manual training as described in O’Duibhir et al, 2018. Colony data were 
analysed in Spotfire HCP 7.5.0 Perkin Elmer informatics. 
 
2.19 Proliferation assay 
Cells were adjusted to 50 000 cells/well in Iscove’s Modified Dulbecco’s Medium (IMDM) with 
10 % FCS, 40 ng/mL of mouse recombinant stem cell factor (SCF) (carrier-free) (Biolegend - 
579702), 20 ng/mL of recombinant mouse IL-3 (carrier-free) (Biolegend - 575502) and IL-6 
(Biolegend - 575702), and plated in a 24-well plate in triplicate. Counting of cells was 
performed by trypan blue exclusion. 
 
2.20 Cell death assay 
Cells were counted to a concentration of 5000 cells/well in Iscove’s Modified Dulbecco’s 
Medium (IMDM) with 10 % FCS, 40 ng/mL of mouse recombinant stem cell factor (SCF) 
(carrier-free) (Biolegend - 579702), 20 ng/mL of recombinant mouse IL-3 (carrier-free) 
(Biolegend - 575502) and IL-6 (Biolegend - 575702), and plated in a 96-well plate in triplicate. 
48 hrs later cells were washed and stained with TO-PROTM-3 Iodide (Molecular Probes, 







2.21 Statistical analysis  
All statistical analyses and graphing were performed with GraphPad Prism Software (v6.0h). 
Data represent mean ± standard error mean, except when data are presented as fold-change 
values. **** for P < 0.0001, *** for P < 0.001, ** for P 0.01, and * < for P 0.05 were considered 
statistically significant and were indicated in related figure legends and graphs. 
 
The number of experiments noted in figure legends indicate independent experiments that 
were performed on different days, with 2-6 biological replicates. For transplantation 
experiments, 5-6 technical recipients were used. The sample size used in each experiment 
was not predetermined or formally justified for statistical power.  
 
To assess the statistical significance of a difference between two treatments a two-tailed 
Student’s t-test or a Mann–Whitney U-test was used. In Chapter 3 and Chapter 5, Control 
(Vav-iCre-) samples were compared separately against Phd1CKO (Phd1fl/fl;Vav-iCre+) samples, 
Phd2CKO (Phd2fl/fl;Vav-iCre+) samples or Phd1/2CKO (Phd1fl/fl;Phd2fl/fl;Vav-iCre+) samples. In 
Chapter 4 and Chapter 5, Control (rtTA) samples were compared against shPhd2/rtTA 
samples. To assess the statistical difference between two treatments at multiple time points, 
a Multiple t-test was used, with statistical significance determined using the Holm-Sidak 
method. The statistical significance of differences in survival was assessed using the Mantel–
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Chapter 3 The role of Prolyl Hydroxylase Domain enzymes in              
steady state haematopoiesis 
3.1 Introduction 
HSCs reside at the top of the hematopoietic differentiation hierarchy and function to sustain 
life-long production of all blood lineages. The pivotal balance between the quiescence, self-
renewal and multi-lineage differentiation of HSCs is orchestrated by the bone-marrow 
microenvironment in which they reside (Mendelson and Frenette, 2014). These so-called bone 
marrow "niches" expose HSCs to numerous cues to regulate their biology, including TGFβ, 
CXCL12, angiopoietin-1, and environmental hypoxia (Arai et al., 2004; Sugiyama et al., 2006; 
Yamazaki et al., 2009).  
 
Cellular responses to low-oxygen conditions are predominantly orchestrated by the 
heterodimeric hypoxia-inducible factors Hif-1 and Hif-2, which consist of the ubiquitously 
expressed HIF-α subunit and a constitutively expressed HIF- β subunit (Wang et al., 1995). 
The activity of the HIF-α subunit is regulated by the HIF prolyl hydroxylase domain enzymes, 
which in the presence of oxygen hydroxylate proline sites on HIF-α, targetting the protein for 
degradation (Epstein et al., 2001). As such the PHD family is integral to the hypoxia response, 
regulating the downstream transcription of hypoxia-related genes. Given that hypoxia is a key 
feature of HSC biology, and therefore downstream haematopoiesis, it is vital to dissect the 












The PHD proteins are part of an evolutionary conserved family of dioxygenases that use 
oxygen and 2-OG as substrates, and iron and ascorbate as cofactors. Although there is only 
one HIF-specific prolyl hydroxylase in lower model organisms such as Caenorhabditis elegans 
(known as EGL-9) and Drosophila melanogaster (dHPH), humans and mammals have three 
PHD isoforms (PHD1, PHD2, PHD3) (Bruick and McKnight, 2001; Schofield and Ratcliffe, 
2005). At an RNA level, all three PHD isoforms are widely distributed across various tissues, 
with PHD1 highest in the testes, and PHD3 highest in the heart. Notably, at a protein level, 
there is greater disparity between the PHD isoforms, with PHD2 the most abundant, and PHD3 
only present at very low levels in normoxia (Berra et al., 2003; Stiehl et al., 2006). As such, 
Berra and colleagues in 2003 found that when various cell lines are cultured in normoxic 
conditions, PHD2 is the main isoform causing HIF-α degradation, quite possibly due to its 
plentiful expression. In addition to the differing affinities to HIF-α, and differential regulation, 
PHDs also have different sub-cellular location profiles, and so often function in distinct roles 















3.1.2 The role of PHDs in in vivo physiology 
Given the importance of the hypoxia response in various tissues and biological processes, 
there have been significant research efforts to identify the role of each PHD isoform in vivo. 
Seminal studies by Takeda et al in 2006 generated transgenic Phd knock-out mice: Phd1-/-, 
Phd2-/- and Phd3-/-, excising the exons required for Fe++ binding, and therefore removing prolyl 
hydroxylase activity. The authors found that the Phd2-/- embryos were not viable, with 
embryonic lethality occurring between E 12.5 and E 14.5, with 70 % of the embryos dead at E 
13.5. Notably, the Phd2-/- mice suffered severe placental and heart defects preceding 
embryonic death. As expected there were increased levels of HIF-1α and HIF-2α in the embryo 
overall, but not within the heart, suggesting the lethal heart defects were a systemic effect of 
PHD2 deletion, or a HIF-independent phenomenon. While the Phd2-/- embryos did not survive, 
Phd1-/-and Phd3-/- mice were born healthy and in normal Mendelian ratios. This identified a 
unique role of PHD2 in embryogenesis, and provided further evidence that PHD2 remains the 
critical PHD isoform.  
 
Unable to produce viable offspring using Phd2 knockout mice, Takeda and colleagues in 2007 
endeavoured to construct a Phd2 conditional knockout transgenic model using tamoxifen-
induced Cre, to study the role of PHD2 in adult mice. Phd2 conditional knockout mice 
(Phd2CKO) treated with tamoxifen had a significant increase in vasculature in vivo, thus 
concluding that PHD2 is a negative regulator for vascular growth. In addition, these PHD2-
deficient adult mice had an approximately 230-fold increase in EPO expression and developed 
severe polycythaemia (Takeda et al., 2007). In concordance with this, in humans, there are 2 
separate point mutations identified in the PHD2 gene, both of which cause red blood cell 








3.1.3 The role of PHDs in haematopoiesis  
Findings from early in vivo studies into the hypoxia pathway, as well as human clinical 
evidence, suggests an important role for PHDs in haematopoiesis. In addition, given that 
haematopoiesis occurs within the hypoxic environment of the BM, there has been notable 
research efforts to dissect the role of PHDs in this process in transgenic murine models. 
 
Since there were no adverse phenotypes observed in the Phd1-/- or Phd3-/- single knockout 
mice, Takeda et al in 2008 generated Phd1-/-;Phd3-/- double knockout (DKO) mice, analysing 
the apparent haematopoietic phenotypes observed in the tamoxifen-treated Phd2CKO mice. 
These mice presented with morphological phenotypes consistent with increased erythropoietic 
activity such as enlarged haematopoietic organs (liver and spleen), and significant elevation 
in red blood cell (RBC) number, haemoglobin levels and haematocrit values in the peripheral 
blood (PB). As expected, flow cytometry analysis of the BM, spleen and liver of these mice 
showed a significant increase in erythroid progenitors (Ter119+ expression). Interestingly, 
analysis of the haematopoietic stem and progenitor cell (HSPC) compartment using Lin- Sca1+ 
cKit+ cell surface markers (known as LSK cells) unveiled a significant increase in this 
compartment within the BM, spleen and liver. Methylcellulose colony formation cell (CFC) 
assay, however, showed no increase in the self-renewal capacity of these cells. Given that 
this transgenic model drives deletion of Phd1 and Phd3 in all tissues, it is possible these 
phenotypes are not a haematopoietic-specific effect. Nonetheless, there is evidence that Phd1 
and Phd3 alter the biological processes surrounding haematopoiesis. In addition, as there are 
significant phenotypes in the DKO model, but none present in the Phd1-/- or Phd3-/- single 
knockout mice alone, there is an evident redundancy between Phd1 and Phd3. 
 
Further haematological analysis of tamoxifen-treated Phd2CKO mice revealed that RBC, 
haemoglobin, haematocrit and white blood cell (WBC) levels were increased in the PB of mice 
with a deficiency of Phd2. As observed in the Phd1-/-;Phd3-/- DKO mice, Phd2CKO mice showed 
increased erythroid expression (Ter119+) by flow cytometry, and an increase in LSK cells. 
Notably, in CFC assay there was no difference in colony formation in cells lacking Phd2 versus 
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the WT. This data provides strong evidence that PHDs are vital in the process of 
haematopoiesis, but given the systemic deletion of Phd2 in this tamoxifen-inducible model, it 
cannot be determined if this is a cell-autonomous or non-cell-autonomous phenotype within 
the haematopoietic system. 
 
Following on from these seminal studies by Takeda, Singh and colleagues in 2013 explored 
the effect of deletion of Phd2 within the haemopoietic system using a CD68 Cre mouse line. 
Using the CD68 promoter, this Phd2CKO strain was found to have reduced Phd2 levels in entire 
BM, as well as epithelial cells, and erythropoietin-producing cells in the kidney and brain. To 
verify that the CD68 Cre transgenic model promoted excision of Phd2 in primitive 
haematopoietic compartments, as well as the total BM, the authors isolated LSK cells from 
tamoxifen-treated Phd2CKO mice and performed RT-qPCR analysis. As hoped, Phd2 CKO cells 
showed reduced expression of Phd2, and a subsequent increase in Phd1 expression versus 
the WT, suggesting a compensatory mechanism between Phd1 and Phd2 in these cells. BM 
analysis of mice with conditional deletion of Phd2 showed an increase in the absolute number 
of LSK cells, but no difference in the number of HSCs (LSK CD48- CD150+). Interestingly, in 
a non-competitive whole BM transplantation experiment, PHD2-deficient cells were able to 
successfully repopulate an irradiated recipient mouse. However, competitive transplantation 
of the LSK cells found that PHD2-deficient cells were outcompeted by their WT counterparts. 
This suggests that, although functional, haematopoietic progenitor cells lacking PHD2 are 
outcompeted under severe stress. 
 
Importantly, the authors in this study employed a conditional PHD2 mouse line using Cre-
recombinase under the control of the human CD68 promoter (Franke et al., 2013). This Cre 
was originally developed as a macrophage-specific Cre, deleting in monocytes and 
macrophages, and so does not delete in a large number of haematopoietic cells (Gough et al., 
2001). In addition, this promoter also results in deletion in other tissues such as epithelial cells. 
Although significantly more specific than the tamoxifen-treated Phd2CKO mice engineered by 
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Takeda et al, the CD68 Cre conditional knockout system still does not answer the fundamental 





3.2 Aims and objectives of Chapter 3 
Evidence from multiple studies in the field suggest significant roles for the PHD family in 
haematopoiesis. Previous in vivo studies have either employed a haematopoietic-specific Cre, 
with off-target deletions in non-haematopoietic tissues, or an inducible Cre-lox system driven 
by Tamoxifen or antibiotics such as Tetracycline, or its synthetic derivative Doxycycline (Dox). 
As such, to fully explore to the role of PHDs in haematopoiesis, this thesis utilises both models; 
the haematopoietic-specific Vav-iCre, and a Dox-inducible model, which generates a short-
hairpin targeting Phd2. These models are described in Chapter 3, and Chapter 4 respectively.  
 
Previous studies published by the Kranc laboratory investigating the effect of haematopoietic-
specific deletion of Hif1-α and Hif2-α found no significant or deleterious effect on steady-state 
haematopoiesis (Guitart et al., 2013; Vukovic et al., 2015; Vukovic et al., 2016). As such, this 
study hypothesises that haematopoietic-specific deletion of Phd1, Phd2, or both Phd1 and 
Phd2, therefore stabilising Hif1-α and Hif2-α, will have no effect on steady-state 
haematopoiesis. To address this, the aim of this chapter is to investigate the role of Phd1 and 
Phd2 in steady-state haematopoiesis of adult mice using the Vav-iCre system. Flow cytometric 
analysis of the haematopoietic stem and progenitor cell compartment, as well as mature blood 
cells in the BM, will unveil if deletion of Phd1, Phd2, or both Phd1 and Phd2 have a cell-













3.3 Loss of Phd1, or both Phd1 and Phd2 results in an altered stem 
cell compartment 
In order to determine the role of the PHD family within steady-state haematopoiesis, I analysed 
the HSPC and differentiated haematopoietic compartment of young adult mice (8-12 weeks 
old) with conditional deletions of Phd1 (Phd1fl/fl;Vav-iCre+), Phd2 (Phd2fl/fl;Vav-iCre+), or both 
(Phd1fl/fl; Phd2fl/fl;Vav-iCre+), as well their Vav-iCre- littermate controls . 
 
Phd1fl/fl and Phd2fl/fl mice were kindly provided by our collaborator Prof. Sir Peter Ratcliffe, and 
crossed with Vav-iCre mice (Mazzone et al., 2009, Boer et al., 2003). Notably, the Phd1fl/fl and 
Phd2fl/fl mice are engineered to have loxP sites flanking exon 3 of Phd1 and exon 2 of Phd2, 
which both encode the sequences required for prolyl hydroxylase activity. Thus, upon Cre-
loxP-mediated recombination with Vav-iCre, PHDs are unable to function to hydroxylate HIF-
α (Epstein et al., 2001). Conditional knockout mice of Phd1 (Phd1fl/fl;Vav-iCre+), Phd2 
(Phd2fl/fl;Vav-iCre+), or both (Phd1fl/fl; Phd2fl/fl;Vav-iCre+), referred to as Phd1CKO, Phd2CKO, 
Phd1/2CKO respectively were born in normal Mendelian ratios, and had no apparent health 
issues before analysis at 8-12 weeks. 
 
Analysis of the BM of Phd1CKO, Phd2CKO and Phd1/2CKO mice revealed a significant decrease 
in the BM cellularity of Phd1CKO and Phd1/2CKO mice versus the control (Fig. 3-1B, 3-2B). The 
frequency and total number of Lin- cells was also significantly reduced in Phd1CKO and 
Phd1/2CKO mice (Fig. 3-1C, 3-2C). Importantly the percentage of both primitive progenitor Lin- 
cKit+ (LK) cells and Lin- cKit+ Sca-1+ cells is significantly higher in the Phd1CKO and Phd1/2CKO 
mice, suggesting a shift in haematopoiesis towards the progenitor populations (Fig. 3-1D). 
However, due to the decrease in total BM cellularity, this phenotype is not reflected in the total 
LK and LSK numbers (Fig. 3-2D).  
 
Further flow cytometric analysis of the LSK compartment was conducted using the SLAM 
family marker CD150, alongside the CD48. This experiment allows for more in depth analysis 
of the stem and progenitor cell compartment, with the identification of haematopoietic stem 
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cells (HSCs: LSK CD48-CD150+), multipotent progenitors (MPPs: LSK CD48-CD150-), 
haematopoietic progenitor cells-1 (HPC-1: LSK CD48+CD150-) and haematopoietic 
progenitor cells-2 (HPC-2: LSK CD48+CD150) (Oguro et al., 2013). Focusing on the 
distribution of the LSK compartment, as shown in Figures 3-1E-H, there are no significant 
differences between the conditional knockout and control mice. Notably, however, there is an 
increase in total HSC number in the mice lacking both Phd1CKO and Phd2CKO versus the control 
(Fig. 3-2E). 
 
Notably, contrary to published research in the field, there is no apparent phenotype in the 
Phd2CKO mice. This is likely due to the use of the haematopoietic-specific Vav-iCre opposed 
to other non-haematopoietic specific Cres, or the systemic ablation of Phd2 in adult mice using 
tamoxifen. Unlike other models, Vav-iCre deletes only within the haematopoietic system, thus 
this study unveils the cell-autonomous effect of PHD deletion. Notably, however, there is 
strong evidence of an altered stem-cell compartment in Phd1/2CKO mice, suggesting there is a 










































Figure 3-1 - Mice lacking Phd1 or both Phd1 and Phd2 show an increased percentage of LSK cells 
(A) Schematic representation of the control, Phd1CKO, Phd2CKO and Phd1/2CKO transgenic mice (B) Total 
numbers (per 2 femurs and 2 tibias) of white blood cells (WBC). Percentage of Lin- (C), and Lin- cKit+ 
and Lin- cKit+ Sca-1+ cells (D) in the total bone marrow (BM). Percentage of haematopoietic stem and 
progenitor cells within the LSK compartment. Characterisation was based on expression of SLAM 
markers: haematopoietic stem cells (HSCs: LSK CD48-CD150+) (E) multipotent progenitors (MPPs: LSK 
CD48-CD150-) (F) haematopoietic progenitor cells-1 (HPC-1: LSK CD48+CD150-) (G); haematopoietic 
progenitor cells-2 (HPC-2: LSK CD48+CD150+) (H). n=3-8 biological replicates per genotype. Data are 

















































































































































































Figure 3-2 - Mice deficient in Phd1 or both Phd1 and Phd2 have lower BM cellularity and an altered 
HSPC compartment (A) Schematic representation of the control, Phd1CKO, Phd2CKO and Phd1/2CKO 
transgenic mice (B) Total numbers (per 2 femurs and 2 tibias) of white blood cells (WBC), Lin- (C), and 
Lin- cKit+ and Lin- cKit+ Sca-1+ cells (D). Characterisation of haematopoietic stem and progenitor cells 
was based on expression of SLAM markers: haematopoietic stem cells (HSCs: LSK CD48-CD150+) (E) 
multipotent progenitors (MPPs: LSK CD48-CD150-) (F) haematopoietic progenitor cells-1 (HPC-1: LSK 
CD48+CD150-) (G); haematopoietic progenitor cells-2 (HPC-2: LSK CD48+CD150+) (H). n=3-8 biological 































































































































3.4 PHD1 and PHD2 are not required for mature haematopoietic cell 
differentiation 
To investigate the role of PHD1 and PHD2 in differentiated haematopoietic cells, I analysed 
the BM of 8-12-week-old Phd1CKO, Phd2CKO and Phd1/2CKO mice using B cell (CD19, B220), T 
cell (CD4, CD8) and myeloid (Mac1 and Gr1) cell surface markers. Flow cytometric analysis 
revealed there are no significant differences in the frequency of B cell, T cell or myeloid cells 
in the Phd conditional knockout mice versus the control (Fig. 3-3). Notably, there is a decrease 
in the percentage of myeloid cells in both Phd1CKO and Phd1/2CKO mice, but this is not 
significant.  
 
There is a significant decrease in the number of B cells and myeloid cells in mice lacking Phd1, 
and both Phd1 and Phd2 (Fig. 3-4E). Notably, this reduction is in concordance with a decrease 
in the total BM cellularity, as shown in Figure 3-4E. As such, the significant decrease in B cells 
and myeloid cells, along with further decreases in other differentiated compartments that were 
not analysed, are likely to have contributed to the overall decrease in BM cellularity.  
 
Overall, it is evident that PHD1 and PHD2 do not play a significant role in differentiated blood 



























Figure 3-3 - Deletion of Phd1, Phd2 or both Phd1 and Phd2 has no effect on mature 
haematopoietic cells (A) Schematic representation of the control, Phd1CKO, Phd2CKO and Phd1/2CKO 
transgenic mice (B) Total numbers (per 2 femurs and 2 tibias) of white blood cells (WBC). Percentage 
of B cells (CD19+B220+) (C), T cells (CD4+CD8+) (D), and myeloid cells (Mac1+Gr1+) (E). n=3-8 biological 
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Figure 3-4 - Ablation of Phd1, or both Phd1 and Phd2 reduces total numbers of B cells and 
myeloid cells (A) Schematic representation of the control, Phd1CKO, Phd2CKO and Phd1/2CKO transgenic 
mice (B) Total numbers (per 2 femurs and 2 tibias) of white blood cells (WBC). Total numbers in the BM 
of B cells (CD19+B220+) (C), T cells (CD4+CD8+) (D), and myeloid cells (Mac1+Gr1+) (E). n=3-8 biological 
































































































In conclusion, work in this chapter unveils new roles for Phd1 and Phd2 in steady state 
haematopoiesis, with ablation of Phd1, or both Phd1 and Phd2 resulting in a decrease in BM 
cellularity and an altered stem cell compartment. Although phenotypes presented in this 
chapter are somewhat less significant than other research published in this field, especially 
with regards to the effect of deletion of Phd2 (Takeda et al., 2007; Takeda et al., 2008; Singh 
et al., 2013), my research focused on dissecting the role of PHDs specifically within the 
haematopoietic system. As such, utilising Vav-iCre gave specific deletion with blood and 
immune cells, with significant accuracy over other haematopoietic Cres. In fact, a study by 
Abram et al in 2014 analysed various hematopoietic deleting strains, and found Vav1-
cre:ROSA-EYFP mice had the largest percentage of expression with a 98-100 % deletion in 
all hematopoietic cells. As such, using Vav-iCre in this study ensures near-complete deletion 
of Phd1 and Phd2 within the cell compartments studied. 
 
Most notably, Singh et al in 2013 generated a Phd2CKO mouse model utilising the CD68 Cre, 
with BM analysis of these mice showing an increase in LSK cell number, a phenotype not 
observed in results in this chapter. This result was also recorded in tamoxifen-treated Phd2CKO 
mice, where Phd2 is deleted in all tissues upon tamoxifen induction (Takeda et al., 2008). In 
comparison to CD68-Cre, Vav-iCre is often regarded as the gold standard for hematopoietic-
specific Cre strains and is restricted to only cells of the haematopoietic system, apart from 
some low-level expression in the testis and ovaries (de Boer et al., 2003). CD68, on the other 
hand, is known to be expressed in multiple other cell types, including epithelial tissue (Gough 
et al., 2001). This suggests that Phd2 is not essential for cell-autonomous LSK function, but 
does have a wider, systemic role in the biology and maintenance of the LSK compartment.  
 
This chapter unveiled a new role for Phd1 specifically within the haematopoietic system. 
Previous work focused solely on Phd1-/- knockout mice, or Phd1-/-;Phd3-/- double knockout 
mice, with deletion of Phd1 or Phd1 and Phd3 in all tissues. Notably, the haematopoietic 
system in Phd1-/- knockout mice has not been analysed, but Phd1-/-;Phd3-/- double knockout 
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mice presented with an increased LSK compartment. Opposing data published by Takeda et 
al in 2008 revealed that ablation of Phd1 within the haematopoietic system resulted in a 
significant decrease in BM cellularity (Fig. 3-1B). Ablation of both Phd1 and Phd2 also yields 
a decrease in BM cellularity, but deletion of Phd2 does not reduce this further (Fig. 3-1B). 
Thus, Phd1 has an important cell-autonomous effect on BM cellularity.  
 
Notably, as a consequence of the reduced BM cellularity, there are also decreases in the Lin- 
and LK populations in the Phd1CKO and Phd1/2CKO mice (Fig. 3-2C, 3-2D). Interestingly, 
however there is a significant increase in the percentage of LSK cells in the BM of Phd1CKO 
and Phd1/2CKO mice, perhaps mirroring the results of Takeda and colleagues in 2008. 
However, when adjusted to total cell number using the BM cellularity, there is no decrease in 
the total number of LSK cells (Fig. 3-1D, 3-2D).  
 
The most striking phenotype from the steady-state analysis is the significant increase in the 
frequency and total number of HSCs in mice lacking both Phd1 and Phd2 versus the control 
(Fig. 3-1E, 3-2E). This is especially remarkable given the noted decrease in BM cellularity of 
these mice. Given the lack of phenotype in Phd1CKO and Phd2CKO mice, it can be concluded 
that there is a cell-autonomous synergistic role between Phd1 and Phd2 in the HSC 
compartment. As deletion of both Phd1 and Phd2 increases HSC number, further analysis of 
Phd1/2CKO cells, including cell-cycle and transplantation assays, would unveil the fitness of 
these cells versus the WT. Notably, it is possible that these cells have expanded, but are no 
longer fit, to the detriment of the haematopoietic system. Given that HSCs are dispensable for 
steady-state haematopoiesis (Busch et al., 2015), putting these cells under stress inducing 
conditions such as IFNα or serial HSC transplantation would test their functionality (Essers et 
al., 2009). If HSCs lacking Phd1 and Phd2 were indeed functional, it is possible that Phd1 and 
Phd2 could be targets in the in vitro expansion of HSCs.  
 
Notably, this chapter did not focus on the role of Phd3 in steady-state haematopoiesis, as the 
isoform is expressed at very low levels in the blood system (Stiehl et al., 2006). However, 
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given the significant phenotypes observed in the Phd1/2CKO mice, especially within the 
primitive and HSC compartments, the generation of Phd1/2/3CKO mice (Phd1fl/fl; Phd2fl/fl; ; 
Phd3fl/fl Vav-iCre+), would give interesting further insight into the role of the PHD family in 
haematopoiesis.    
 
In conclusion, this chapter has contributed significantly to the field, demonstrating that Phd2 
is dispensable in cell-autonomous steady-state haematopoiesis. In addition, the expansion of 
HSCs in Phd1/2CKO mice merits further investigation as the PHD family may unveil themselves 
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Chapter 4 The role of systemic Phd2 knockdown in 
haematopoiesis  
4.1 Introduction 
As described in Chapter 3, several studies have attempted to the define the physiological or 
pathological activities of the PHD proteins using genetic inactivation. PHD2 is the most 
abundantly expressed of the PHD isoforms, and thus has been studied extensively (Berra et 
al., 2003; Stiehl et al., 2006). At the whole animal level, knockout of Phd2 results in 
developmental defects and embryonic lethality (Takeda et al., 2006). Conditional knockout of 
Phd2 using a tamoxifen-inducible Cre, systemically deleting Phd2 in all adult tissues, lead to 
an increase in angiogenesis, erythrocytosis and changes in energy metabolism, with ultimately 
lethal consequences (Minamishima et al., 2008; Takeda et al., 2008; Takeda et al., 2007). 
Additionally, recent research success of PHD2 inhibitors for the treatment of diseases such as 
ischemia and chronic kidney disease, and their subsequent use in multiple clinical trials, gives 
further weight for precise analysis of the effect of Phd2 depletion in vivo (Haase, 2017). 
 
Data presented in Chapter 3, utilising the Vav-iCre system to delete Phd2 specifically within 
the haematopoietic system concluded that Phd2 was not required for steady state 
haematopoiesis. Given that this data is at odds with that published within the field (Takeda et 
al., 2008; Singh et al., 2013). I chose to further investigate the role of Phd2 in haematopoiesis 
using an inducible RNA interference gene knockdown in vivo. This offers the advantages of 
timed, reversible and specific gene silencing in mature cells, producing effects potentially more 









4.1.1 Inducible shPhd2-mediated knockdown model 
As outlined in Chapter 2 and Figure 2-1, rtTA/shPhd2 and Control rtTA mice were donated 
by Chris W Pugh and Sir Peter J Ratcliffe and are described in Yamamoto et al, 2019 (in 
submission, JCI). Notably, the reverse tetracycline trans-activator (rtTA) is placed under 
control of the CAG promoter which gives a stronger and greater ubiquitous expression than 
under the R26-rtTA promoter (Dow et al., 2012). Upon doxycycline (Dox) treatment, there is 
activation of the tetracycline response element (TRE) controlled GFP-shPhd2 cassette (TRE-
shPhd2), which results in transcription of both GFP and shPHD2 in the rtTA/shPhd2 mice. 
Control rtTA mice do not have the GFP-shPhd2 cassette, and so upon Dox treatment, there 
is no transcription of GFP or shPHD2. Notably, the GFP reporter was utilised in flow cytometry 
and fluorescence activated cell sorting (FACS) to identify cells lacking Phd2 under this 




















4.2 Aims and objectives of Chapter 4 
Given that results described in this thesis (Chapter 3) contradict those already published in 
the field, the aim of this chapter is to determine the effect of Phd2 knockdown in the 
haematopoietic system of adult mice using immunophenotypic and transplantation assay 
analysis. shPhd2/rtTA mice, which upon Dox treatment transcribe a short-hairpin targeting 
Phd2, as well as GFP, were utilised to perform acute Phd2 depletion in both steady-state 
haematopoiesis and transplantation experiments. In concordance with published research in 
the field (Singh et al., 2013; Takeda et al., 2008; Takeda et al., 2007; Takeda et al., 2006), this 
chapter hypothesises that systemic deletion of Phd2 will impact haematopoiesis under steady 
and stressed conditions. 
 
Analyses of the primitive and differentiated hematopoietic compartments were performed in 
both experiments to fully dissect the role of Phd2 in all stages of haematopoiesis. Notably, 
following the exposure of myeloid-specific phenotypes in Chapter 3, this chapter sub-divides 
the myeloid compartment (Mac1+Gr1+) into monocytes (Mac1+), which can develop into 
dendritic cells or macrophages, and granulocytes (Mac1+Gr1+), which are either neutrophils, 
eosinophils or basophils (Yam et al., 1971). Results from these experiments will determine if 














4.3 Validation of the shPhd2/rtTA transgenic model 
Upon receiving shPhd2/rtTA and rtTA (Control) mice from Chris W Pugh and Sir Peter J 
Ratcliffe from the University of Oxford, I first set out to validate this novel and unpublished 
transgenic in vivo model. Notably, qPCR analysis conducted at the University of Oxford found 
than upon Dox treatment, shPhd2/rtTA mice displayed significant reduction in Phd2 levels in 
multiple tissue types including liver, kidney, thymus, spleen, heart, skin and BM. As expected, 
as a consequence of reduced Phd2 levels, there was an increase in Phd3 and Bnip3 (a HIF 
target gene) in these tissues measured by qPCR. This suggests that the tissues are able to 
compensate for the reduction of Phd2 and HIF activity is increased, respectively (Yamamoto 
et al., in submission).  
 
To validate this mouse strain for further haematopoietic analysis, shPhd2/rtTA and rtTA 
(Control) mice were treated with Dox for 5 weeks (as advised by Chris W Pugh and 
colleagues). Following this, BM cells were extracted and GFP expression was measured by 
flow cytometry analysis.  As shown in Figure 4-1C and Figure 4-1D, there is strong GFP 
expression in the BM of shPhd2/rtTA mice, but no GFP expression in the BM of control mice. 
To ensure that GFP expression was correlated with a reduction in Phd2 levels, RNA was 
extracted from control, as well as the GFP-, and GFP+ fraction of shPhd2/rtTA BM cells, and 
qRT-PCR was performed. Notably the GFP- and GFP+ shPhd2/rtTA BM cells were isolated by 
FACS. Figure 4-1B shows that, as expected, there is a significant reduction in Phd2 mRNA 
levels in the GFP+ shPhd2/rtTA cells when compared to the control. There is a slight reduction 
in Phd2 expression in the GFP- shPhd2/rtTA cells, this, however, is likely an artefact of FACS 






















Figure 4-1 - Upon Dox treatment, shPhd2/rtTA mice show a decrease in Phd2 levels and 
expression of GFP (A) Schematic representation of the rtTA (Control) and shPhd2/rtTA transgenic 
mice. Control and shPhd2/rtTA mice were treated with 2 mg/ml Dox in their drinking water for 5 weeks 
and BM cells were isolated. GFP+ and GFP- cells were collected by FACS, and RNA extracted (B) 
qRT-PCR analysis of control, GFP- shPhd2/rtTA and GFP+ shPhd2/rtTA cells. Data are represented as 
fold change over control after normalising to β-actin levels using the ΔΔCT method. Representative 



























































4.4 Knockdown of Phd2 results in a reduction of mature blood cells 
in the PB 
To investigate the effect of systemic knockdown of Phd2 in steady state haematopoiesis, 5-
week old control and shPhd2/rtTA mice were treated with Dox for 8 weeks, with subsequent 
final BM analysis at 12 weeks of age. Notably, analysis of these young adult mice ensured 
exclusion of any aged phenotypes, and allowed for valid comparisons with the Phd2CKO mice, 
investigated in Chapter 3, which were analysed at 8 - 12 weeks of age. Although there is no 
evidence of Doxycycline affecting steady-state or stressed haematopoiesis, treating both 
shPhd2/rtTA and control mice with Dox ensures any phenotypes observed in shPhd2/rtTA 
mice are independent of Dox, thus a direct consequence of knockdown of Phd2.  
 
In addition to final BM analysis, peripheral blood (PB) samples from control and shPhd2/rtTA 
mice were taken at 4 weeks and 8 weeks during Dox treatment to evaluate the effect of Phd2 
depletion on the peripheral blood. As shown in Figure 4-1B and 4-1E, at both 4 and 8 weeks 
of Dox treatment there is significant GFP expression in the PB of shPhd2/rtTA mice, with an 
average GFP expression of 68.75 %. Notably there is no GFP expression in the control mice 
treated with Dox. This suggests there is a significant reduction of Phd2 levels in the peripheral 
blood of shPhd2/rtTA mice.  
 
After 4 weeks of Dox treatment, there is a significant decrease in the percentage of T cells 
(CD4+ CD8+), and an increase in granulocytes (Mac-1+ Gr1+). 4 weeks later, there is no 
difference in the percentage of T cells in the PB when comparing the control and shPhd2/rtTA 
mice, but there is instead a significant decrease in B Cells (CD19+ B220+). Notably, the 
increase in the granulocyte population shown at week 4 is still present, and has increased 
further at week 8 (Fig. 4-1C, 4-1F). 
 
Haematological parameters of the PB samples were measured at week 4 and week 8 of Dox 
treatment using a HEMAVETÒ 950 analyser, and it was discovered that at week 8 the WBC, 
RBC, haemoglobin (HGB) and haematocrit (HCT) values were decreased in the shPhd2/rtTA 
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mice versus the control. Notably, these phenotypes were also observed in parallel experiments 
at the University of Oxford (Yamamoto et al., in submission). As these changes only became 
apparent after 8 weeks of Dox treatment, it is evident that the long-term reduction of Phd2 



























































Figure 4-2 - Systemic reduction of Phd2 levels results in abnormal haematological parameters 
(A) Schematic representation of the rtTA (Control) and shPhd2/rtTA transgenic mice. Control and 
shPhd2/rtTA mice were treated with 2 mg/ml Dox in their drinking water for 8 weeks. PB blood samples 
were taken at 4 and 8 weeks of Dox treatment. At week 4, the percentage of GFP (B) and mature blood 
cells (B cells (CD19+B220+), T cells (CD4+CD8+), monocytes (Mac1+) and granulocytes (Mac1+Gr1+)) 
were analysed by flow cytometry (C) Haematological parameters; White Blood Cell (WBC), Red Blood 
Cell (RBC), haemoglobin (HGB), haematocrit (HCT), Mean Cellular Volume (MCV), Mean Cellular Height 
(MCH), Mean Corpuscular Haemoglobin Concentration (MCHC) and Platelets (PLT) were measured 
using a HEMAVETÒ 950 analyser (D). Flow cytometry analysis was conducted (E)(F), and 
haematological parameters (G) were measured again at week 8. n=6 biological replicates per genotype. 
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4.5 Phd2 is not required for mature haematopoietic cells in the BM 
In order to investigate the role of Phd2 in differentiated haematopoietic cells, I analysed the 
BM of control and shPhd2/rtTA mice described in Section 4.1.1. As shown in Figure 4-3, there 
was no difference in the BM cellularity or the number of RBCs in the mice with knockdown of 
Phd2 versus control.  
 
In concordance with data presented in Figure 4-1C and Figure 4-1D, flow cytometry analysis 
of the BM found significant GFP expression in the shPhd2/rtTA mice, when compared to the 
control, with mean percentage GFP expressions of 82.37 % and 0.23 % respectively (Fig. 4-
4B). Further immunophenotypic analysis of the BM using B cell (CD19, B220), T cell (CD4, 
CD8) and myeloid (Mac1 and Gr1) cell surface markers found there was no difference in the 
mature haematopoietic compartment following acute reduction of Phd2 levels (Fig. 4-4D).  
 
Additionally, given that tissue hypoxia is known to regulate the process of erythropoiesis, I 
decided to study the role of systemic Phd2 knockdown in the differentiation of erythroid 
progenitors using the cell-surface markers CD71 and Ter119 (Koulnis et al., 2011). The co-
staining of Ter119, which specifically marks maturing erythrocytes, and CD71, a transferrin 
receptor expressed on all proliferating cells, is widely used in erythropoiesis research (Levy et 
al., 199) (Fraser et al., 2007). Zhang and colleagues in 2003 dissected this novel flow 
cytometry-based staining, comparing it to the morphological phenotypes of the analysed cells, 
and found that the TER119- CD71-population corresponded to the most primitive erythropoietic 
cells; the proerythroblasts and early basophilic erythroblasts. In the TER119- CD71+ they found 
early and late basophilic erythroblasts, in the TER119+ CD71+ population chromatophilic and 
orthochromatophilic erythroblasts, and finally the most differentiated cells (late 
orthochromatophilic erythroblasts and reticulocytes) in the TER119+ CD71- population. 
Analysis of the BM of shPhd2/rtTA and control mice showed no difference in any of the stages 
of erythropoiesis. This, in addition to the RBC counts shown in Figure 4-3C, suggest that, 
despite the role of the hypoxia pathway in erythropoiesis, there is no effect of systemic 
knockdown of Phd2 in the BM of adult mice (Fig. 4-4F).  
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Notably, GFP expression in the B cell, monocyte and granulocyte compartments suggest there 
is a significant knockdown of Phd2 in these differentiated haematopoietic cells (Fig. 4-4C). In 
the Ter119/CD71 staining, however, there is disparate GFP expression between the most 
primitive erythroid compartments (with high GFP expression), and the more differentiated 
stages of erythropoiesis (with low GFP expression) (Fig. 4-4E). Notably, low GFP expression 
may correlate with a less significant knockdown of Phd2, and may explain the lack of 













Figure 4-3 - Systemic ablation of Phd2 has no effect on WBC and RBC numbers (A) Schematic 
representation of the rtTA (Control) and shPhd2/rtTA transgenic mice. Control and shPhd2/rtTA mice 
were treated with 2 mg/ml Dox in their drinking water for 8 weeks. (B) The number of White Blood Cells 
(WBC) and Red Blood Cells (RBC) (C) were measured using a HEMAVETÒ 950 analyser n=5-6 biological 














































































Figure 4-4 - Phd2 has no role in the differentiated haematopoietic compartment of the BM     
(A) Schematic representation of the rtTA (Control) and shPhd2/rtTA transgenic mice. Control and 
shPhd2/rtTA mice were treated with 2 mg/ml Dox in their drinking water for 8 weeks. (B) GFP expression 
in the total BM. GFP expression (C), and percentage of mature blood cells (B cells (CD19+B220+), 
monocytes (Mac1+) and granulocytes (Mac1+Gr1+) (D) were analysed by flow cytometry. GFP expression 
(E), and percentage of TER119- CD71-, TER119- CD71+, TER119+ CD71+ and TER119- CD71- cells. 





































































































































































4.6 Systemic knockdown of Phd2 alters the HSPC compartment 
Given the contentious debate surrounding to role of Phd2 in the HSPC compartment, I utilised 
the Dox-inducible shPhd2 transgenic model to analyse the effect of systemic Phd2 knockdown 
on the stem and progenitor compartments of the haematopoietic system within steady state 
conditions. Control and shPhd2/rtTA mice were treated with Dox for 8 weeks, and 
immunophenotypically analysed by flow cytometry.  
 
In concordance with studies by Takeda et al in 2008, there is an increase in the frequency of 
the LSK compartment in the shPhd2/rtTA mice versus the control (Figure 4-5C). Further 
analysis of the LSK compartment using CD48 and CD150 cell-surface markers, displayed an 
altered stem cell compartment, with a significant decrease in the most primitive compartments; 
HSC and MPP, and an increase in the least primitive compartment; HPC-2 cells. This result 
overall shows a global increase in CD48 expression within the LSK compartment, suggesting 
a trend towards the progenitor populations HPC-1 and HPC-2. Thus, a systemic decrease in 
Phd2 levels decreases the HSC pool in the BM, and in turn, increases the frequency of 
haematopoietic progenitors further down the differentiation hierarchy (Fig. 4-5D).  
 
Notably, GFP expression is highest in the HSC compartment at the top of the haematopoietic 
hierarchy, and decreases in expression through the LK and Lin- populations. This is very 
interesting, and confirms there is substantial knockdown of Phd2 in the primitive 
























Figure 4-5 - Mice lacking Phd2 show a decrease in the most primitive HSPC compartments (A) 
Schematic representation of the rtTA (Control) and shPhd2/rtTA transgenic mice. Control and 
shPhd2/rtTA mice were treated with 2 mg/ml Dox in their drinking water for 8 weeks. (B) GFP expression 
in total BM, Lin-, LK (Lin- cKit+), LSK (Lin- cKit+ Sca-1+), HSCs (LSK CD48-CD150+), MPPs (LSK CD48-
CD150-), HPC-1s (LSK CD48+CD150-) and HPC-2s (LSK CD48+CD150+). (C) LK and LSK cells as a 
frequency of the Lin- compartment. (D) Percentage of haematopoietic stem and progenitor cells within 
the LSK compartment. n=5-6 biological replicates per genotype. Data are mean ± SEM. **, P < 0.01 




























































































4.7 Reduction of Phd2 levels results in an expansion of 
haematopoietic cells in the spleen 
Previous published work has shown that, in addition to changes with the BM, knockdown of 
Phd2 can have effects on sites of extramedullary haematopoiesis, including the spleen 
(Takeda et al., 2008). Notably, extramedullary haematopoiesis can often be a readout of the 
fitness of the BM or BM niche, with multiple factors including infection, bone marrow failure or 
malignancy increasing extramedullary haematopoiesis in peripheral organs such as the liver 
or spleen (Kim., 2010). As such, it may be possible that Phd2 is essential to the BM 
microenvironment, and its loss results in an active extramedullary haematopoiesis response 
in the spleen. To investigate this hypothesis further, I treated control and shPhd2/rtTA mice 
with Dox for 8 weeks, and analysed the spleen for mature and primitive haematopoiesis.  
 
Haematopoietic parameter analysis of the spleen using the HEMAVETÒ 950 analyser, 
revealed that the number of WBCs and RBCs in mice with reduced levels of Phd2 was 
substantially higher than the control (Fig. 4-6B, 4-6C). In accordance with this, there is a 
significant increase in spleen weight in shPhd2/rtTA mice when compared to the control, with 
mean spleen weights of 308.63 mg and 69.8 mg respectively (Fig. 4-6D). This confirms a 
significant expansion of extramedullary haematopoiesis in the spleen following knockdown of 
Phd2 levels.  
 
Notably, one shPhd2/rtTA mouse recorded a significantly higher spleen weight of 759.8 mg 
versus others in the cohort, and is responsible for the outlining data point present in Figures 




















Figure 4-6 - Systemic ablation of Phd2 increase WBC and RBC numbers in the spleen (A) 
Schematic representation of the rtTA (Control) and shPhd2/rtTA transgenic mice. Control and 
shPhd2/rtTA mice were treated with 2 mg/ml Dox in their drinking water for 8 weeks before analysis of 
the spleen. (B) The number of White Blood Cells (WBC) and Red Blood Cells (RBC) (C) were measured 
using a HEMAVETÒ 950 analyser. (D) Spleen weights of Dox-treated control and shPhd2/rtTA animals. 
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4.8 Systemic knockdown of Phd2 does not affect the distribution of 
mature blood cell lineages  
Given there was a significant increase in the WBC and RBC numbers in the spleen of 
shPhd2/rtTA mice when compared to the control, I sought to analyse the differentiated 
haematopoietic compartment to investigate if there was any difference of the lineage 
distribution in these mature blood cells.  
 
Despite dramatic expansion of haematopoiesis in the spleen of mice with reduced Phd2 
expression, and therefore a global increase in the number of differentiated cells (Fig. 4-8), 
there is no strong evidence of lineage bias in the differentiated compartment. There was no 
difference in the percentage of B cells, T cells, or granulocytes in the shPhd2/rtTA mice versus 
the control (Fig. 4-7C). However, there was a significant increase in the percentage of the 
monocyte population, a trend also shown in the BM, although not significant (Fig. 4-4D). 
Notably, as shown in the BM in Figure 4-4C, there is evidence of GFP expression in the B 
cell, T cell, monocyte and granulocyte compartments. Additionally, as found in the BM 
experiments, there is an increased GFP expression in myeloid cells (monocytes and 
granulocytes), versus lymphoid cells (B cells and T cells). As such, it cannot be ruled out that 
Phd2 may have a significant role in lymphopoieses, but the levels of Phd2 are not as reduced 
as in the myeloid compartment, so the phenotype is concealed. qRT-PCR analysis of the 
separate differentiated haematopoietic compartments would verify this hypothesis.   
 
Surprisingly, despite the strong link between hypoxia and increased ectopic erythropoiesis in 
the spleen, there were no evident differences in the Ter119/CD71 staining between the control 
mice, and mice with the knockdown of Phd2 (Fig. 4-7E) (Adamson., 1988). Notably, as shown 
in the BM experiments in Figure 4-4E, there is increased GFP expression in the primitive 
erythroid cells (Ter119-CD71-, Ter119-CD71+) versus the more mature erythroid cells 




Overall, these results conclude that there is no lineage bias in the extramedullary 



















Figure 4-7 - Reduction of Phd2 has no effect on the lineage bias of differentiated cells (A) 
Schematic representation of the rtTA (Control) and shPhd2/rtTA transgenic mice. Control and 
shPhd2/rtTA mice were treated with 2 mg/ml Dox in their drinking water for 8 weeks before analysis of 
the spleen. (B) GFP expression and the percentage of total cells (C) of B cells (CD19+B220+), T cells 
(CD4+CD8+), monocytes (Mac1+) and granulocytes (Mac1+Gr1+). GFP expression (D), and percentage 
of TER119- CD71-, TER119- CD71+, TER119+ CD71+ and TER119- CD71- cells in the spleen (E). n=5-6 































































































































































Figure 4-8 - Reduction of Phd2 increases the number of mature blood cells in the spleen (A) 
Schematic representation of the rtTA (Control) and shPhd2/rtTA transgenic mice. Control and 
shPhd2/rtTA mice were treated with 2 mg/ml Dox in their drinking water for 8 weeks before analysis of 
the spleen. (B) Total numbers in the spleen of B cells (CD19+B220+) (C), T cells (CD4+ or CD8+) (D), 
monocytes (Mac1+) and granulocytes (Mac1+Gr1+) (E). n=4-5 biological replicates per genotype. Data 












































































































4.9 Increased extramedullary haematopoiesis results in an 
increased cell numbers within the LK compartment in mice 
with Phd2 depletion 
In order to further investigate the effect of Phd2 knockdown on the spleen, and the effect of 
the significant increase in extramedullary haematopoiesis observed in Figure 4-6, I analysed 
the LK progenitor cell compartment in shPh2/rtTA and control mice.  
 
Initial analysis by flow cytometry showed, as expected, significant GFP expression in the mice 
expressing the knockdown of Phd2, versus the control (Fig. 4-9B).  shPh2/rtTA mice had a 
mean GFP expression of 41.2 %, with a range of 5.9 %, compared to a GFP expression of 
0.14 % in the control. Notably, this is globally lower than the GFP expression values observed 
in the BM, suggesting there is smaller reduction in Phd2 in the spleen (Fig. 4-7E).  
 
Overall, there was a trend of an increased LK population in the shPh2/rtTA mice versus the 
control. However, as shown in Figure 4-9C, the data, represented as a frequency of Lin- 
cells, is spread, with two obvious outliers. Further analysis of this data revealed that an 
increase in spleen weight, which is an indicator of increased extramedullary haematopoiesis, 
results in a pronounced expansion of the LK progenitor compartment. This is best 
demonstrated when the flow cytometry analysis plots of a control mouse, with a spleen 
weight of 77 mg (Fig. 4-9D), is compared to a shPh2/rtTA mouse, with a spleen weight of 
759.7 mg (Fig. 4-9F). The LK population in the spleen is 1.18 % in the control mouse and 
3.20 % in the mouse with reduced levels of Phd2. Notably, as represented in Figure 4-9E, 
there were multiple shPhd2/rtTA mice with an increased spleen weight (142.5 mg), but with 
equal or a decrease in the LK population when compared to the control mice. Thus, only 
under great extramedullary expansion is there a significant increase in the percentage of LK 
progenitor cells in the spleen. The disparity shown between shPhd2/rtTA mice, in both 
spleen weights and the frequency of LK cells, versus results from BM experiments in 
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Section 4-6, suggest that systemic ablation of Phd2 levels results in a varied active 






















Figure 4-9 - Mice lacking Phd2 show an increase in the LK progenitor compartment (A) Schematic 
representation of the rtTA (Control) and shPhd2/rtTA transgenic mice. Control and shPhd2/rtTA mice 
were treated with 2 mg/ml Dox in their drinking water for 8 weeks. (B) GFP expression in spleen. (C) 
Frequency of LK cells as a percentage of the Lin- compartment. (D-F) Representative flow cytometry 
plots of control and shPhd2/rtTA mice. Corresponding spleen are stated below each plot. n=6-7 biological 
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4.10 HSCs with Phd2 knockdown are less fit than their control 
counterparts  
After discovering that systemic reduction of Phd2 levels under steady-state conditions results 
in contraction of the HSC compartment (Fig 4-5D), I sought out to investigate the fitness of 
these Phd2 deficient cells under extreme stress, using an HSC transplantation assay. Notably, 
HSC transplants are considered the "gold standard" to detect and characterise the functionality 
of HSCs as upon transplantation, quiescent HSCs are forced to exit dormancy to self-renew 
and differentiate into functional mature blood cells (Wilson et al., 2009). 
 
In this experiment, 200 CD45.2+ HSCs from shPhd2/rtTA and control mice were isolated by 
FACS and injected via the tail vein into sub-lethally irradiated (11Gy) CD45.1+/CD45.2+ 
syngeneic recipient mice. Notably, at this stage, neither the shPhd2/rtTA or control mice have 
been treated with Dox, so both have WT levels of Phd2.  Importantly, transplantation of 
CD45.2+ donor cells into CD45.1+/CD45.2+ recipient mice allows for the engraftment and 
differentiation potential of donor HSCs to be tracked by flow cytometry analysis of the CD45.2 
cell-surface marker. 
 
Multilineage reconstitution is considered to be stable approximately 3 - 6 weeks following 
transplantation, with WT HSCs able to sustain haematopoiesis in the recipient mouse for a 
minimum of 16 weeks (Ema et al., 2014; Morrison et al., 1997). To analyse the CD45.2+ 
engraftment and multilineage repopulation potential of the transplanted HSCs, PB samples 
were collected from recipient mice at 4-, 6-, 8-, 10-, 14- and 18-weeks post-transplantation. At 
6 weeks post-transplantation, the engraftment of CD45.2+ cells had increased from analyses 
at week 4, and reached a mean value of 89.01 % in the control mice and 87.8 % in the 
shPhd2/rtTA (Fig. 4-10B). Given these significant levels of engraftment shown in the PB at 
week 6 post-transplantation, recipient mice transplanted with shPhd2/rtTA and control HSCs 
were given 2 mg/ml Dox in their drinking water to induce the transcription of a short-hairpin 
targeting Phd2 and GFP. Thus, unlike previous experiments described in this chapter which 
induced systemic knockdown of Phd2, this experiment reduces Phd2 levels specifically within 
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the transplanted HSCs and their progeny. These experiments, therefore, can investigate the 
effect of Phd2 depletion on the biology of HSCs. 
Following confirmation of stable CD45.2+ engraftment at 6 weeks post-transplantation, mice 
were treated with 2 mg/ml Dox. PB samples were collected from recipient mice at 8-, 10-, 14- 
and 18- weeks post-transplantation, measuring GFP expression and CD45.2+ engraftment by 
flow cytometry analysis. Prior to Dox induction, in PB samples taken at week 4 and week 6 
post-transplantation, there was no expression of GFP in the PB of recipient mice transplanted 
with either shPhd2/rtTA or control HSCs. However, at week 8, following Dox treatment, there 
is significant GFP expression in the PB of mice transplanted with shPhd2/rtTA HSCs versus 
the control. This confirms successful transcription of the GFP/shPhd2 cassette upon Dox 
induction. GFP expression remains in PB of mice transplanted with shPhd2/rtTA HSCs until 
the mice were sacrificed at 18 weeks post-transplantation. Notably, there is a slight but notable 
decrease in the percentage of GFP positive cells over time, suggesting a decrease in the 
number of HSCs lacking Phd2. (Fig. 4-10C). Moreover, analysis of CD45.2+ engraftment in 
the recipient mice, found that mice transplanted with HSCs with knockdown of Phd2 had a 
decrease in engraftment versus control HSCs (Fig. 4-10B).  
 
Analysis of the WBC and RBC counts in the PB of recipient mice using the HEMAVETÒ 950 
analyser found that there was no difference in the number of RBCs across all recipient mice 
(Fig. 4-10E). Importantly, there were significant decreases in the WBC count at 8-, 10-, 14- 
and 18 weeks post-transplantation in the recipient mice transplanted with HSCs deficient in 
Phd2 versus the control. There is, however, a global decrease in the number of WBC over 
time, across all recipient mice (Fig. 4-10D). PB samples from all recipient mice were collected 
and analysed on the same day, so the general decrease in WBC count may be an artefact of 
measurement variations in the HEMAVETÒ 950 analyser. Conversely, global reductions in the 
WBC count may indicate that both the control and shPhd2/rtTA HSCs are exhausting over 
time under the transplantation stress. Thus, at all times, samples from recipient mice 
transplanted with shPhd2/rtTA or control HSCs are collected and analysed in parallel. This 
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ensures a direct comparison of the fitness and biology of the control and Phd2 knockdown 
HSCs, eliminating other external factors where possible. 
 
Overall, it is evident from the CD45.2+ engraftment data and WBC counts from recipient mice, 

















































Figure 4-10 - HSCs deficient in Phd2 have decreased engraftment and a decrease in WBC number 
in the PB (A) 200 CD45.2+ LSK CD48-CD150+ HSCs from control shPhd2/rtTA mice were transplanted 
into lethally irradiated (11Gy) syngeneic CD45.1+/CD45.2+ recipient mice. Following stable CD45.2+ 
engraftment at 6 weeks post-transplant, recipient mice were treated with 2 mg/ml Dox in their drinking 
water, driving production of a short-hairpin targeting Phd2, transcription of GFP. (B) Percentage of donor 
cells engraftment and GFP expression (C) measured by flow cytometry analysis at 4-, 6-, 8-, 10-, 14- 
and 18- weeks post-transplantation. (D) The number of White Blood Cells (WBC) and Red Blood Cells 
(RBC) (E) were measured using a HEMAVETÒ 950 analyser at 4-, 6-, 8-, 10-, 14- and 18- weeks post-
transplantation.  n=5 recipients per biological replicates (n=3-4). Data are mean ± SEM. *, P < 0.05 
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4.11 HSCs with a knockdown of Phd2 have an altered multilineage 
reconstitution potential 
In order to address if HSCs lacking Phd2 operate under a lineage bias upon transplantation, I 
analysed the percentage of B cells, T cells, monocytes and granulocytes in the PB of recipient 
mice by flow cytometry analysis.  
 
As shown in Figure 4-11, the multilineage reconstitution was altered in HSCs with reduced 
levels of Phd2, resulting in an increase of T cells and granulocytes, and a decrease in the 
percentage of B cells in the PB. These results corroborate those found in the steady state 
analysis of the PB of non-transplanted shPhd/rtTA mice, which displayed an increase in the 
percentage of granulocytes, and a decrease in the B cell population following 8 weeks of Dox 
treatment (Fig. 4-2F). 
 
Overall, these results suggest that Phd2 does present a lineage bias, as reduction of Phd2 
levels consistently increases the granulocyte population, and decreases the B cell population, 




































Figure 4-11 - Upon transplantation, HSCs with a knockdown of Phd2 have altered multilineage 
haematopoietic differentiation (A) 200 CD45.2+ LSK CD48-CD150+ HSCs from control shPhd2/rtTA 
mice were transplanted into lethally irradiated (11Gy) syngeneic CD45.1+/CD45.2+ recipient mice. 
Following stable CD45.2+ engraftment at 6 weeks post-transplant, recipient mice were treated with 2 
mg/ml Dox in their drinking water, driving production of a short-hairpin targeting Phd2, transcription of 
GFP. Mature blood cells (B cells (CD19+B220+) (B), T cells (CD4+CD8+) (C), monocytes (Mac1+) (D) and 
granulocytes (Mac1+Gr1+)) (E) were analysed by flow cytometry at 4-, 6-, 8-, 10-, 14- and 18- weeks 
post-transplantation. n=5 recipients per biological replicates (n=3-4). Data are mean ± SEM. *, P < 0.05 































































































4.12 Reduction of Phd2 in HSCs does not affect the repopulation of 
mature haematopoietic cells in the BM 
In order to investigate the ability of HSCs deficient in Phd2 to repopulate the differentiated 
haematopoietic cell compartment of the BM, I analysed the BM of recipient mice 18 weeks 
following the transplantation of 200 CD45.2+ HSCs from control and shPhd2/rtTA mice.  
 
I found that there was a significant GFP expression in the mice transplanted with shPhd2/rtTA 
HSCs when compared to recipient mice transplanted with control HSCs (Fig. 4-12B). In 
addition, despite significant decreases found in the PB samples (Fig. 4-10B), there was no 
difference found in CD45.2+ engraftment between recipient mice (Fig. 4-12C). 
 
Flow cytometry analysis of the BM of recipient mice revealed that there was a decrease in the 
B cell population in mice transplanted with Phd2 deficient HSCs versus those transplanted 
with control HSCs. Notably, this phenotype was also observed in the PB experiments. There 
were, however, no significant differences in either of the myeloid compartments (Fig. 4-12D).  
 
As found in the steady state analysis experiments in the BM (Fig. 4-4C) and spleen (Fig. 4-
7B) there is stable GFP expression in the B cell, T cell, monocyte and granulocyte 
compartments. There is an increased GFP expression in myeloid cells (monocytes and 
granulocytes), versus lymphoid cells (B cells and T cells), suggesting there is a reduced 
knockdown of Phd2 in these cells (Fig. 4-12E). It is possible, that given a more significant 
knockdown, there would be an even greater decrease in the B cell compartment. 
 
Overall, when transplanted into recipient mice, shPhd2/rtTA HSCs are able to successfully 
repopulate the BM of lethally irradiated recipient mice.  In addition, shPhd2/rtTA HSCs present 
a lineage bias in both the PB and BM tissues, favouring granulocyte production over B cell 






















Figure 4-12 - HSCs lacking Phd2 are able to repopulate the BM of recipient mice (A) 200 CD45.2+ 
LSK CD48-CD150+ HSCs from control shPhd2/rtTA mice were transplanted into lethally irradiated (11Gy) 
syngeneic CD45.1+/CD45.2+ recipient mice. Following stable CD45.2+ engraftment at 6 weeks post-
transplant, recipient mice were treated with 2 mg/ml Dox in their drinking water, driving production of a 
short-hairpin targeting Phd2, transcription of GFP. (B) Percentage of GFP expression and CD45.2+ 
engraftment (C) measured by flow cytometry analysis. (D) Mature blood cells (B cells (CD19+B220+), 
monocytes (Mac1+) and granulocytes as a percentage of CD45.2+ cells (Mac1+Gr1+)). (E) GFP 
expression in the B cell, monocyte and granulocyte compartments. n=5 recipients per biological 
















































































































4.13 Upon transplantation, HSCs with reduced levels of Phd2 
generate an altered stem cell compartment  
Previous experiments in this chapter provided evidence that systemic reduction of Phd2 levels 
results in an altered stem cell compartment. These data show that under steady state 
haematopoietic conditions, a decrease in Phd2 levels results in a decrease in the primitive 
HSC and MPP compartments, and a compensatory increase in less primitive HSPC cells; 
HPC-1 and HPC-2 (Fig. 4-5). Given this interesting phenotype, I sought to investigate the 
effect of depletion specifically within transplanted HSCs and their progeny, and the influence 
this would have on the HSPC compartment of the recipient animals.   
 
In concordance with the steady state BM analysis conducted in Figure 4-5, GFP expression 
is highest in the HSC compartment, and is significantly decreased in the LK and Lin- 
populations. High expression of GFP in the primitive compartment, especially in the HSC, 
MPP, HPC-1 and HPC-2, proves that the HSCs lacking Phd2 were indeed functional and able 
to self-renew and differentiate into primitive progenitor cells (Fig. 4-13B).  
 
In contrast with published results by Takeda et al in 2008, and experiments in this chapter 
(Fig. 4-5C), there is no difference in the frequency of the LK or LSK compartments of mice 
transplanted with shPhd2/rtTA HSCs versus those transplanted with control HSCs. Flow 
cytometric analysis of the LSK compartment using CD48 and CD150 cell-surface markers, 
displayed an altered stem cell compartment, with a significant decrease in the HSC and MPP 
compartments (not significant). As before (Fig. 4-5D), the reduction in the most primitive cells 
of the haematopoietic hierarchy is compensated by an increase in the progenitor population 
of HPC-1 (Fig. 4-13D).  
 
Thus, both a systemic decrease of Phd2, and a decrease of Phd2 levels specifically within 
transplanted HSCs, both result in an altered HSPC compartment, with a significant decrease 




















Figure 4-13 - HSCs with reduced levels of Phd2 repopulate adult BM with an altered HSPC 
compartment (A) 200 CD45.2+ LSK CD48-CD150+ HSCs from control shPhd2/rtTA mice were 
transplanted into lethally irradiated (11Gy) syngeneic CD45.1+/CD45.2+ recipient mice. Following stable 
CD45.2+ engraftment at 6 weeks post-transplant, recipient mice were treated with 2 mg/ml Dox in their 
drinking water, driving production of a short-hairpin targeting Phd2, transcription of GFP. (B) GFP 
expression in total BM, Lin-, LK (Lin- cKit+), LSK (Lin- cKit+ Sca-1+), HSCs (LSK CD48-CD150+), MPPs 
(LSK CD48-CD150-), HPC-1s (LSK CD48+CD150-) and HPC-2s (LSK CD48+CD150+). (C) LK and LSK 
cells as a frequency of the Lin- compartment. (D) Percentage of haematopoietic stem and progenitor cells 
within the LSK compartment. n=5 recipients per biological replicates (n=3-4). Data are mean ± SEM. *, 
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Work in this chapter provides further insight into the role of Phd2 in haematopoiesis. In 
particular, the shPhd2/rtTA transgenic mouse model used here allowed for timed and systemic 
depletion of Phd2 when investigating steady state haematopoiesis, as well as reduction of 
Phd2 levels within HSCs transplanted into recipient mice. Thus, the role of Phd2 could be 
accurately investigated in non-cell-autonomous haematopoiesis, as paralleled in experiments 
conducted by Takeda and colleagues in 2008, and in addition, could also be used to dissect 
the role of Phd2 in the biology of HSCs. 
 
The shPhd2/rtTA transgenic mouse line used in this chapter is comparable to the R26-rtTA 
promoter driven tamoxifen-inducible Phd2CKO model used by Takeda et al in 2008. However, 
results shown in this chapter differ between the models. Notably, in the shPhd2/rtTA model, 
the reverse tetracycline trans-activator (rtTA) is placed under control of the CAG promoter, 
which is known to give stronger and increased ubiquitous expression than the R26-rtTA 
promoter (Dow et al., 2012). Importantly, the Dox-inducible model generates a short-hairpin 
targeting Phd2, thus, unlike the Phd2CKO mouse model, it does not eliminate the protein, but 
reduces Phd2 expression. This model, however, is somewhat beneficial, as opposed to a 
knockout model, reduction of Phd2 levels is considered to be more faithful to physiological 
levels, pathological levels and pharmaceutical intervention.  
 
Experiments designed to validate the shPhd2/rtTA model found that, following Dox treatment 
for 5 weeks, shPhd2/rtTA mice had reduced levels of Phd2 mRNA when compared to the Dox-
treated control mice. In concordance with these findings, upon validating this novel mouse 
model, our collaborators at the University of Oxford found that the shRNA sequence used was 
effective at knocking down Phd2 mRNA levels in all tissues. In addition, it was discovered that 
knockdown of Phd2 was sufficient to upregulate Phd3 and Bnip3, two HIF target genes. At a 
protein level, western blot analysis of Dox-treated liver tissue found that PHD2 levels were 
decreased and HIF-1α and HIF-2α were stabilised. This suggests that phenotypes observed 
are, at least in part, a result of HIF-α stabilisation. Notably, in vivo validation experiments at 
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the University of Oxford were also conducted with a second shPhd2 construct, and agreed 
with those described (Yamamoto et al, in submission).  
Investigations into the effect of the systemic depletion of Phd2 on steady state haematopoiesis 
found a skewed lineage bias in the differentiation compartment in the PB, with a significant 
decrease in the B cell population, and an increase in the granulocyte population. Notably, this 
result was also shown in the HSC transplantation assay, with HSCs deficient in Phd2 giving 
rise to an increased frequency of B cells, and a decreased frequency of granulocytes (Fig. 4-
11). 
 
Moreover, in the PB samples analysed during the steady state experiments, there were 
significant decreases found in various haematological parameters including WBC count, RBC 
count, haemoglobin and haematocrit values in the mice with knockdown of Phd2 versus the 
control (Fig. 4-2). Previous published research using a systemic knockdown of Phd2, however, 
found a significant increase in WBC, RBC, haemoglobin and haematocrit values using the 
Rosa-CreER Phd2CKO mouse model (Takeda et al., 2008). These stark differences in 
phenotype may be accounted for by the aforementioned differences in the Rosa-CreER 
Phd2CKO versus shPhd2/rtTA transgenic models. Additionally, mice in the in vivo studies 
presented in Figure 4-2 had reduced levels of Phd2 for 8 weeks, versus 6 weeks in the Takeda 
2008 paper. Thus, it is possible that between 6 and 8 weeks, prolonged deficiency of Phd2 
has a detrimental effect on the PB compartment.  
 
In agreement with results published utilising the Rosa-CreER Phd2CKO mice (Takeda et al., 
2008), results presented in this chapter found that reduction of Phd2 levels results in an 
increase in the LSK compartment (Fig. 4-5C). Experiments in this chapter elaborated on this 
phenotype, analysing the LSK compartment using CD48 and CD150 cell-surface markers, and 
unveiled a reduction in the frequency of the HSC and MPP populations, accompanied by an 
increase in the frequency of HPC-1 progenitors (Fig. 4-5D). Importantly, analyses of the BM 
of recipient mice transplanted with HSCs isolated from shPhd2/rtTA mice also found a 
decrease in the most primitive cells of the LSK compartment (HSC and MPP), and an increase 
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in the HPC-1 population (Fig. 4-13D). This suggests that both systemic and HSC cell-
autonomous levels of Phd2 are essential for the maintenance of HSCs.  
  
To investigate the role of Phd2 in the fitness of HSCs, a transplantation experiment was 
performed with FACS isolated HSCs from shPhd2/rtTA and control mice. Once CD45.2+ 
engraftment was established in recipient mice, Dox treatment began, reducing Phd2 levels 
specifically within the transplanted HSCs and their progeny. Under the stress of a 
transplantation assay, it was clear that the HSCs with a knockdown of Phd2, were significantly 
less fit than their control counterparts, exhibiting a reduction in CD45.2+ engraftment and WBC 
numbers (Fig. 4-10). Notably, unpublished experiments conducted by Dr Guitart in the Kranc 
laboratory, found that HSCs isolated from Phd2fl/fl;Vav-iCre+ (Phd2CKO) mice, also presented 
with a reduced CD45.2+ engraftment when transplanted into lethally irradiated mice. Moreover, 
in further agreement with results presented in this chapter, transplantation experiments 
published by Singh and colleagues in 2013 found that recipient mice injected with 
Phd2fl/fl;CD68-Cre+ (Phd2CKO) LSK cells, had a significant reduction in CD45.2+ chimerism. 
Together, these results suggest that cell-autonomous depletion of Phd2 fundamentally 
reduces the fitness of HSCs.  
 
Interestingly, systemic depletion of Phd2 has a substantial effect on extramedullary 
haematopoiesis, with significant increases in the spleen weight, WBC count and RBC count in 
Dox-treated shPhd2/rtTA mice versus the control (Fig. 4-6). Additionally, analysis of the HSPC 
compartment by flow cytometry found that, overall, splenic tissue isolated from shPhd2/rtTA 
mice exhibited significant increases in the LK compartment versus the control mice (Fig. 4-9). 
This increase, however, was strongly related to an increase in spleen weight, suggesting that 
an increase in Phd2 deficient extramedullary haematopoiesis directly results in expansion of 
haematopoietic progenitor cells in the spleen. Notably, experiments by Takeda et al in 2008 
found that there was an increase colony formation in splenic tissue derived from Phd2CKO mice 
versus the control. Importantly, this result suggests that these expanded HSPC cells are also 
functional as they are able to form colonies in CFC assay. Notably, these results somewhat 
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parallel the haematological disorder polycythaemia vera, a condition which is also evident in 
patients with a somatic point mutation in the PHD2 gene (Barradas et al., 2018; Percy et al., 
2006; Spivak et al.). As a result, this phenotype merits further investigation such as more 
detailed analysis of this tissues and transplantation of these splenic cells. Overall, these data 
confirm that systemic depletion of Phd2 results in extramedullary haematopoiesis in the 
spleen, leading to an increase in the HSPC compartment. 
 
In addition, qPCR analysis of Phd2, as well HIF-target genes such as Aldoa, Pdk1, Bnip3, 
and Egln3 in spleen, BM and blood tissues would demonstrate if the phenotypes observed 
were related to the level of Phd2 knockdown, and its relation to HIF activity. Further molecular 
analysis of FACS isolated haematopoietic compartments such as LK, LSK and HSCs could 
indicate the mechanism through which HSCs lacking Phd2 have a reduction in fitness, as well 
as the expansion of extramedullary haematopoiesis in the spleen.  
 
In conclusion, this chapter has successfully dissected the role of Phd2 in haematopoiesis 
utilising a novel CAG-promoter driven shPhd/rtTA mouse model. Importantly, given that 
systemic depletion of Phd2, and transplantation-induced stress in HSCs lacking Phd2, both 
lead to decrease in the frequency and functionality of the HSC compartment, further 
investigations into the role of Phd2 in the biology HSCs is merited. Such research is of 
therapeutic and clinical importance, especially in regards to the production and utilisation of 


































The role of Prolyl Hydroxylase Domain 







Chapter 5  The role of Prolyl Hydroxylase Domain enzymes in 
Acute Myeloid Leukaemia 
5.1 Introduction 
Acute Myeloid Leukaemia (AML) is a complex, heterogeneous disease characterised by 
uncontrolled overproduction of immature leukocytes (Papaemmanuil et al., 2016). In the UK, 
AML is the second most common form of leukaemia in adults and children, with an increase 
in disease incidence of 30 % since the 1990s, versus an increase in incidence of just 15 % in 
all other leukaemias (CRUK; www.cancerresearchuk.org). Long-term outcomes have not 
improved significantly for over 3 decades, with a median survival rate of 1 year (Döhner et al., 
2015). Current conventional chemotherapy achieves disease remission in > 70 % of patients, 
but the majority will relapse within 5 years (Appelbaum et al., 2006). This clinical challenge 
derives from the stem-cell source of AML, first identified by John Dick et al in 1994. Studies 
into the biology of LSCs have unveiled their stem cell characteristics such as self-renewal, 
quiescence and low rate of apoptosis. In addition, these cells have an increased drug efflux, 
which gives them strong resistance to chemotherapies aimed at eradicating bulk AML disease 
(Wulf et al., 2001). As such, there is a significant research effort to further dissect the biology 
of LSCs, aiming to expose vulnerabilities, with the ultimate aim of targeting LSCs in 













5.1.1 Hypoxia pathway in AML 
Multiple studies, including that of Spencer et al in 2014 and Passaro et al in 2017, have shown 
that normal and malignant haematopoiesis occurs under hypoxic conditions within the bone 
marrow niche. Moreover, this hypoxic niche is thought to promote LSC self-renewal, as well 
as quiescence, which is believed to be one mechanism through which LSCs evade 
chemotherapy (Ishikawa et al., 2007). Given these findings, the Kranc laboratory focused on 
the role of oxygen sensing pathways in leukaemic transformation and development.  
 
Cellular responses to hypoxia are predominantly orchestrated by the hypoxia-inducible factors 
Hif-1 and Hif-2, which regulate gene expression, facilitating the hypoxia response. Several 
studies have investigated the roles of Hif-1α and Hif-2α in human and murine models of AML, 
unveiling both oncogenic and tumour-suppressor roles. HIF-2α knockdown in AML patient 
samples led to a reduction in CD34+ engraftment, and a reduction of AML disease upon 
transplantation into recipient mice (Rouault-Pierre et al., 2013). Additionally, Wang et al in 
2011 found that reduction of HIF levels, through the inhibitor echinomycin, reduced the self-
renewal capacity of AML cells. However, a recent study using a Mx1-Cre driven Hif-1α 
conditional knockout mouse model showed that there was no effect on the development or 
maintenance of AML in the absence of Hif-1α (Velasco-Hernandez et al., 2014). Moreover, 
new research in the field has demonstrated that MLL-AF9 driven AML with deletion of Hif-1α 
accelerates the progression of chemotherapy treated disease in vivo (in press; personal 
communications with Profs K. Kranc and J. Cammenga). These findings corroborate 
experiments published by the Kranc laboratory, which found that while deletion of Hif-1α and 
Hif-2α had no impact on normal stem cell self-renewal (Guitart et al., 2013; Vukovic et al., 
2016), it dramatically enhanced LSC formation and AML leukaemogenesis in a Meis1/Hoxa9 







5.1.2 The role of PHDs in AML 
Given the evidence of the tumour suppressor function of Hif-1α and Hif-2α in AML, it can be 
hypothesised that stabilisation of Hif-1α and Hif-2α, through the inhibition of Phds may hold 
therapeutic potential in the targeting of LSCs. Notably, when compared to research focusing 
on Hif-1α and Hif-2α, there is little published on the role of Phds in AML.   
 
Micro-array gene expression profiling used in the MILE (Microarray Innovations in Leukaemia) 
study of AML patient samples show both up-regulation and down-regulation of Phd1 (ELGN2) 
when compared to control BM (Labaj et al., 2017). Interestingly, the same dataset shows a 
significant fold-change increase in Phd2 (ELGN1) expression in AML, and multiple forms of 
ALL (Haferlach et al., 2010). Conversely, a recent paper published in Molecular Cell found that 
PHD3 expression is significantly decreased in some cancers, including AML. Mechanistic 
studies discovered that over-expression of PHD3 in AML limits leukaemia cell proliferation 
through a reliance on fat catabolism (German et al., 2016). 
 
Notably, murine in vivo work by Leite et al in 2012 demonstrated that systemic inhibition of 
Phd2 during chemotherapy-based AML treatment has a therapeutic benefit in vivo, increasing 
survival and reducing drug toxicity. Thus, dissection of the roles of Phd1 and Phd2 in AML is 
essential and will reveal if PHDs are in fact tumour suppressors or oncogenes, and therefore, 












5.1.3 Meis1/Hoxa9 retroviral model 
The Meis1/Hoxa9 retroviral AML mouse model is well characterised and widely used in in vivo 
AML studies, with both genes being implicated in leukaemic transformation in murine and 
human AML. Early studies by Kroon et al in 1998 showed that retroviral infection of over-
expression vectors for Meis1 and Hoxa9 gave rise to AML < 3 months after transplantation, 
whereas overexpression of either Meis1 or Hoxa9 alone failed to give AML even 6 months 
post-transplantation. Notably, in murine AML, it was shown that Hoxa9 promotes immortal self-
renewal of haematopoietic progenitors, whereas Meis1 activates leukaemogenicity and 
transcription of multiple stem-cell genes including Flt3 (Morgado et al., 2007). Further studies 
confirmed this, and showed that only when there is co-expression of both Meis1 and Hoxa9 
specifically within the primitive or progenitor haematopoietic compartment will mice develop 
blood cancer with the characteristics of AML (Krivtsov et al., 2006; Lessard and Sauvageau, 



















5.2 Aims and objectives of Chapter 5 
Evidence from previous work in the Kranc laboratory demonstrated that deletion of Hif-1α and 
Hif-2α increased LSC formation and AML leukaemogenesis, thus reducing disease latency 
and survival in vivo (Vukovic et al., 2015). This led to the hypothesis that constitutive activation 
of the HIF system, through inhibition of Phd1, Phd2, or both Phd1 and Phd2 will reduce 
leukaemogenesis in vitro and inhibit leukaemia development and maintenance in vivo. The 
role of PHDs in leukaemogenesis was investigated using a Vav-iCre conditional knock-out 
model (as explored in Chapter 3), as well as a shPhd2 doxycycline inducible model (as 
explored in Chapter 4). This allowed the study both the impact of Phd gene deletion on the 
development and maintenance of AML, as well as the effect of the reduction of Phd2 levels on 




















5.3 Experimental design 
A Meis1/Hoxa9 retroviral model was used to investigate the role of the PHD enzymes in the 
development and maintenance of AML. In this model, primitive, or haematopoietic stem and 
progenitor cells (HSPCs) were isolated from CD45.2+ 14.5 dpc embryo FL cells, enriched for 
the cKit+ cell population, and infected with retroviruses overexpressing Meis1 and Hoxa9. The 
cells over-expressing Meis1 and Hoxa9 were then positively selected based on their antibiotic 
resistance to puromycin and neomycin, respectively. These cells then underwent serial re-
plating in semi-solid methylcellulose media, and after 3 re-plating assays, only the most 
primitive and oncogenic cells survived, generating pre-leukaemic stem cells (pre-LSCs). 
Following this, a primary transplant was performed, with 100 000 pre-LSCs mixed with 200 
000 WT CD45.1+ unfractionated BM cells, and injected into sub-lethally irradiated (11Gy) 
CD45.1+/CD45.2+ syngeneic recipient mice in order to follow leukaemic disease development 
in vivo. Once mice developed AML, they were sacrificed and secondary transplants were 


















5.3.1 Vav-iCre-mediated conditional knockout model 
In order to address the role of PHDs in the development of murine AML, the Meis1/Hoxa9 
model described above was used with FLs of control embryos (Vav-iCre-), and embryos with 
Vav-iCre conditional deletions of Phd1 (Phd1fl/fl;Vav-iCre+), Phd2 (Phd2fl/fl;Vav-iCre+), or both 
(Phd1fl/fl; Phd2fl/fl;Vav-iCre+) (Fig. 5-1). Notably, each experiment using conditional knockout 
embryos with deletion of Phd1, Phd2, or both Phd1 or Phd2 was conducted in parallel with 
their appropriate Vav-iCre- littermate controls, e.g. Control (Phd1fl/fl;Vav-iCre-) and Phd1CKO 
(Phd1fl/fl;Vav-iCre+); Control (Phd2fl/fl;Vav-iCre-) and Phd2CKO (Phd2fl/fl;Vav-iCre+); Control 
(Phd1fl/fl; Phd2fl/fl;Vav-iCre-) and Phd1/2CKO (Phd1fl/fl; Phd2fl/fl;Vav-iCre+). This ensured tight 
control of the Vav-iCre conditional knock-out system, with all embryos containing a floxed Phd 
allele. Importantly, control and conditional knock out cells were all genotyped at various stages 
to ensure correct results were recorded. Cells were genotyped; after CFC1, after CFC3 prior 





Figure 5-1 - Meis1/Hoxa9 retroviral model using Vav-iCre conditional knock out mice. Schematic 
representation of the Meis1/Hoxa9 retroviral model. Foetal liver (FL) cells from Control (Vav-iCre-), 
Phd1CKO (Phd1fl/fl;Vav-iCre+); Phd2CKO (Phd2fl/fl;Vav-iCre+); or both Phd1/2CKO (Phd1fl/fl; Phd2fl/fl;Vav-
iCre+) embryos were enriched for cKit+ and infected with Meis1 and Hoxa9 over-expressing retroviruses 
and serially re-plated, generating pre-leukaemic stem cells (pre-LSCS). pre-LSC cells were then 
transplanted into primary recipient mice, which developed murine AML. Once mice showed signs of 








5.3.2 Inducible shPhd2-mediated knockdown model 
To further dissect the role of PHD2 in leukaemia, the Meis1/Hoxa9 retroviral model was 
followed, using FL tissue taken from rtTA (Control) and shPhd2/rtTA embryos. As previously 
described in Chapter 4, upon Dox treatment, shPhd2/rtTA mice transcribe a short-hairpin 
targeting Phd2, as well as GFP. This model allows the further investigation the role of Phd2 
on AML development, but also, more importantly, the inducible nature of the system allows 
the study of Phd2 on established leukaemic disease, reducing Phd2 levels at multiple stages 
of leukaemia development. GFP expression was measured via flow cytometry at all stages as 
a read-out of shPhd2 expression, and to ensure correct identification of samples. As shown 
below in Figure 5-2A, this model was initially tested in vitro to investigate the effect of acute 
reduction of Phd2 levels in pre-LSCs. Following this, the shPhd2 doxycycline-inducible model 











Figure 5-2 - Meis1/Hoxa9 retroviral model using inducible shPhd2 mice. Schematic representation 
of the Meis1/Hoxa9 retroviral model. Foetal liver (FL) cells from rtTA (Control) or shPhd2/rtTA embryos 
were enriched for cKit+ and infected with Mesi1 and Hoxa9 over-expressing retroviruses and serially re-
plated, generating pre-leukaemic stem cells (pre-LSCS). (A) These cells were then used for doxycycline 
titration experiments in vitro and in in vitro assays. (B) pre-LSC cells, not exposed to doxycycline were 
transplanted into primary recipient mice, which developed murine AML. Once mice showed signs of 









5.4 Loss of Phd1, Phd2, or both results in a reduction in cell number 
and colony formation  
In order to determine the role of PHD1 and PHD2 in leukaemic transformation, I employed the 
Meis1/Hoxa9 retroviral model using Vav-iCre+ conditional knock-out cells. As described in 
Figure 5-1, haematopoietic stem and progenitor cells isolated from the foetal liver of 14.5 dpc 
Control (Vav-iCre-), Phd1CKO (Phd1fl/fl;Vav-iCre+), Phd2CKO (Phd2fl/fl;Vav-iCre+), or both 
Phd1/2CKO (Phd1fl/fl; Phd2fl/fl;Vav-iCre+) embryos were enriched for cKit+ and infected with 
Meis1 and Hoxa9 over-expressing retroviruses and plated into methyl-cellulose to perform a  
Colony Forming Cell (CFC) assay, with antibiotic selection for both Meis1 and Hoxa9 
(puromycin and neomycin respectively). The Meis1/Hoxa9 transformed cells were then serially 
re-plated from CFC1 into CFC2, and CFC2 into CFC3. Importantly, the cells remain in 
antibiotic selection throughout the CFC assay to ensure all live cells remain fully transformed 
with retrovirus. After every CFC, live cells were counted using the Trypan Blue exclusion 
method, and 2500 live cells were plated at each stage into semi-solid methylcellulose. This 
was important, as shown in Figure 5-3, there are significant differences in live cell number 
after each CFC. After each stage, i.e. CFC1, CFC2 and CFC3 colonies were counted. After 
CFC3, these cells are referred to as pre-LSCs. Importantly, for all repeat experiments, each 
PHD isoform, as well as its Vav-iCre- control, was infected with the same batch of Meis1 and 
Hoxa9 viruses. This ultimately results variability in cell number and colony number between 
PHD isoform experiments, but ensures paired comparisons between the specific PhdCKO and 
its appropriate control.  
 
As mentioned above, following CFC assay, there was a significant decrease in live cell number 
in the Phd1CKO, Phd2CKO and Phd1/2CKO cells versus their appropriate controls (Fig. 5-3). This 
suggests that the lack of either Phd1, Phd2, or both, reduces the leukaemic potential of cells 
over-expressing Meis1 and Hoxa9. Notably, there does not seem to be a synergistic effect 
between Phd1 and Phd2, as loss of both Phd1 and Phd2 together (Phd1/2CKO) produces a 
less significant cell number reduction than that of either Phd1 or Phd2 alone. This suggests 












Figure 5-3 - Cells lacking Phd1, Phd2, or both show reduced cell number Live cell counts via Trypan-
Blue exclusion after Colony Forming Cell (CFC) assay, per 2500 cells plated. Phd1CKO (A), Phd2CKO (B), 
and Phd1/2CKO (C), versus their Vav-iCre- littermate controls. n=2-8 biological replicates per genotype, in 
1-4 independent experiments. Data are mean ± SEM. *, P < 0.05; **, P < 0.01 (Mann-Whitney U test).  
 
 
Additionally, perhaps as expected, re-plating of these cells results in a reduction in colony 
formation in Phd1CKO, Phd2CKO and both Phd1/2CKO when compared to their Vav-iCre- 
littermate controls. These results suggest that loss of either Phd1 or Phd2 reduces leukaemic 
transformation in a Meis1/Hoxa9 murine model of AML, especially with regards to their stem-
cell regenerative capacity. Notably, the reduction in colony formation is more pronounced in 
Phd2CKO, when compared to either the single Phd1CKO or both Phd1/2CKO. This suggests that 
Phd2 may be the principal Phd isoform in leukaemic transformation. Additionally, as previously 
shown in Figure 5-3, there is no evidence of a synergistic effect between Phd1 and Phd2, with 
no further reduction in the Phd1/2CKO versus that of Phd1CKO or Phd2CKO alone. However, 
Phd1/2CKO experiments are n=2, whereas Phd1CKO is n=8, and Phd2CKO n=6 per biological 
genotype, thus further experiments with the Phd1/2CKO genetic model could be used to confirm 
this result. 
 
Overall, these results suggest that PHDs have a significant role in leukaemic transformation 
in vitro, with reductions in both live cell number and colony formation from CFC assay. 
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Figure 5-4 - Cells deficient in Phd1, Phd2, or both show reduced colony formation Colony forming 
cell (CFC) counts (colony number) at each re-plating per 2 500 live cells plated. Phd1CKO (A), Phd2CKO 
(B), and Phd1/2CKO (C), versus their Vav-iCre- littermate controls. n=2-8 biological replicates per 
genotype, in 1-4 independent experiments. Data are mean ± SEM. **, P < 0.01; ****, P < 0.0001 (Mann-
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5.5  Phd-deficient cells exhibit a reduction in cell growth 
In order to determine whether the Meis1/Hoxa9 pre-LSCs deficient for Phd displayed a growth 
disadvantage in vitro, I conducted a proliferation assay with PhdCKO cells, and their control 
counterparts. Following CFC3, the pre-LSCs were harvested from methylcellulose and placed 
in liquid culture to measure the proliferation capacity of the fully transformed cells. All cells 
were plated at the same concentration and live cells counted using Trypan Blue exclusion 
method at 24, 48 and 72 hours. As shown below in Figure 5-5, cells lacking Phd1, Phd2, or 
both Phd1 and Phd2, have reduced proliferation rates in comparison to their Vav-iCre- controls. 
This suggests that although viable, these cells have a reduced mitotic capacity, a valuable 
asset in an anti-leukaemic target. Moreover, Phd2CKO cells show the most significant decrease 
in proliferation when compared to the control, further confirming its significance in the anti-
oncogenic activity of PHD inhibition. Additionally, there is no evidence of a collaborative role 
between Phd1 and Phd2, with Phd1/2CKO cells showing a less significant reduction than that 
of the Phd1 CKO or Phd2 CKO alone.  Therefore, it can be concluded that Phd1 and Phd2 act in 















Figure 5-5 - Phd1 and Phd2 are essential in the proliferation activity of pre-LSCs 50 000 live pre-
LSCs were plated and counted at 24 hrs, 48 hrs and 72 hrs (Trypan-Blue exclusion). Phd1CKO (A), 
Phd2CKO (B), and Phd1/2CKO (C), versus their Vav-iCre- controls. Data are mean ± SEM. n=2-3 biological 
replicates per genotype, cells plated in triplicate. *, P < 0.05; **, P < 0.01 (Mann-Whitney U test). 
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5.6 Expression of Phd1 and Phd2 increases leukaemic burden in 
vivo 
To investigate whether the deletion of Phd1, Phd2, or both, impacts leukaemia development 
in vivo, I performed transplantation assays with the Meis1/Hoxa9 transformed pre-LSCs. 100 
000 CD45.2+ pre-LSCs from CFC3 were isolated and mixed with 200 000 WT CD45.1+ 
unfractionated BM cells, and transplanted into sub-lethally irradiated (11Gy) CD45.1+/CD45.2+ 
syngeneic recipient mice in order to follow leukaemic disease development in vivo. This 
experimental design allows tracking of leukaemic disease as it develops in vivo through the 
flow cytometric analysis on CD45.2+ expression in the peripheral blood (PB) of recipient mice. 
Given correct transformation and transplantation of Meis1/Hoxa9-transduced cells, the 
CD45.2+ expression will increase over time. We chose to take PB samples from recipient mice 
at 4 weeks, 8 weeks and 12 weeks. This is due to the fact that murine haematopoietic cells 
often take 2-3 weeks to fully engraft (Zijlmans et al., 1998), and as shown by Kroon et al, the 
Meis1/Hoxa9 retroviral model should give rise to AML < 3 months after transplantation. Once 
recipient mice showed signs of leukaemic disease such as weight loss, shortness of breath, a 
hunched position, impaired motion or pale paws, they were sacrificed and the date of death 
recorded. Death from an AML-like disease was confirmed by high CD45.2+ Mac-1+Gr1+ 
expression through flow-cytometry analysis in the BM of deceased mice. All transplanted mice 
developed an AML-like disease and were sacrificed by 105 days post-transplant, with an 
average survival of 84 days.   
 
Peripheral blood samples taken at 4 weeks and 8 weeks post-transplant show a significant 
decrease in CD45.2+ cell engraftment in the mice transplanted with Phd1CKO, Phd2CKO and 
Phd1/2CKO cells compared to their controls (Fig. 5-6). Again, there seems to be no co-operation 
between of Phd1 and Phd2, with recipient mice transplanted with Phd1/2CKO cells showing 
much lower engraftment than that of either Phd1CKO or Phd2CKO cells.  Notably, the in vivo 
transplantation of Phd1/2CKO and control cells was conducted in one independent experiment 
using n=2 biological replicate donors, each donor being transplanted into 6 recipient mice. In 
comparison, both the Phd1CKO and Phd2CKO experiments feature 2 independent experiments, 
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of n=3-4 biological replicates into 5 recipient mice. Repetition of the Phd1/2CKO will shed further 





Figure 5-6 - Transplantation of cells lacking Phd1, Phd2, or both show reduced engraftment 
Percentage of leukaemic cells (% CD45.2+ engraftment) following primary transplantation of 100 000 
pre-leukaemic stem cells. Peripheral blood samples taken at 4 weeks and 8 weeks post-transplant and 
CD45.2+ engraftment measured by flow cytometry analysis. Phd1CKO (A), Phd2CKO (B), and Phd1/2CKO 
(C), versus their Vav-iCre- controls. n=5-6 recipients per biological replicates (n=2-4), 1-2 independent 
























































































5.7 Loss of Phd1, Phd2, or both decreases LSC development in vivo 
In addition to leukaemic cell engraftment analysis, in vivo transplantation experiments were 
also used to investigate the role of PHDs in development of leukaemic disease in vivo. 
Following transplantation of pre-LSCs, once recipient mice showed signs of ill-health, they 
were sacrificed and analysed to confirm their AML disease, and date of death was recorded. 
As is shown in Figure 5-7, loss of Phd1, Phd2, or both extended survival in a Meis1/Hoxa9 
model of leukaemia. Recipient mice transplanted with Phd1 CKO cells had a mean survival rate 
of 82 days versus mice transplanted with Phd1 control cells with a survival rate of 58.5 days. 
Meanwhile, mice transplanted with Phd2 CKO cells had a mean survival rate of 80.5 days versus 
mice transplanted with Phd2 control cells with a survival rate of 59 days. Finally, mice 
transplanted with cells lacking both Phd1 and Phd2 had a mean survival of 84.5 days versus 
63.5 days in their control counterparts. Overall, the increase in mean survival is very similar 
with 23.5 days, 21.5 days and 21 days for  Phd1 CKO, Phd2 CKO and Phd1/2CKO respectively.  
 
Although there were differences in vitro, notably with Phd2 presenting the most significant 
phenotype in leukaemic transformation, when translated in vivo, this effect is lost, with all 





























Figure 5-7 - Deletion of Phd1, Phd2, or both increases survival in vivo Kaplan-Meier survival curve 
of recipients transplanted with 100 000 pre-leukaemic stem cells. Phd1CKO (A), Phd2CKO (B), and 
Phd1/2CKO (C), versus their Vav-iCre- controls. n=5-6 recipients per biological replicates (n=2-4), 1-2 
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5.8 LSCs lacking Phd1 have reduced stem-cell potential 
In vitro and in vivo experiments conducted using pre-LSCs found that deletion of Phd1, Phd2, 
or both has a significant anti-leukaemic effect. Following this, I sought to investigate the role 
of Phds in the propagation of Meis1-Hoxa9 driven AML using LSCs isolated from the recipient 
mice used in the primary transplantation experiments described in Section 5-6 and 5-7. 
Following the development of leukaemic disease, recipient mice were sacrificed and BM 
samples were analysed to confirm AML. Notably, these leukaemic cells derived from adult BM, 
having generated AML in the murine recipients are now said to be leukaemic stem cells 
(LSCs). These cells give an interesting insight into the biological processes behind the 
development of pre-LSCs into LSCs in vivo, and further functional assays can unveil the role 
of the Phds in leukaemia maintenance. 
 
Total BM cells from recipient mice transplanted with control (Vav-iCre-) and Phd1CKO cells were 
first placed in CFC assay to isolate the transformed colony forming cells for further studies. In 
addition, the CFC assay can also be used experimentally to compare the potency of Phd1 CKO 
LSCs versus the control LSCs. As shown in Figure 5-8A, LSCs with a deficiency of Phd1 
exhibit a significant decrease in colony formation versus control LSCs. This suggests that 
although all recipient mice eventually succumbed to AML, with BM CD45.2+ engraftment of 
between 98.9 % and 100 % for both Phd1 CKO and control experiments (Fig 5-8C), there is an 
apparent decrease in stem-cell and self-renewal potential in LSCs lacking Phd1. 
 
After harvesting LSCs from the CFC assay, a proliferation experiment was conducted to study 
the growth of these cells lacking Phd1. Mirroring the result of the pre-LSC proliferation curve 
(Fig 5-5A), cells with a deficiency of Phd1, although viable, showed a pronounced growth 
stagnation when compared to control LSCs (Fig 5-5B).  Additionally, harvested LSC cells were 
immunophenotypically analysed by flow cytometry and Phd1 CKO LSCs showed a significant 
decrease in cKit expression, a marker of primitive haematopoiesis, as well as a dramatic 
increase in Mac1+ expression, which marks differentiated monocytes (Fig 5-5C). This, in 
combination with results from Figure 5-8A and Figure 5-B gives strong evidence that the 
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phenotype shown in primary transplant in vivo is due to a loss of Meis1/Hoxa9 derived stem-
cell activity. Notably, there is a marked decrease in the Gr1+ and Mac1+Gr1+ compartments, 
which are also markers of differentiated myeloid cells, this may be a Gr1+ specific phenotype. 


















Figure 5-8 - LSCs deficient in Phd1 have reduced stem-cell activity (A) 2 500 BM LSCs were plated 
in CFC assay and counted after 6 days (B) 50 000 LSCs were plated in triplicate and counted by Trypan-
Blue exclusion 24 hrs, 48 hrs and 72 hrs later (C) Flow cytometry analysis of Control and Phd1 CKO LSCs. 










































































5.9 Phd1 promotes AML maintenance 
To investigate the ability of Phd1-deficient LSCs to propagate AML, a secondary 
transplantation experiment was performed. 50 000 LSCs were transplanted into sub-lethally 
irradiated (11Gy) CD45.1+/CD45.2+ syngeneic secondary recipient mice to functionally test the 
role of Phd1 in AML maintenance. As before, mice were serially bled at 4, 8- and 12-weeks 
post-transplantation to track development of the disease. These experiments showed that 
there is a decrease in leukaemic cell engraftment in the mice transplanted with LSCs lacking 
Phd1 versus the control (Fig. 5-9A). As such, all control mice succumbed to AML and were 
sacrificed by week 12, whereas a large number of Phd1 CKO recipient mice remained. Notably, 
although statistically significant, the engraftment data is noticeably more variable than that of 
the primary transplant experiment (Fig. 5-7A). This is due to the in vivo source of the LSCs 
which are inherently more biologically divergent than in vitro cultured pre-LSCs. As such, a 
significant decrease in engraftment in secondary transplant gives real strength to the 
hypothesis that a deficit in Phd1 impairs AML in vivo. 
 
All recipient mice in the secondary transplant succumbed to AML disease, with LSC infiltration 
present in the BM and spleen of all animals. The latency of the disease was drastically 
increased in mice transplanted with Phd1 CKO LSCs with an average survival of 85 days, versus 
52.5 days in control mice. Additionally, the longest surviving mouse transplanted with Phd1 
CKO LSCs mice remained alive for 136 days, versus just 61 days in the control group (Fig. 5-
9B). At 61 days, 76.9 % of the mice transplanted with Phd1 CKO LSCs were still alive. Thus, it 
is evident, that in addition to the importance of Phd1 in the transformation and development of 
AML, it also serves a vital role in the long-term self-renewal capacity of LSCs. This is especially 
important when exploring therapeutic targets for AML as patients will often present with 
advanced disease fuelled by LSCs that must be eradicated.  
 
Notably, although these experiments have proved successful with Phd1 CKO LSCs, they must 
be repeated with Phd2 and Phd1/2 in order to fully dissect the role of Phds in AML 
maintenance. As demonstrated with Phd1CKO LSCs, it is possible that the reduction in 
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proliferation and colony growth shown in the Phd2 CKO pre-LSCs (Figs 5-5B, 5-6B) will 
translate to an even more significant defect in Phd2 CKO LSCs. Further in vivo and mechanistic 
studies on Phd1 CKO, Phd2CKO and Phd1/2 CKO LSCs will unveil the role of each Phd isoform in 













Figure 5-9 - LSCs deficient in Phd1 have reduced engraftment and increased survival following 
transplantation assay (A) Percentage of leukaemic cells (% CD45.2+ engraftment) following secondary 
transplantation of 50 000 BM LSCs. Peripheral blood samples taken at 4 weeks, 8 weeks and 12 weeks 
post-transplant, and CD45.2+ engraftment measured by flow cytometry analysis. At 12 weeks, all control 
mice were sacrificed having developed AML. n=5 recipients per biological replicates (n=3-4), 1 
independent experiment. Data are mean ± SEM. ****, P < 0.0001 (Mann-Whitney U test). (B) Kaplan-
Meier survival curve of recipients transplanted with Phd1CKO LSCs versus the Vav-iCre- control. n=5 
recipients per biological replicates (n=3-4), 1 independent experiment. Data are mean ± SEM. ****, P < 

















































5.10 Inducible Phd2 knockdown in Meis1/Hoxa9-transformed cells 
results in increased cell death in vitro 
 
After discovering that deletion of Phd1, Phd2, or both results in decreased leukaemogenesis 
both in vitro and in vivo, the shPhd2 doxycycline inducible model was employed (as described 
in Chapter 4) to knockdown Phd2 at different stages of leukaemic disease progression. As 
described in Section 5.3.2, the Meis1/Hoxa9 retroviral model was further utilised, using FL 
cells taken from rtTA (Control) and shPhd2/rtTA embryos. Upon treatment with Dox, 
shPhd2/rtTA cells will transcribe a short-hairpin targeting Phd2, as well as GFP, whereas when 
treated with Dox, rtTA (Control) cells will not transcribe a short-hairpin targeting Phd2, or GFP. 
Experiments began by testing this model in vitro to investigate the effect of acute reduction of 
Phd2 levels in pre-LSCs. Following this, the model was used in vivo to address the role of 
Phd2 in AML disease evolution. This mouse model offers great insight into the therapeutic 
potential of inhibition of Phd2, as Phd2 levels can be decreased, even once leukaemic 
engraftment has been established in vivo.  
 
Following infection with Meis1 and Hoxa9 over-expressing retroviruses, and antibiotic 
selection, control and shPhd2/rtTA were plated in CFC assay to select for the most oncogenic 
and primitive pre-LSC clones. As shown in Figure 5-11A, when plated in CFC assay in the 
absence of Dox, there is no difference in colony formation between the control and 
shPhd2/rtTA mice. As such, there is no evidence of activation of the shPhd2/rtTA construct in 
the Meis1/Hoxa9 transformed shPhd2/rtTA cells. 
 
Notably, there is some evidence that Dox itself can have a cytotoxic effect in human leukaemia 
cell lines including HL-60 (AML), KG1a (acute myelogenous leukaemia) and K562 (chronic 
myelogenous leukaemia), promoting apoptosis through caspase activation and cleavage of 
PARP and Bcl-2 (Mouratidis et al., 2007; Onoda et al., 2006). This effect, however, is slight, 
and uses significantly higher concentrations 0.5–100 µg/ml for 24 hr (Song et al., 2014). 
Regardless, to ensure the effect is from acute deletion of Phd2 and not Dox, both control and 
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shPhd2/rtTA cells are consistently treated with the same concentration of antibiotic. Thus, all 
phenotypes observed in experiments with Dox-treated shPhd2/rtTA cells versus Dox-treated 
control cells, are a direct consequence of Phd2 knockdown. 
 
After harvesting cells from CFC3, a Dox titration experiment was performed to determine the  
correct concentration of antibiotic to use in vitro to activate transcription of the short-hairpin 
targeting Phd2. All in vitro experiments used 2 biological replicates plated in triplicate, with 
both control and shPhd2/rtTA cells treated with Dox for 48 hrs before flow cytometry 
analysis. This ensured there was no Dox-specific effect on the Meis1/Hoxa9 transformed 
cells. Additionally, GFP expression was measured as a direct read-out of shPhd2 
expression, and ensured the correct identification of control and shPhd2/rtTA cells. To 
investigate the role of Phd2 in Meis1/Hoxa9 driven AML, the rate of apoptosis was measured 
in shPhd2/rtTA and control cells after treatment with Dox for 48 hrs. For this TO-PROTM-3 
Iodide (referred to as ToPro) was used. Notably To-Pro is a carbocyanine monomeric nucleic 
acid stain, which is regularly used as a dead cell indicator. Thus, it was chosen to measure 
the rate of cell death in vitro. 
 
Primary Dox titration experiments using concentrations of 1.56 ng/ml to 100 ng/ml of Dox show 
a steady increase in GFP expression, with 100 ng/ml showing a maximum GFP expression of 
84.2 %. Importantly, as expected, there is no GFP in the control group, or when shPhd2/rtTA 
cells were in the absence of Dox (Fig 5-10A). There is no difference in the percentage of 
ToPro+ cells at lower concentrations of Dox, but a significant increase in apoptosis at 100 ng/ml 
(Fig 5-10 B). However, there is a noticeably high level of apoptosis in all experiments, including 
cells that were not exposed to Dox in both the control and shPhd2/rtTA. As such, a new batch 
of Mesi1/Hoxa9-transformed control and shPhd2/rtTA cells were thawed, and the Dox titration 
experiment was repeated, this time at higher concentrations of Dox.  
 
As before, control and shPhd2/rtTA cells were exposed to increasing concentrations of Dox, 
from 62.5 ng/ml to 1000 ng/ml. These concentrations were chosen to include 100 ng/ml, where 
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there was a marked increase in apoptosis in shPhd2/rtTA pre-LSCs. Importantly, there is a 
significantly lower level of background apoptosis in this experiment, with an average of 3.29 
% To-Pro+ cells in the control and non-treated samples 48 hr after plating (Fig 5-10D). This 
result allows for a more accurate measurement of apoptosis in the Dox treated shPhd2/rtTA 
pre-LSCs. In addition, in concordance with the previous experiment, there is no GFP 
expression in either the non-treated cells, or the control cells lacking the shPhd2 construct. 
The GFP expression reaches its maximum when shPhd2/rtTA cells are treated with 250 ng/ml 
Dox, suggesting a peak in shPhd2 activity (Fig 5-10C). Moreover, in addition to a peak in GFP 
expression, To-Pro+ expression is at its highest when shPhd2/rtTA pre-LSCs are treated with 
250 ng/ml Dox, with an average of 33.45 % To-Pro+ cells, versus 3.27 % To-Pro+ cells in the 
treated control. Increasing the Dox concentration above 250 ng/ml has no increased effect on 
apoptosis, with 500 ng/ml and 1000 ng/ml showing a decrease in both GFP and To-Pro 
expression. This suggests concentrations above 250 ng/ml may saturate the system, 
moderately decreasing shPhd2 transcription, and thus significantly decreasing its cytotoxic 
effect. 
 
Taken together, these experiments indicate that knockdown of Phd2 in vitro results in an 
increase in apoptosis in Meis1/Hoxa9 leukaemia. Based on these results, all further in vitro 

































Figure 5-10 - Dox treatment of shPhd2/rtTA pre-LSCs results in increased GFP expression and 
apoptosis Meis1Hoxa9 pre-LSCs from control (rtTA) and shPhd2/rtTA mice were harvested from CFC3 
and treated with increasing concentrations of Dox as described. 48 hr later, GFP (A, C) and To-Pro+ cells 
(B, D) were measured by flow cytometry. Data are mean ± SEM. n=2 biological replicates plated in 





















































































































5.11 Suppression of Phd2 reduces the potency of pre-LSCs  
After determining the appropriate Dox concentration to use in vitro, a CFC assay was 
performed on control and shPhd2/rtTA pre-LSCs in the presence and absence of Dox. As 
shown in Figure 5-11A, in the absence of Dox, there is no difference in colony number 
between control and shPhd2/rtTA pre-LSCs. Interestingly, however, when the CFC assay was 
repeated, and both groups were treated with 250 ng/ml Dox, the cells with a deficiency in Phd2 
showed a significant decrease in colony number (Fig 5-11B). This suggests acute knockdown 
of Phd2 in potent pre-LSCs can significantly reduce their leukaemic activity.  
 
In addition, when imaged with the Operetta high-content automated microscope, colonies  
derived from shPhd2/rtTA cells were GFP+ and were significantly smaller and more dispersed 
than the control. Notably, large, dense, compact colonies, as represented in the bottom panel 
of  Figure 5-11C, are known to contain more stem cells, resembling that of colonies generated 
by primitive haematopoietic cells. Smaller colonies like that shown in middle panel of Figure 
5-11C  have a compact centre, surrounded by differentiated cells. These are thought to derive 
from haematopoietic progenitors, with a lower stem-cell capacity. Finally, looser colonies, as 
represented in the top panel of Figure 5-11C, are comprised of long-term myeloid progenitor 
cells, and, as such, are considered to be more differentiated haematopoietic cells. These  
colonies are classified as Type 1, Type 2, and Type 3 respectively (Lavau et al., 1997). 
Moreover, these phenotypes have a clinical relevance as Somervaille et al in 2006 showed 
that murine models of aggressive human leukaemias induced by MLL-AF9 or MLL-ENL 
produced compact colonies, with a higher proportion of stem-cell derived, "blast-like" cells 





























Figure 5-11 - Acute reduction of Phd2 results in reduced colony number and size (A) Meis1Hoxa9 
pre-LSCs from control (rtTA) and shPhd2/rtTA mice were plated into CFC assay, and in parallel plated 
into a CFC assay with 250 ng/ml Dox (B), counted 6 days after plating. Imaging was performed using 
the Perkin Elmer Operetta high content imaging system 6 days after plating. (C) Representative images 
of Type 1 (bottom panel), Type 2 (middle panel) and Type 3 (top panel) colonies are shown, taken with 
a 585 - 605 nm and brightfield filter respectively. Data are mean ± SEM. n=2 biological replicates plated 





































5.12 Knockdown of Phd2 in established AML decreases 
engraftment and LSC development in vivo 
To investigate the effect of acute Phd2 knockdown in established AML disease, I transplanted 
control and shPhd2/rtTA pre-LSCs into primary recipient mice and induced shPhd2 expression 
following marked AML engraftment. 100 000 CD45.2+ Meis1/Hoxa9 pre-LSCs from CFC3, 
unexposed to Dox, were isolated and mixed with 200 000 WT CD45.1+ unfractionated BM 
cells and transplanted into sub-lethally irradiated (11Gy) CD45.1+/CD45.2+ syngeneic recipient 
mice. Mice were serially bled at 4 weeks (30 days) and 8 weeks (60 days) to measure 
leukaemic engraftment prior to Dox induction. After 60 days, recipient mice transplanted with 
control and shPhd2/rtTA pre-LSCs showed robust CD45.2 engraftment with an average of 
11.4 % and 16.5 % respectively. Given this result, at 60 days post-transplantation, recipient 
mice were treated with 2 mg/ml Dox in their drinking water to activate transcription of a short-
hairpin targeting Phd2.  
 
As shown in Figure 5-12A, after only 10 days on Dox, shPhd2/rtTA recipient mice have a 
significantly lower engraftment than that of recipient mice transplanted with control pre-LSCs. 
This result is especially powerful given that shPhd2/rtTA recipient mice had a notably higher 
CD45.2 engraftment at 60 days. Although the percentage of CD45.2 increases from day 60 to 
day 70, there is an evident slowing of leukaemia progression (Fig 5-12A). Moreover, this 
translates into an increase in disease latency, with an average survival of 127 days versus 72 
days in mice transplanted with control cells (Fig 5-12B). Notably, there is increased survival 
in the rt/TA control group versus comparative controls in the Vav-iCre transplantation 
experiments (Fig 5-7). This is due to differing batches of Meis1/Hoxa9 virus, and this 
experiment should be repeated with new virus to corroborate this result. Despite this, the 
experiment described in Figure 5-12 gives promising evidence that inhibition of Phd2, in an 
established form of aggressive AML, can prolong survival in vivo. Additionally, this result 
suggests that pharmacological inhibition of Phd2, and possibly other Phd isoforms may hold 





Figure 5-12 - Inhibition of Phd2 reduces engraftment and increases survival in vivo (A) Percentage 
of leukaemic cells (% CD45.2+ engraftment) following primary transplantation of 100 000 rtTA (Control) 
or shPhd2/rtTA pre-leukaemic stem cells into recipient mice. Peripheral blood samples taken at 30 days, 
60 days and 70 days post-transplant. Engraftment measured by flow cytometry analysis. **, P < 0.01 
(Mann-Whitney U test) (B) Kaplan-Meier survival curve of recipients. n=6 recipients per biological 











































This work offers new insights into the role of PHD enzymes in AML, identifying Phd1 and Phd2 
as oncogenes in a Meis1/Hoxa9 retroviral model of AML. From this chapter, it is evident that 
inhibition of Phd1 and Phd2 has a detrimental effect on potency of LSCs, effecting their growth 
and self-renewal potential. 
 
Genetic deletions of Phd1 and Phd2 in Meis1/Hoxa9 transformed pre-LSCs showed a 
significant reduction in growth in CFC assay. This result is corroborated in the Dox-inducible 
shPhd2 experiments, which also show a pronounced decrease in colony growth in pre-LSCs 
with an acute deletion in Phd2. Notably, in addition to a reduced colony number, shPhd2/rtTA 
pre-LSCs treated with Dox have a smaller and more dispersed morphology, consisting of 
myeloid progenitor and differentiated cells, so called "Type 3" colonies (Lavau et al., 1997). 
Somervialle et al in 2006 expanded upon the work conducted by Lavau and colleagues, and 
showed that a Type 3 morphological phenotype in vitro is synonymous with less potent AML 
MLL-subtypes, such as MLL-AF10 or MLL-AF1p. In contrast, colonies produced by MLL-AF9 
and MLL-ENL, produce large, 'blast-like' colonies, which contain a high frequency of aberrantly 
self-renewing LSCs. Translating these findings to the clinic, there was a direct link between 
poor prognosis and LSC frequency. As such, there is much academic and pharmacological 
research into promoting the differentiation of LSCs, overcoming the so-called "differentiation 
block" (Bose and Konopleva, 2018). This evidence reveals Phd2 as a promising therapeutic 
candidate, as it indeed decreases the self-renewal capacity of pre-LSCs, pushing them instead 
to a more differentiated state.  
 
Repeating imaging experiments with Phd1CKO, Phd2CKO and Phd1/2CKO cells, as well as 
selective PHD inhibitors would give further insight into this hypothesis. Use of machine 
learning processes, like that published by the Kranc laboratory in 2018, allow for high-
throughput screening and multi-parameter analysis of CFC assays, ideally suited to quantify 
colony morphology and differentiation (O'Duibhir et al., 2018). This study using retrovirally 
transformed Meis1/Hoxa9 cells, and the human AML cell line THP-1, identified that IOX2, a 
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PHD inhibitor, decreased colony formation and increased differentiation, albeit less 
significantly than other hits in the screen. A notable hit was GSK-LSD1, a LSD1 (also known 
as KDM1A) inhibitor was found in the screen to drastically increase differentiation, and is 
currently in phase I clinical trials in patients with relapsed AML (under the generic name 
GSK2879552, https://www.gsk-clinicalstudyregister.com/study/200200#ps). Notably, IOX2 is 
a PHD inhibitor, but also inhibits multiple other 2-OG oxygenases (Chowdhury et al., 2013), 
some of which are already known to increase LSC activity, and are likely to have reduced the 
anti-oncogenic effect of inhibition of PHDs (Sepulveda et al., in preparation). Using specific 
PHD inhibitors, or further short-hairpin studies, will help to determine the self-renewal effect of 
PHDs in AML. In addition to murine AML, established human AML cell lines, or patient samples 
should also be used to verify the therapeutic potential of PHDs. 
 
When Meis1/Hoxa9 transformed pre-LSCs were transplanted into syngeneic primary recipient 
mice, cells deficient in Phd1, Phd2, or both showed a decrease in leukaemic engraftment, 
resulting in an increase in disease latency. This result was confirmed by acute deletion of Phd2 
in established AML, leading to a reduction in disease progression, shown in both engraftment 
and survival data. Thus, as shown in the in vitro assays, ablation of PHDs reduces the 
oncogenic and self-renewal potential of pre-LSCs. Moreover, in vitro and in vivo assays on 
Phd1CKO and control LSCs showed a decline in LSC potential. To further investigate this, the 
Phd1CKO secondary transplant should be repeated, and similar experiments with Phd2CKO and 
Phd1/2CKO LSCs conducted. Moreover, to test the hypothesis that PHDs help promote LSC 
activity, a limiting dilution assay (or LDA), whereby recipient mice are transplanted with a bulk 
leukemic population (as in the secondary transplantation described in 5.9), but replicates are 
conducted with multiple dilutions of cell number, until a dose with no response is achieved (in 
this case murine survival) would support these findings (Hu and Smyth, 2009). This technique 
should be employed to accurately quantify the active LSC frequency in Phd-deficient and 
control leukaemic cells, and to confirm the hypothesis that deletion of Phds decreases LSC 




Furthermore, this work supports further exploration of the Meis1Hoxa9 retroviral model using 
the shPhd2/rtTA mice. From experiments shown in sections 5-10 to 5-12, there is strong 
evidence to show that acute depletion of Phd2 can have marked effect on pre-LSC and LSC 
biology. Primary transplantations, as described in Fig 5-12 should be repeated, and Dox 
removed following a decrease in shPhd2/rtTA engraftment. This will reveal if acute knockdown 
of Phd2 has a lasting effect on LSCs. Notably, to expose this phenomenon, it is possible that 
fewer LSCs will have to be transplanted in this experiment to extend disease latency. 
Additionally, secondary transplantations with this model should be conducted with two cohorts 
of shPhd2/rtTA recipient mice which in primary transplantation were either in the absence or 
presence of Dox. This will unveil the role of Phd2 at multiple levels of AML disease 
maintenance.  
 
Experiments focusing on chemotherapy in murine models of AML, have shown that deletion 
of Hif-1α in MLL-AF9 driven AML accelerates disease in mice when treated with cytarabine 
and doxorubicin (in press; personal communications with Profs K. Kranc and J. Cammenga). 
This emerging research, in addition to previous studies by the Kranc laboratory, demonstrate 
the negative impact of HIF deletion in AML, especially in regards to chemotherapy treatment. 
In concordance to this hypothesis, systemic genetic deletion of Phd2 decreased drug toxicity 
and increased survival in mice, with Phd2+/- mice surviving for 20 days with doxorubicin 
treatment, versus a survival of only 5 days in WT mice. The authors found that the abnormal 
vasculature found in multiple cancer types is somewhat corrected in Phd2+/- mice, allowing 
more efficient delivery of anti-cancer drugs, at lower concentrations (Leite de Oliveira et al., 
2012). It is possible, therefore, that Phd2 inhibitors may hold a dual function in AML therapy, 
both eradicating LSCs, and enhancing the efficacy of chemotherapy. Using this chemotherapy 
model (Zuber et al., 2009), control (rtTA) and shPhd2/rtTA mice should be transplanted with 
Meis1/Hoxa9 transformed shPhd2/rtTA and control cells, and treated with Dox, as well as 
chemotherapy. This will dissect the multiple roles of Phd2 in AML therapy, and using the Dox-
inducible system, investigate the efficacy of combined pharmacological Phd2 inhibition with 
standard chemotherapy.  
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Notably, Meis1 and Hoxa9 as downstream effectors of MLL, serve as an accurate retroviral 
overexpression model of human AML, deriving from a stem-cell source, with significant self-
renewal and clonogenic capacity. However, there are multiple other murine AML models, such 
as retroviral induction of MLL-AF9 and MLL-ENL translocations (described in (Somervaille et 
al., 2009)), as well as multiple MLL-AF9 transgenic mouse models, such as the Dox inducible 
rtTA;MLL-AF9 model engineered by the Schwaller laboratory (Stavropoulou et al., 2016). 
Notably, other groups studying the role of either HIF or PHD in AML have used other AML 
models, and these studies confirm our hypothesis and results (Leite de Oliveira et al., 2012; 
Velasco-Hernandez et al., 2014). However, it is important to explore other models of AML, as 
it is possible that current anti-leukaemogenic phenotypes resulting from Phd deletion are 
specific to Meis1/Hoxa9 AML model.  
 
Vukovic et al in 2015 provided evidence that deletion of both Hif-1α and Hif-2α increases 
leukaemic disease in vivo. As such, the initial hypothesis was that deletion of both Phd1 and 
Phd2, stabilising both Hif-1α and Hif-2α, would have the most significant effect on AML. As 
shown in Figures 5-3, 5-4, 5-5, 5-6 and 5-7, deletion of both Phd1 and Phd2 has no additive 
effect on the reduction of leukaemic cell growth, colony formation, or engraftment and survival 
in vivo. From this result, it is possible that the effects shown in Phd1 and Phd2 in AML may be 
HIF-α independent, or stabilisation of one HIF-α isoform is sufficient. Western blot analysis 
should be performed to investigate HIF-stabilisation in Phd1CKO, Phd2CKO and Phd1/2CKO cells, 
as well as RNA-seq analysis to identify if other HIF-α independent mechanisms are at play.  
 
Overall, the results shown in this chapter demonstrate that Phd1 and Phd2 have significant 
roles in AML. Deletion of Phd1 or Phd2 results in decreased leukaemogenesis, through the 
reduction in LSC activity. Further genetic and pharmacological studies of Phd1 and Phd2, with 
special focus on human AML cell lines and samples, are essential to determine if Phd1 and 
Phd2 are valid as more general therapeutic targets in AML. Moreover, mechanistic studies are 

















































Chapter 6 Discussion 
Normal and malignant haematopoiesis occur within the hypoxic environment of the BM niche. 
Following characterisation of the various components of this HSC niche, a number of studies 
focused the role and biological significance of the cell-cell interactions in this protective 
environment (Mendez-Ferrer et al., 2008; Morrison and Scadden, 2014). Seminal studies by 
Schofield in 1978 found that the hypoxic BM niche protects HSCs from exhaustion and DNA 
damage, by retaining them in a quiescent state. In addition, experiments by Dexter and 
colleagues in 1977 unveiled that BM stromal cells isolated from the HSC niche have a 
beneficial effect on HSPCs in long-term cultures ex vivo. Interestingly, the LSCs which drive 
leukaemic disease, have been shown to modulate their own BM niche. LSC-induced changes 
in the stroma are consistent with pro-survival and growth-stimulatory signals, theorised to 
contribute to their therapy resistance (Zhou et al., 2016). A recent paper by Cheloni and 
colleagues in 2017 found that leukaemic cell lines cultured in hypoxic conditions equivalent to 
those observed in the stem cell niche, had reduced levels of driver oncogenic proteins. Under 
these conditions, growth is impaired, and suggests that hypoxia may have an impact on LSC 
function (Giuntoli et al., 2007). 
 
Following the discovery of the molecular mechanisms behind the cellular hypoxic response, 
there have been significant research efforts to investigate if this system plays any role in the 
regulation of haematopoiesis (Guitart et al., 2017; Guitart et al., 2013; Semenza, 2000; Takeda 
et al., 2008; Takeda et al., 2007; Vukovic et al., 2016). The cellular response to hypoxia is 
orchestrated by the master transcription factor HIF, which binds to the HRE (hypoxia response 
element) in over 200 genes, facilitating the adaption to low oxygen conditions. This hypoxia 
signalling pathway is controlled by the HIF-prolyl hydroxylase domain enzymes (PHDs), which 
under normoxic conditions hydroxylate specific proline residues on the HIF-α subunit, marking 
it for degradation (Epstein et al., 2001; Jaakkola et al., 2001; Masson et al., 2001).  
 
Research papers published by the Kranc laboratory found that cell autonomous deletion of 
Hif-1α, Hif-2α, or both Hif-1α and Hif-2α had no effect on haematopoiesis in both steady state, 
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or transplantation-induced stress conditions (Guitart et al., 2013; Vukovic et al., 2015). 
Notably, when Hif-1α and Hif-2α were deleted in pre-LSCs, it was unveiled that HIFs had a 
strong tumour suppressive role in AML (Vukovic et al., 2015). 
 
Given these results, and the emerging roles of hypoxia in HSC biology and AML, the general 
























6.1 PHDs in normal haematopoiesis  
Experiments in Chapters 3 & 4 investigated the role of Phd1 and Phd2 in normal 
haematopoiesis using state-of-the-art transgenic mouse models. Opposing published 
research in the field (Takeda et al., 2007; Takeda et al, 2008; Singh et al., 2013), it was found 
that deletion of Phd2 specifically within the haematopoietic system using Vav-iCre had no 
effect on the differentiated blood lineages or the HSPC compartment. Notably, previous 
research that found a fundamental role for Phd2 in the haematopoietic system, used 
transgenic models which deleted Phd2 either systemically, or in other tissues as well as the 
haematopoietic system. Given the role of stromal tissues within the hypoxic BM niche, this 
result it to be expected.  
 
In addition to the Vav-iCre model, I also investigated the role of acute Phd2 knockdown in 
haematopoiesis using Dox inducible shPhd2/rtTA transgenic mice. Here I found an altered 
differentiation compartment in the PB and BM of mice with reduced levels of Phd2. 
Additionally, within the HSPC compartment, systemic reduction of Phd2 levels lead to a 
decrease in primitive haematopoietic cells, accompanied by an increase in the progenitor 
population. Given the systemic and acute nature of this gene knockdown experiment, it is 
possible that the protective HSC BM niche is altered by reduced Phd2 levels, yielding a stress-
like haematopoietic response, and thus HSC emergence. 
 
Following this, as there was a notable effect of Phd2 depletion in the HSC compartment, a 
transplantation experiment was performed with FACS isolated HSCs from shPhd2/rtTA and 
control mice. Under the stress of a transplantation assay, it was clear that the HSCs with a 
knockdown of Phd2 were significantly less fit than their control counterparts. Due to the 
experimental design of this experiment, Phd2 levels were only reduced in the transplanted 
HSCs, not systemically. This suggests that the stem cell compartment is affected both by acute 
systemic and cell-autonomous depletion of Phd2. This may be a result of Phd1 or Phd3 




Notably, this thesis unveiled an undiscovered role for Phd1 in haematopoiesis. Ablation of 
Phd1 within the haematopoietic system resulted in a significant decrease in BM cellularity. 
This phenotype was also shown in mice with deletion of both Phd1 and Phd2, but not in mice 
with deletion of Phd2 alone. Additionally, mice with deletion of both Phd1 and Phd2 had a 
dramatic expansion of the HSC compartment, which was not recorded in the single Phd1 
knockout or Phd2 knockout mice. This suggests as cell-autonomous synergistic role between 

























6.2 PHDs in AML 
Previous published research in the Kranc laboratory found that deletion of Hif-1α and Hif-2α 
accelerated AML disease in a Meis1/Hoxa9 retroviral model of leukaemia (Vukovic et al., 
2015). As such, in Chapter 5 this thesis explored the effect of HIF-α stabilisation on AML 
through deletion of its inhibitor PHD.  
 
Phd1CKO, Phd2CKO and Phd1/2CKO pre-LSCs derived from Meis1/Hoxa9 transformed foetal liver 
cells were tested for their proliferative and colony forming ability. These assays revealed that 
deletion of Phd1, Phd2 or both Phd1 and Phd2, reduces the potency of pre-LSCs, when 
compared to the control. Transplantation of these cells into lethally irradiated recipient mice 
resulted in a significant increase in disease latency. 
 
To further dissect the role of Phd2 in murine AML, I transformed foetal liver cells from 
shPhd2/rtTA and control embryos with Meis/Hoxa9 viruses. This experimental model allowed 
for the depletion of Phd2 levels at any point in the development or maintenance of AML. In 
concordance with the results shown in the conditional knockout experiments, acute reduction 
of Phd2 levels resulted in a decrease in colony formation and an increase in disease latency 
in vivo. Given that acute deletion of Phd2 reduces leukaemic burden, even in established 













6.3 Final conclusions and future directions 
As described in this thesis, there is desperate need for new, targeted AML therapies. Whilst a 
large proportion of the field endeavours to target the genetic mutations and translocations that 
generate AML, others have hypothesised that current chemotherapies in conjunction with 
drugs that specifically target LSCs will reduce the risk of relapse, significantly improving the 
outcome for patients with AML (Kumar, 2011; Pollyea and Jordan, 2017). 
 
Given the intimate relationship between HSC and LSC biology, it is essential that any 
therapeutic option must successfully eliminate LSCs, but does not harm the fundamental 
process of haematopoiesis. Here I describe that deletion of Phd1, Phd2 or both has no 
significant detrimental effect on normal haematopoiesis, but does reduce leukaemic burden 
and extend survival in a retroviral model of AML. In addition to this encouraging data, evidence 
from the labs of Dr Mazzone and Prof Cammenga show that reduction of Phd2 levels also 
improve the efficiency of chemotherapy, and alleviate some of the cytotoxic side effects. 
Furthermore, PHD inhibitors are already safely used in the clinic for diseases such as stroke, 
anaemia and chronic kidney disease (Haase et al., 2017; Ogle et al., 2012; Nangaku et al., 
2007). 
 
As such, there is a substantial case for further exploration into the therapeutic potential of 
PHDs in AML. RNA-seq analysis of Phd1CKO, Phd2CKO and Phd1/2CKO pre-LSCs and LSCs will 
unveil the mechanism through which Phd deletion impacts LSC biology. Importantly, these 
experiments will also disclose if these encouraging phenotypes work through a HIF-dependent 
of HIF-independent mechanism. Given the heterogeneity of AML, it is vital to explore the role 
of PHDs in other transgenic AML mouse models, as well as human patient samples. Finally, 
other leukaemias and cancers such as CML, pancreatic cancer and glioblastoma are known 
to be driven by cancer stem cells, and reside in a hypoxic environment. As such, the 
therapeutic significance of PHDs may extend beyond AML, and have potential in multiple other 
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